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The aim of this project was to determine the effect that route of infection has
on the incubation period and terminal pathology of experimental scrapie. Infection
was established either by injection into the peritoneum or the biceps femoralis of the
leg, or orally by administration of the agent with food. As a secondary study an
experiment was devised to investigate the possible transport of scrapie infectivity in
the central nervous system (CNS) ofmice lacking a functional prn-p gene. The
primary study was carried out using a combination of immunohistochemistry,
histopathology and computerised image analysis. The study of agent transport was
done by bioassay for reasons of sensitivity.
C57B1 mice were infected with ME7 scrapie by the routes described above
and groups of animals were serially sacrificed at between 5 and 7 timepoints during
the course of the disease. The timepoints were chosen so that tissues representative
of early, mid and late/terminal infection could be collected for study. Specific
antibodies were used to detect the presence of PrP and GFAP whilst vacuolation was
detected by standard haematoxylin and eosin staining.
The results of this study indicate that the oral route of infection in
experimental scrapie can be used to establish an infection with much more efficiency
than has previously been reported. It is possible that the technique used to introduce
the infection, by admixture with food as opposed to the more traditional gavage
method is a significant factor in this increased efficiency.
Other important observations relate to the distribution and intensity of lesions
in the brain following infection by each of the three routes examined. The
distribution of vacuolation, PrP and GFAP following both muscular and peritoneal
injection of infectivity are very similar; there are differences in the severity of the
pathology such that intramuscular infection results in an advanced lesion but the
distribution is almost identical. This is interesting considering how close together the
incubation periods for these two routes are. These observations are in stark contrast
to the results seen following oral infection. Not only is the incubation period
extended, the lesions are much more severe throughout the brain and the pattern of
distribution is completely dissimilar from that seen in the animals infected by the
other routes.
In the experiment to study the transport of infectivity in mice devoid of
endogenous PrP the results suggest that some limited transport is possible. This is
the result of a study using the projections of the optic nerve as a controlled system for
assessing the transport of infectivity along defined neuroanatomical pathways.
In conclusion, the results of the work described in this thesis show that oral
infection, at least in experimental systems, is a highly efficient route of infection that
results in significantly more severe pathology than either the intramuscular or
intraperitoneal routes. The efficiency of oral infection may have implications for
human disease with reference to new variant CJD (nvCJD). Other results show that a
limited degree of transport of infectivity may be possible in mice lacking a functional




Scrapie, a naturally occurring disease of sheep, and more rarely goats (MacKay
and Smith, 1961), is the oldest member of a group of diseases known as the spongiform
encephalopathies. This disease is endemic in Britain where its presence has been
documented for over two hundred years (Comber as cited by McGowan, 1914).
Scrapie has been reported in many other countries and has recently been found in
countries that were earlier thought to be free of the disease such as Cyprus (Toumazos,
1988) and the former Yugoslavia (Knezevic and Jovanovic, 1986). It had been
previously reported in the Antipodes (Parry, 1964) although these countries are now
thought to be scrapie free (Foster and Hunter, 1998). Scrapie gets its name from the
characteristic pruritus which results in the scraping that affected sheep display.
Other diseases of this group have been identified in a variety of animal species
and in man. They share a characteristic spectrum of pathology that is the result of
infection with a common type of agent. Pathology will be discussed in greater detail in
section 1.3. Table 1 lists these scrapie-like diseases and the species affected by them.
1.1 History of Scrapie and the TSEs
Scrapie is transmissible: this was first demonstrated by Cuille and Chelle and
reported in works published between 1936 and 1942, reviewed by Pattison, 1988.
Their studies involved the passage of spinal cord homogenate, obtained from scrapie
affected sheep, to unaffected sheep by the intraocular (i.o.) route. Of nine animals
experimentally infected two eventually succumbed to the disease after unusually long
incubation periods of 16 and 23 months. This extended period between infection and
onset of illness is now a recognised feature of this class of diseases. There was
initially scepticism that, because of the long incubation period, transmission of the
scrapie agent had occurred. However, this observation was inadvertently confirmed
when several hundred sheep acquired the disease after being injected with a
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Reference.
Scrapie sheep/goats McGowan, 1922.
Transmissible Mink
Encephalopathy (TME)





Williams and Young, 1980.
Bovine Spongiform
Encephalopathy (BSE)'
cattle Wells etal., 1987.
Feline Spongiform
Encephalopathy (FSE)H
cats (domestic and zoo
species)
Wyatt et al., 1990.
Spongiform Encephalopathy" exotic ungulates (nyala,
gemsbok, oryx, kudu)
Jeffrey and Wells, 1988
Bradley, R. 1997






Scheinker syndrome (GSS) man Gerstmann, 1928.
Fatal familial Insomnia (FFI) man Medori et. al., 1992
New variant CJD"' (vCJD) man Will etal., 1996.
Tablel. The spectrum of spongiform diseases and the species that they affect
H There is epidemiological and strain typing evidence to suggest that these diseases are related to the
advent of BSE (Bruce et. al., 1994). ' There is recent evidence to suggest that these two diseases are
caused by a common agent (Bruce et. al., 1997; Hill et. al., 1997). * CJD can be classified as sporadic,
iatrogenic or familial. (Collinge and Palmer, 1997 for review).
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The vaccine had been prepared from formalin treated sheep brains and it is
thought that at least one of the sheep used was incubating scrapie without displaying
clinical signs (Gordon, 1946). Subsequent studies by others in the field confirmed
that the disease transmitted with an unusually long incubation period (reviewed by
Kimberlin 1981). The successful transmission of disease from affected to healthy
animals suggested that scrapie occurred as the result of infection with a causitive
agent. Serial passage of the disease through nine generations of sheep provided
confirmation that there was a transmissible agent, (reviewed by Pattison 1988). It
was considered likely that a virus was responsible for scrapie (Wilson et. al., 1950).
The source of infectivity in these cases was brain homogenate prepared from affected
animals. The protracted incubation period which is a feature of infection by the
scrapie (and scrapie-like) agents led to its description as an unconventional slow
virus by Sigurdsson (1954). The belief that the agent responsible for scrapie was a
virus were based on the observations that the diseases are transmissible and the agent
had a very small size (Stamp et. al, 1959), although even now, almost 45 years later,
a scrapie specific virus has still to be isolated. The lack of an identifiable specific
virus caused some to consider that there was another cause of scrapie. The
possibility that scrapie was a genetic disease was postulated (Parry, 1962; 1964), but
whilst host genetics are acknowledged to exert an influence on the susceptibility to
and the progression of the disease, scrapie (and the associated diseases) are not
considered to be true genetic diseases.
A major milestone in scrapie research was reached in the early 1960s when
the first successful transmission of scrapie to rodents was achieved (Chandler, 1961;
Zlotnik and Rennie, 1962). Experimental infection of mice by the intracerebral (i.e.)
route produced a practical model with relatively short incubation periods, making it
much easier to study the disease. The availability of a reliable rodent model for
scrapie has greatly advanced study in the field of this and other associated diseases.
The associated conditions, including BSE and CJD share common pathological
features and are commonly referred to as members of a group of diseases known as
transmissible spongiform encephalopathies (TSEs).
The demonstration of scrapie as a transmissible disease led to speculation that
the naturally occurring disease was caused by vertical (ewe-to-lamb) transmission in
the womb (Dickinson et ah, 1965). It has been noted that the eventual scrapie status
of a lamb depends more on the status of the ewe than it does of the ram (Dickinson,
1976) however, there is evidence to suggest that vertical transmission is not the only
way in which the disease is spread. Instances of what can only be described as
'contact transmission' have been reported between sheep and goats (MacKay and
Smith, 1961) and there is even a report of transmission between laboratory rodents
(Dickinson et. al, 1964) although this has not been reported in any of the literature
since. Contagious spread of this nature is not completely understood but it seems
likely that the oral route of infection is important (Pattison and Millson, 1961;
Gordon, 1966). Placental material from scrapie affected ewes has been demonstrated
to contain high levels of scrapie infectivity (Pattison et al., 1974), this raises the
possibility that grazing sheep on pasture land contaminated with infective ovine
placentae can lead to transmission of the disease.
Since the first successful laboratory transmissions of the disease there have
been around 20 distinct strains ofmouse adapted scrapie identified. Of these 20 or so
strains the present investigation is being carried out using the ME7 strain of the
scrapie agent (Zlotnik and Rennie, 1962 and 1963). Strains are separated on the basis
of incubation period and specific patterns of pathology on passage in certain strains
of mouse (Outram et. al., 1973). Incubation periods for the various strains of mouse
adapted scrapie can range from around 150 days up to and exceeding the lifespan of a
mouse.
Incubation period in murine scrapie is influenced by the Sine genotype of the
affected mouse (Dickinson et. al., 1968). Sine, for Scrapie INCubation, which is
found on chromosome 2 in mouse, is functionally similar to the STg gene in sheep.
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The Sine gene is also known as Prn-i. The gene has two alleles designated s7 and p7.
These alleles determine whether or not the incubation period of the ME7 scrapie
strain is short or long respectively. It is now accepted that the Sine designation
reflects the function of the gene. The product of the gene is the host-encoded
sialoglycoprotein PrP, and it has been shown that the Sine gene and the gene that
codes for PrP, Prn-v, are in fact the same gene and the influence that the gene has
over incubation period is controlled by PrP dimorphisms at codon 108 (L108F) and
/or codon 189 (T189V; Hunter et. ah, 1992; Moore et. al, 1998).
The exact nature of the scrapie agent is a matter of some controversy and will
be discussed in section 1.2, then pathogenesis of the disease will be considered. The
popular view now is that the infective agent is a prion (Prusiner, 1982). Prions -
which are an abnormal isoform of a host-encoded protein, prion protein (PrP)- will
be discussed in greater detail in section 1.2 but basically a prion is postulated to be a
self-replicating pathogenic protein devoid of a nucleic acid informational molecule.
However, the prion theory struggles to explain scrapie strain diversity and stability
upon passage and there are still those who advocate the possibility that the agent is a
virus (Diringer et. al, 1994; Diringer et. al., 1997; Manuelidis, 1997; Murdoch et. al,
1990). The suggestion is that due to its very small size and unusual physico-chemical
properties (Stamp et. al, 1959; Alper et. al, 1966) a virus has not yet been isolated.
The exact nature of the agent is still a matter of some controversy. What is irrefutable
about the nature of the disease and can be considered here are its very unusual
physical and chemical characteristics. The agent displays a very high stability under
conditions that would be detrimental to most conventional viral and bacterial agents.
Furthermore, infection fails to induce a specific cell mediated immune or
inflammatory response (Kimberlin, 1976) but other inflammatory reactions involving
microglia and cytokines may occur (Williams et. al., 1994; Williams et. al., 1995)
within the CNS.
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1.2 The nature of the agent.
Despite what is often recorded in textbooks, the exact nature of the agents
responsible for TSE infections is still an unresolved issue. There are several
hypotheses as to the aetiology of these diseases. These include the possibility that the
TSEs are genetic diseases (in familial cases), are caused by an unconventional virus
or are the result of infection with a novel type of agent composed solely of protein
(Griffith, 1967; Prusiner, 1982).
Until recently most of the experimental information on these agents has
come from studies of experimentally transmitted scrapie in laboratory rodents (mice
and hamsters). Early studies of the scrapie agent demonstrated that the infectious
agent displayed unusual physical and chemical properties. These include a resistance
to heating; the agent survived prolonged heating at temperatures in excess of 120°C
in the absence ofwater. There was even evidence to suggest that some infectivity
could survive prolonged boiling (Gordon, 1946). Other unusual properties included
the partial protease resistance of the agent and the resistance of infectivity to ionising
radiation, a treatment that normally degrades nucleic acids (Alper et. al., 1966).
These observations, and the inherent suggestion that the agent was devoid of DNA or
RNA led some to postulate that the agent may be composed mostly or entirely of
protein (Griffiths, 1967; Pattison and Jones, 1967; Alper et. al., 1967).
Other groups maintain faith in the dogma that biological information such as
that pertaining to propagation/replication of infectivity and faithful replication of
strain characteristics can only come from a nucleic acid. These groups (see Braig and
Diringer, 1985; Manuelidis et. al., 1995 for examples) believe that the agent is a virus
or possibly a virino. A virino is described as a molecule composed mostly of protein
but with a small nucleic acid element (Dickinson and Outram, 1988; Somerville,
1991). However, to date no TSE specific nucleic acid has been isolated.
Furthermore it has been demonstrated that, while infectivity was selectively
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decreased by treatment with proteases there was no appreciable loss of infectivity
titre following treatment with nucleases, lipases or glycosidases (see Millson et. al.,
1976 for review). These observations argued against the agent being a conventional
virus and suggested that a protein was critical for infectivity.
The idea that the agent may be a new type of infectious agent, one that
replicates without a conventional informational molecule led Professor Stanley
Prusiner to coin the term 'prion' (adapted from/?roteinaceous infectious agent;
Prusiner, 1982). Bolton and colleagues were the first to identify a protein which co-
purified with scrapie infectivity (Bolton et. al., 1982). The candidate protein was
identified as PrP -also known as protease resistant protein or the 'prion' protein
(Bolton et. al., 1982). This protein is the constituent element of the amyloid plaques
seen in many cases of TSE infection (Merz et. al., 1981; Prusiner et. al., 1983). PrP
is a highly conserved protein expressed by mammalian species, primarily in the CNS
where it is expressed in astrocytes and at the neuronal cell surface where it is
anchored by a GPI-moeity (Collinge et. al., 1994; Moser et. al., 1995). PrP exists
primarily in one of two forms (although there are postulated transient intermediaries,
see Harris, 1999 for a review of the molecular nature of the PrP conversion to
PrPSc). The native form ofPrP (known as PrPc), which is expressed in normal CNS
tissue, has a molecular weight of 33-35 kilodaltons (kDa), is a mainly alpha-helical
protein (Approximately 40% alpha-helix, little or no beta-sheet). This form of PrP is
sensitive to digestion by proteolytic enzymes. The disease associated form of the
protein, known as PrPsc has a far higher beta-sheet content than the native form
(60% beta-sheet and 20 % alpha-helix; Martins, 1999) and is formed as a result of
post-translational modifications. PrPsc undergoes limited proteolysis and the product
of the reaction is a protein core, designated PrP27-30, which can polymerise to form
c sc •
amyloid rods (Prusiner, 1993). The conformational change from PrP to PrP is
autocatalytic with PrPsc propogating itself by facilitating the conversion, the exact
mechanism of this conversion is not clear (Nixon, 1999).
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Although primarily a CNS protein PrP can be found in other tissues (Kubo et.
al., 1995; Horiuchi et. ah, 1995; Doi, 1991). The high degree of sequence
conservation seen between PrP proteins from various species and its expression early
in development (Manson et. al., 1992) tends to suggest that the protein must have an
important function. However, to date no definitive function for the protein has been
identified (Estibeiro, 1996) although several possibilities have been mooted such as
the regulation of diurnal rhythms (Tobler at. al., 1996) or involvement in the
regulation of copper/zinc superoxide dismutase (SOD), suggesting a role for PrPc in
cellular resistance to oxidative stress (Brown et. al., 1997). One of the more puzzling
facts with respect to the function of the protein is that ablation of the gene which
controls production of the protein is not a lethal event. (Biieler et. al., 1992; Manson
et. al., 1994).
What is not in dispute with regard to the infectious agent is that the presence
of the PrP protein is essential for disease propagation. This has been evidenced by
studies involving mice where the PrP gene has been ablated or otherwise disrupted.
Animals which have this knockout mutation are resistant to infection by the scrapie
agent (Bueler et. al., 1992; Biieler et. al., 1993;). It has been shown that expression
of PrP is required for replication of the infectivity in the CNS (Sailer et. al., 1994),
for neurodegeneration to occur (Brandner et. al., 1996a) and for the transfer of
infectivity from the periphery to the CNS (Blattler et. al., 1997). However in these
experiments the transfer of infectivity has been related to the accumulation of disease
specific PrP in neural grafts which over-express normal PrP. Sakaguchi and
colleagues (1993) have demonstrated that levels of infectivity in lymphoid tissues of
mice infected with the human CJD agent do not correlate with the levels of disease
specific protein detected. Work by Somerville and Dunn (1996) concludes that at
least some of the PrPsc in the brain is not directly associated with infectivity, recent
work by Hill et. al. (1999) using in vitro conversion assays supports this. These
studies suggest that while PrPsc accumulation is associated with replication of the
infective agent it is not clear that the protein itself is the agent.
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Experiments designed to detect infectivity were carried out by bioassay of
tissues from the visual system ofmutant mice that did not produce PrP protein and
their wild-type counterparts which did. The visual system is a well-characterised
system and has proven useful to study the neural spread of the scrapie agent (Fraser,
1982a,b; Scott and Fraser, 1987). Bioassays are a method of detecting infectivity
or
alone and do not relate the deposition of PrP in the CNS to the activity or the
identity of the infectious agent. It was felt that this approach was valid given the
concerns surrounding the exact nature of PrP's role in the pathogenesis of these
diseases and the questions that still surround the exact nature of the agent.
1.3 Pathology and Pathological Markers of TSE infection.
In the murine model of scrapie, onset of clinical disease is difficult to detect
as there is a long asymptomatic period following experimental infection. During this
period the agent replicates and accumulates in the organs of the lymphoreticular
system; spleen, lymph nodes, Peyers patches and the brain (Outram 1976; Race and
Ernst, 1992). The early signs are generally subtle and there is a spectrum of clinical
signs that might suggest a diagnosis of TSE infection. These can include altered gait,
pruritus (in the case of scrapie at least) and hyperexcitibility in response to a range of
stimuli, for example, sound, touch and movement (Bradley, 1997). There is, as has
been previously mentioned no specific host mediated immune response. A definite
diagnosis can, at present, only be made following post mortem pathological
examination of the brain although there is currently much interest in the development
of reliable antemortem diagnostic tests.
The first signature lesion to be identified in natural scrapie was a vacuolation
of the perikaryon in the ventral horn of the spinal cord; this was described by Besnoit
and Morel in the 19th century (reviewed by Bradley, 1997). Subsequent intraneuronal
vacuolation in the brain was also found (Zlotnik and Rennie, 1962).
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All the identified TSEs share a common type of pathology. In general this is
characterised by spongiform degeneration, mainly of the grey matter neuropil in
murine scrapie, and the deposition throughout the CNS of an abnormal, disease
associated, form of a host encoded amyloidogenic protein known as PrP or the prion
protein (Prusiner, 1982). The disease-associated form of this protein is known as
g /-i
PrP , or PrP-scrapie, and is formed from a normally present precursor PrP , or
cellular-PrP as discussed previously.
In contrast with transmissible spongiform encephalopathies of man, the
neuropathology of scrapie in sheep and goats often includes vacuolation of neuronal
cell bodies. This and the frequently vacuolation of the neuropil is readily detected in
paraffin sections of brain stained with haematoxylin and eosin (H&E, Figure 1
illustrates vacuolation of the neuropil as seen in an H&E stained section). This
disease specific vacuolation of the neuropil is caused by the loss of organelles and
swelling in the dendrites and axonal terminals (Jeffrey et. al., 1992) and is discernible
from non-specific damage by the presence of membrane and granular debris (Chou
et. al., 1980; Sato et. al., 1980).
It is possible to detect amyloid plaques in H&E stained paraffin sections due
to the eosinophilic nature of the amyloid; this is readily confirmed by the use of dyes
such as Congo Red or Thioflavin-T which selectively stain amyloid deposits (Vasser
and Culling, 1959; Puchtler et. al., 1962). The availability of specific anti-PrP
antibodies has made the detection and visualisation of plaques and the less
aggregated, non-amyloid, forms of the protein involved in TSE infections easier
(Zanusso et. al., 1998; Farquhar et. al., 1989).
Amyloid forms of PrPsc have not been observed in all cases of the natural
disease (Gilmour et. al., 1986). PrP aggregations have a variety of appearances this
includes plaques as well as more diffuse deposits (Fig 2a and 2b). Although it is
widely thought that PrPsc is the pathological agent it is unclear how it effects
damage.
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It is possible that the abnormal protein is neurotoxic, there is evidence, from
in vitro studies that at least a portion of the prion protein, the fragment represented by
amino-acid residues 106-123, can be directly neurotoxic (Selvaggini et. al., 1993;
Forloni et. ah, 1996). This PrP neurotoxicity possibly occurs by a microglia
associated mechanism (Brandner et. al., 1998). Alternatively, the withdrawal of
PrP , the precursor molecule, could be detrimental to neuronal survival (Brandner et.
al., 1996b; Aguzzi et. al., 1997).
Other pathological features include astrocytic hypertrophy and hyperplasia
and, in some models, neuronal loss, which may occur by an apoptotic mechanism
(Giese et. al., 1995; Kretzschmar et. al., 1997) which may account for the lack of
inflammation in the central nervous system. The astrocytic hypertrophy is marked by
an upregulation of glial fibrillary acidic protein (GFAP). The role of astrocytes in the
disease process is unclear but it may involve trafficking of the abnormal protein;
Q[p
astrocytes have been demonstrated to accumulate PrP prior to the development of
the other neuropathological changes (Diedrich et. al., 1991a). The importance of this
observation with respect to the pathogenesis of disease is not clear. It had been
suggested that the astrocytosis was the primary lesion in TSE infection and that the
nerve cell vacuolation was a secondary change initiated by faulty metabolism of
astrocytes (Field and Raine, 1964). However, there are others who believe that
astrocytic hypertrophy is a reactive change (Fraser, 1979a). The upregulation of
GFAP (Diedrich et. al., 1991b) can occur late in the incubation period of certain
scrapie models, after the appearance of vacuolation or PrP, this seems to suggest that
astrocytic hypertrophy and hyperplasia is a secondary lesion.
Figures 1-3 illustrate the types of pathology that are seen in scrapie and other
TSE infections. Where the pathology shown is from sources other than experimental
ME7 scrapie, the sources are noted. These are accepted as the defining features of
pathology, which are common to all diseases of this type. The lesions seemingly
arise without activating the host immune system. Exactly how these pathological
features translate into the clinical phenotypes that occur in cases of these diseases is
unclear, especially as the clinical presentation is not always the same (particularly in
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Figure 3.
Figures 1-3. Illustration of the three major pathological markers observed in cases of transmissible
spongiform encephalopathy infection. Figure 1 shows vacuolar degeneration of the neuropil often
referred to as spongiform change. Figure 2a PrP in the form of plaques. Figure 2b shows a more
diffuse form of PrP that can be found in TSE infections. Figure 3 shows reactive astrocytes, identified
by immunohistochemical detection of glial fibrillary acidic protein (GFAP).
(Figures 1-3, x200 magnification).
noting that although these are characteristic brain lesions, there exists a broad
spectrum of human neuropathology in terms of the severity of lesion and the
distribution of damage throughout the brain (Lantos, 1992). Under experimental
conditions the distribution and severity of the lesion can be faithfully reproduced in
rodent models where host strain, with particular emphasis on the Sinc/Prn-i
genotype, the agent strain and the route of exposure are kept constant (Fraser and
Dickinson, 1976; Fraser, 1979b). The recognition of these characteristic features of
scrapie infection made it possible to develop a tool for identifying scrapie strains in
defined mouse models. The method relies on simple measurement of disease
characteristics. The major features that are measured are the incubation period and
the degree of vacuolar pathology in specific regions of the scrapie-affected murine
brain (the lesion profile) where agent strains show faithfully reproducible differences
in the severity and distribution of vacuoiation in the neuropil of genetically identical
animals (Bruce, 1986).
1.4 Assessment and Quantification of Pathology
Different strains of the scrapie agent will produce distinctive patterns of
pathology in certain strains of laboratory mice. These differences include variation in
spatial distribution and severity of lesions in the CNS and can include differences in
the type of PrP that can be detected, as defined in terms of its aggregated or more
widely dispersed state. In some cases the protein is deposited as plaques whereas in
others there may be less structure to the protein deposits. It is notoriously difficult to
objectively measure/quantify the degree of pathology that is present in cases of TSE
infection. The most important lesion in the TSEs is vacuoiation of the grey matter; it is
this feature which forms the basis of a semiquantitative method of strain
discrimination, the lesion profile (Fraser and Dickinson, 1973). This is a means of
assessing the amount of pathology in the brain of a mouse at the late clinical, or
terminal, stages of the disease, it is not a tool that lends itself to the sequential mapping
and quantification of pathology during the incubation period. It is however very useful
in determining the causative strain of agent in a given strain of mouse. To assess the
degree of vacuoiation, the severity of the lesion is scored in nine grey matter areas and
three white matter areas, grey matter vacuoiation is scored from 0-5 where 5 is the most
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severe and white matter vacuolar change is scored on a scale from 0-3 (Bruce, 1996).
There are verbal definitions of each score which aid consistency between examiners
and representative photographs are available (Fraser, 1970). Each animal in a given
experimental scrapie transmission group is scored according to these criteria. The
mean scores for each of the twelve areas is calculated and a lesion profile can be
constructed. Lesion profiles are signatures for a given strain of agent in a given mouse
strain (Figure 4 illustrates this point) and are dictated by the combination of agent strain
and mouse genotype (Bruce et. al., 1991). The shape of the lesion profile produced is
independent of the initial infecting dose and can also be used to determine the fatal
strain if an animal is infected with a mixture of strains. It was lesion profiling that led
to the discovery that BSE and new variant CJD were caused by the same agent (Bruce
et. al., 1997), and that BSE was caused by a single stable strain of agent (Bruce et. al..,
1994).
Lesion profiling is a time consuming and labour intensive procedure that is
prone to examiner fatigue, this is a potential source of error and inconsistency. Each
examiner has to be trained in the same way, to the same standard so as to maintain a
level of uniformity between examiners. Because of these requirements there are
generally very few people who are actually able to produce these profiles. Although
lesion profiling was designed as a semiquantitative tool it is limited to the examination
of the mouse brain in the 12 defined areas and is used only at the terminal stage of the
disease. It is not a suitable tool for measurement of pathology through the course of
disease incubation, and as such is not suitable for tempero-spatial investigations of
pathogenesis. This is because, certainly in some models, during the early stages of
infection the distribution of vacuolation is influenced by the spread of the infectious
agent, which is likely to be the same for other strains that are inoculated in the same
way, and does not necessarily reflect the eventual lesion profile that is found at the
terminal stage (Cole and Kimberlin, 1984). In such studies a more quantifiable and
thorough, in terms of the number of regions that can easily be examined, method of
measuring pathology is desirable.
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(a)
ME7 scrapie in C57BI mice. Grey Matter
Vacuolation Lesion Profile
(b)
ME7 scrapie in VM mice. Grey Matter
Vacuolation Grey Matter Lesion Profile
Figure 4: Shows a representation of the grey matter portion of two complete lesion profiles. C57BI
mice (4a) produce different lesions that VM mice (4b) when they are both infected with the same
strain of the scrapie agent -ME7. This illustrates to some degree the effect that host genetics exerts on
pathology and pathogenesis of disease. In both plots the X-axis represents the nine grey matter
regions that are examined as standard and the Y-axis denotes the pathological 'score'.
Although invaluable in discriminating between strains, the lesion profile does
not allow for a complete picture of pathology and pathogenesis to be produced.
Vacuolation is the major lesion in the TSEs but there are other pathological indices that
should be considered in order to understand more fully the disease process. It has been
demonstrated that the distribution of vacuolar change in the neuropil correlates closely
with the accumulation of PrP (Bruce et. ah, 1989; Bruce et. al., 1991). However, the
distribution and accumulation of PrP is not considered in terms of the lesion profile.
The other major pathological features, astrocytosis and neuronal loss are not
incorporated into the lesion profile either. A time course study of the disease, involving
the computer aided mapping and measurement of the major pathological features,
vacuolation, astrocytosis and PrP deposition, would help to expand the understanding
of disease pathogenesis and serve to illustrate the potential use of computers in a
routine pathological context.
By using a computerised system, measurements of vacuolation, PrP
deposition and astrocytosis can be made in a reliable and semi-objective way. The
visualisation of PrP and GFAP (the astrocyte marker) is made possible due to the
availability of specific antisera and effective immunohistochemistry protocols.
GFAP is a cytoskeletal protein found in mature astrocytes. Levels of GFAP are
regulated under pathological conditions and upregulation ofGFAP is one of the main
characteristics of the astrocytic reaction that is commonly seen following CNS insult
(Gomes et. al., 1999). Vacuolation is assessed in routine/H&E sections.
1.5 The BSE Epidemic and vCJD.
The most widely reported animal spongiform encephalopathy of the past ten
years has been bovine spongiform encephalopathy (BSE). The first report of BSE or
"mad cow disease" was made in 1987 (Wells et. al.) following confirmation in
November of 1986 at the Central Veterinary Laboratory in Weybridge (Bradley,
1997). It is likely that the affected cattle were infected as calves in 1981-82
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(Wilesmith, 1991). The neurohistological lesions observed in these cases were
scrapie-like, that is characterised by spongiform change in the central nervous
system. Subsequent epidemiological studies confirmed that BSE was a new disease
and the first clinical case probably occurred as early as April of 1985 (Wilesmith et.
ah, 1988; Taylor 1992). The peak incidence of cases occurred in late 1992 and early
1993 (Anderson et. ah, 1996). Since then there has been a progressive reduction in
the number of cases seen annually. By the end of January 1998 there had been
170259 confirmed cases of BSE in the mainland UK (Ferguson et. ah, 1998). The
greatest number of cases reported from outside the UK was Switzerland with 234
(Collee and Bradley, 1997a).
Epidemiology suggests that BSE is an orally acquired disease resulting from
contaminated animals feed. It appears that the epidemic was initiated by the
inadvertent transmission of the scrapie agent from sheep to cattle. Sheep carcasses
were commonly rendered to produce meat and bone meal (MBM) as a protein
supplement for cattle. As mentioned, the first infections probably occurred in 1981-
82, this coincides with changes to the rendering process by which the MBM was
produced. It was at this time that most rendering plants abandoned the use of organic
solvents in the preparation of MBM (Nathanson et. ah, 1997). BSE is thought to
have been caused by scrapie infectivity which was able to survive this modified
process (Taylor, 1992). Recent evidence (Taylor et. ah, 1998), however, has
suggested that the abandonment of solvent extraction was not the sole key factor that
allowed BSE to emerge, although it may still have played a part.
A major concern that was voiced during the BSE epidemic was that there
might be a risk of infection to humans from the consumption of tainted beef and beef
products. Studies of the tissue distribution of infectivity in bovine tissues have been
carried out. The purpose of these studies was to identify the possible risk to humans
from consumption of meat/meat product from potentially infected animals (Collee
and Bradley, 1997b). In general the BSE agent is not as widely detectable in a range
of bovine tissues as the scrapie agent is in ovine tissues (Kimberlin, 1994). BSE
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infectivity is generally limited to the central nervous system: brain and spinal cord.
These offal were banned from human consumption in 1989 (Anderson et. ah, 1996).
What is important from a human health aspect is that there is no detectable infectivity
in either milk or skeletal muscle (Bradley, 1994). However, it was recognised that
the population of the UK had possibly been exposed to the BSE agent through the
food chain before the offal ban was put in place.
In 1994 and 1995 two cases of the human TSE Creutzfeldt-Jakob disease
(CJD) were identified in unusually young patients (Britton et. ah, 1995; Bateman et.
ah, 1995). At this time there had only been four previous cases reported in this age
group (Almond, 1995). In 1996 it was reported that these two cases as well as eight
others had suffered from a new form of CJD. This new variant of CJD (vCJD) was
distinguished from sporadic, familial and iatrogenic CJD on the basis of atypical
electroencephalogram features, young age of the cases, unusual clinical presentation
and a new and distinct neuropathological profile (Will et. ah, 1996; Zeidler et. al,
1997a; Zeidler et. ah, 1997b). It was suggested that this new disease was the result of
infection with the BSE agent, the most likely route of infection was the oral route.
There is evidence for the oral transmission of human TSEs in the case of Kuru. Kuru
is the archetypal acquired human TSE. It is associated with the ritualistic
cannibalism that was practised by the Fore people of Papua New Guinea (Zigas and
Gadjusek, 1957; Alpers, 1968), however, the neuropathology which has been
described for Kuru is markedly different from that seen in vCJD (McLean et. ah,
1998). This suggests that if vCJD is transmitted by the oral route that the strain of
agent being passed is different. Epidemiological studies of vCJD incidence indicate
the existence of a link between this disease and BSE. Of 28 confirmed cases of
vCJD only one has occurred outside of the UK (Delsys et. al., 1997). Recent studies
have all but confirmed that the strain of agent responsible for BSE in cattle is the
same strain that causes vCJD in humans (Bruce et. al., 1997; Hill et. al., 1997).
Kuru and vCJD are not the only examples of acquired TSEs in humans.
Iatrogenic infection with the TSE agent has been demonstrated. These cases are
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usually referred to as CJD although the cases arising from peripheral infection, such
as growth hormone injections, present with a clinical picture that is more similar to
Kuru than to sporadic CJD (Collinge and Palmer, 1997). Iatrogenic transmission of
CJD has occurred in a number of cases as the result of medical procedures. These
accidental infections have occurred by a number of routes (Brown et. al., 1992) and
include the use of inadequately decontaminated neurosurgical instruments (Bernoulli
et. al., 1977), dura mater and corneal grafts (Duffy et. al., 1974; Thadani et. al., 1988)
and the use of human cadaveric pituitary derived growth hormone (Koch et. al.,
1985). It appears that the route of infection affects the clinical syndrome.
Intracerebral (from neurosurgical instruments) and ocular (corneal grafts) inoculation
present as classical CJD whereas infection by a peripheral route, as in the growth
hormone cases, presents more like a kuru type infection with more severe lesions in
the cerebellum and basal ganglia (deVillemeur et. al., 1996; Weller et. al., 1986).
The three major factors that influence disease phenotype in experimental TSE
infections are agent strain, host genetics and route of infection. Recent evidence
suggests differences in the neuropathology of kuru and vCJD are more a function of
agent strain than of host genetics (McLean et. al., 1998). The work presented in this
thesis attempts to determine whether route of infection has an appreciable effect on
developing and eventual neuropathology when host genotype and agent strain are
kept constant.
1.6 Objectives of Study.
This body of work described in this thesis outlines an experiment to
test the hypothesis that the early stage pathology observed in the CNS of a constant
scrapie strain/mouse strain combination is influenced by the route of infection. This
involved the use of computerised image analysis techniques to map and measure the
major pathological features of TSE infection, vacuolation, GFAP accumulation and
PrP accumulation. The information gathered from this experiment will be used to
examine the kinetics of disease. In the case of this thesis the model of infection is
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C57BL mice infected with the ME7 strain of scrapie. Details of the system are
described below but it is broadly similar to the system in use at the National CJD
Surveillance Unit in Edinburgh (Sutherland et. al., 1996; MacDonald et. al., 1996).
The experiments were designed to make it possible to examine the pathogenesis of
the disease following parenteral and peripheral infection. Initially this was to involve
spinal cord pathogenesis, but due to unforeseen problems, as outlined in Chapters 3
and 4, was eventually restricted to the brain.
A further objective of this work was an attempt to determine whether or not
transportation of scrapie infectivity can occur in animals (mice) that do not possess a
functional copy of the PrP gene and subsequently cannot produce the PrP protein.
The approach adopted in this study is significantly different from that chosen by
previous groups (Brandner et. al., 1996b; Blattler et. al., 1997). Instead of working
with PrP null mice (Biieler et. al., 1992) grafted with neuroectoderm from tga20 (PrP
over-expressing) mice (Fischer et. al., 1996) the work described in this thesis relates
to a bioassay experiment using a different strain of PrP null mice (12901a mice with
a disrupted ability to produce PrP protein). These mice were generated in-house at
the Neuropathogenesis Unit (Manson et. al., 1994).
A final objective of this thesis is a qualitative comparison of the appearance
of vacuolar and PrP pathology in murine and human acquired TSE infection. This
was considered potentially interesting in light of the putative oral route of acquisition
for vCJD in humans. This study was intended to investigate the extent to which
pathology in human disease is influenced by route of acquisition by comparing the
pathological phenotypes seen in different types of human CJD with the animal model
of scrapie used elswhere in this thesis. Of course the route of infection is not the sole
influencing factor on the eventual pathological profile of a TSE infection, there are
other factors which are acknowledged as being very important but were not
considered in this attempted study. This highlights the major shortcoming of this
study and the susbsequent value of any observations is diminished as a result.
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Materials and Methods.
2. Materials and Methods.
2.1 Experimental mice.
All experimental animals were taken from the specified-pathogen free (SPF)
colony maintained at the Neuropathogenesis Unit. Further information regarding the
excluded pathogens is in Appendix I. Details of the mouse strains used are given
below. The generation of the particular PrP null mice used in this study is described
by Manson et. al. (1994).
Most of the experimental work was carried out on C57BL/FaBtDk (referred
to in the text as C57BL) mice. This was for two main reasons. Firstly, the
combination ofME7 scrapie and C57BL host has been well studied, especially in the
case of intracerebral infection; secondly, the number of C57BL mice that were
available was sufficiently high where those for other inbred mouse strains were not.
This allowed reliable sentinels to be included in the experimental group to indicate
effective transmission of disease at an early stage and calculation of infectivity titres
from a standard dose response curve (Appendix II). It was not possible to carry out
all of the experimental work in a single sex group ofmice. Although this would have
been preferable in terms of experimental control, it has been reported that the gender
effect that is often seen with some scrapie strain/host combinations (where the
incubation time for the disease is longer in females ), is not observed when ME7
scrapie is used (Outram, 1976). The other strains of mice used in this work were the
129/Ola mice (Hooper et al., 1987) and a genetically modified strain of 129 that has
an interrupted PrP gene which results in a complete loss ofmRNA production and
subsequent protein translation (Manson et al., 1994). These mice are referred to as
129 and PrPnull mice (or PrP_/") respectively. All these strains of mice carry the s7
allele of the gene Sine. This gene controls the length of the incubation period and has
two alleles, s7 or p7 (Dickinson et. al., 1968). The effects of the Sine gene are
described in Chapter 1.
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2.2 Mouse Husbandry.
Mice are kept in groups of not more than six. They are given food and water
ad libitum, drinking water is acidified to a pH in the range 2.3-3.0. Food pellets
(Teklad extruded lab diet, Harlan) are irradiated. All animal bedding (Illico gold
range, dust free) is autoclaved prior to use in the animal colony. The animals are
checked twice weekly at cleaning by experienced animal technicians for signs of
illness. In the period from 30 to 60 days before the predicted end-point of the disease
the mice are also scored once a week for clinical signs of disease. Mice in the animal
unit are maintained in a controlled environment. This is a 12-hour light/dark cycle.
Intensity of the light in the animal rooms varied from 50 to 200 lux (Foster et al.,
1986). Temperature in the animal colony is thermostatically controlled within the
range 19-23°C
2.3 Strains of Scrapie.
There are over twenty discrete strains of scrapie but for the work outlined in
this thesis only one, the ME7 strain, was used. The ME7 strain has been widely
studied and faithfully produces precise and regular incubation periods in all mouse
strains. ME7 was the strain used in the early scrapie genetic experiments when the
Sine gene was identified, and the s7 (shortening) or p7 (prolonged) refer to the
influence on the incubation ofME7 in certain strains of mice. ME7 was originally
isolated from the spleen of a Suffolk sheep affected with natural scrapie (Zlotnik and
Rennie, 1963). Passage into mice was via intragastric challenge of Moredun random
bred mice. The agent was then passaged intracerebrally (i.e.) once more into the




Inocula for use in oral, intramuscular and intraperitoneal infection were all
prepared using standard methods employed at the Neuropathogenesis unit. These
methods are unpublished but are described, briefly, below.
The sources of infectivity for most experimental murine scrapie work are the
brains of terminally infected mice. These are removed using aseptic techniques and
stored at -30°C until they are needed. Full and detailed records of the source and
destination of each tissue are maintained. When required tissues are thawed,
weighed and then transferred to a new, sterile Griffith tube. This is a glass tube with
a close fitting glass pestle for grinding. The tissues are homogenised in sterile saline
to give either a 1% or 10% wet weight concentration. All the inocula used in these
studies, with the exception of the bioassay material from the null mice (detailed
below) were prepared at the 1 % concentration. In some instances the resultant
homogenate is centrifuged to remove large particulate matter and the supernatant
used as the inoculum source. However, it has been shown previously at the
Neuropathogenesis Unit that this centrifugation can result in up to a 10-fold
reduction in the infectivity titre (Jan Fraser, personal communication). For this
reason the inocula for these experiments was used unspun and care was taken to
ensure that the maceration of the tissue was sufficient not to result in a suspension
containing large fragments of tissue. Care was taken at every stage of the preparation
to avoid cross-contamination of the inocula with other scrapie strains. Due to the
extreme resistance of certain strains to conventional sterilisation techniques all new
glass wear was autoclave sterilised before use and disposed of after a single use. All
inocula were prepared in a safety cabinet.
For the bioassay experiment the preparation of inocula was slightly different.
Bioassay can be defined as the inoculation of tissue from one animal into another in
order to determine the presence of infectivity. The tissues used as inocula for this
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experiment, optic nerve, superior colliculus and dorsal lateral geniculate nucleus
were taken serially, at six different time points, over a period of 117 days from both
129 and PrPnull mice. These mice had been infected with lpl of standard ME7
scrapie inoculum (prepared as described above) by the intraocular route. Injection
was into the right eye. Consequently when the tissues were harvested the optic nerve
from the right side was taken while the superior colliculus and dorsal lateral
geniculate nucleus was taken from the left side of the brain. This is due to the almost
complete crossover of nerve fibres at the optic chiasm (Sefton and Dreher, 1985).
Since the amount of tissue that can be harvested from the visual system of an
individual animal is very small it was necessary to pool the tissues from six animals
at each of the six time points to ensure sufficient inoculum for the bioassay
experiment. The concentration of these inocula (w\v) was calculated using figures for
the mean weight of 10 samples. The tissues were homogenised in 300pi of sterile
saline, the minimum volume that could be used to ensure sufficient inoculum to
inject a group of nine animals. Details of these weights and the inoculum
concentrations are given in table 2.
Tissue Mean Weight of 10
samples (mg)
Working Dilution
Optic Nerve 0.72 ± 0.044 1%
Superior Colliculus 5.62 + 0.33 10%
Dorsal Lateral Geniculate 22.45 ± 1.40 10%
Table 2: Standard weights and dilutions for assayed tissues (adapted from Jan Fraser, Ph.D. Thesis
1988).
When the tissues were harvested for assay, care was taken to sample
approximately equal quantities of tissue from each time point. Pools of tissue were
stored in sealed eppendorf tubes at -30°C until animals became available for assay.
These tissues were harvested using methods of sampling which were similar to those
used by Jan Fraser (Ph.D. Thesis, 1988) and are described in Fig 5. Optic nerves
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were cut at the chiasm prior to extraction of the globe from the orbit. The nerve was
then cut away from the caudal aspect of the globe.
Figure 5: The red regions denote superior colliculus (a) and dorsal lateral geniculate
nucleus (b). The heavy black lines illustrate the incisions that must be made in order to
harvest these tissues.
When required for injection the pools of tissue are removed from the freezer,
one at a time, and the frozen tissue is ground in situ using 300pl of saline and a
disposable sterile teflon Eppendorf grinder (Fisher Scientific). Because the agent
responsible for scrapie and the associated diseases has not been categorically isolated
bioassay is the only truly effective way ofmeasuring "the amount ofdisease causing
agent" - this is commonly referred to as infectivity. There is a demonstrable inverse
relationship between incubation period (the time from infection to death) and the
dilution/concentration (which controls the amount of infectivity) of the inoculum
(Eklund et. al., 1963; Kimberlin and Walker, 1979; Prusiner et. al., 1980).The
regular increase in incubation times with increasing dilution (reduced concentration)
of the inoculum forms the basis of an assay which is at least as accurate as quantal
endpoint titration in determining the amount of infectivity in an inoculum source
(Prusiner et. al., 1980).
By infecting groups of animals with inoculum of known
dilution/concentration (in the form of a serially diluted, titration experiment) and
measuring the respective incubation periods it has been possible to construct dose-
response curves for a series of agent-strain, mouse strain combinations. These
curves can be presented in the form, dilution of inoculum against incubation period.
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Alternatively the amount of infectivity in the infecting dose of inoculum can be
calculated by the method of Karber (Parker, 1959) and this can be plotted as the
number of infectious units against incubation period. By using these curves the
amount of infectivity in the inocula used in the bioassays described in this thesis can
be calculated (at least in terms of i.e. equivalent doses) without the need to perform a
full endpoint titration.
Since the purpose of the bioassay is to detect infectivity, and the quantities of
tissue being assayed were very small, none of the samples were centrifuged prior to
injection as this is known to reduce the infectivity titre, as previously mentioned.
2.5 Inoculation Procedure.
All of the animal work carried out in the course of this study was conducted
under the terms of a Home Office Licence and was subject to scrutiny by the in-
house ethical approval committee at the Neuropathogensis Unit.
The procedures used for different inoculation routes are described below:
2.5.1 Intracerebral (i.e.)
Intracerebral injections were given under halothane anaesthesia (fluothane).
Injection volume for the i.e. route was 20pl. The injections were given with a 27G
needle with a needle guard that prevents more than 2mm of the needle penetrating the
brain. This limits the injection site to the cerebral cortex, i.e. injections were made
to the right of the midline of the skull through the parietal bone. Some i.e. injections
were performed for me by Dawn Drummond, as I did not have the necessary
experience at the time when the animals were available. However by the time I was




Intraocular injections were performed under halothane anaesthesia, using a
combination of anaesthetic chamber and a mask to maintain anaesthesia whilst the
injection was being given. Injection was into the globe of the right eye. To achieve
this the globe was exposed by applying pressure above and below the orbit. A 27G
needle was used and the injection made at the scleral margin. The needle was
inserted until the tip could be seen through the lens, injection volume for these
experiments was 1 pi. In the event of a poor injection, usually the result of a mouse
"twitching" on the needle, the animal was replaced. On recovery from anaesthetic
the mice appeared normal and did not exhibit any ill effects. Ocular pressure in the
injected eye was low for at least the first 24 hours after injection; this was observed
when the first group of animals were sacrificed for bioassay tissue, but appeared to
have returned to normal at time points after this.
2.5.3 Intraperitoneal (i.p.)
Mice were injected by Dawn Drummond into the ventral abdominal cavity
using a 27G needle. Injection volume was 20pl.
2.5.4 Intramuscular (i.m.)
Under anaesthesia mice were injected in to the large muscle of the thigh, the
biceps femoralis, of the right leg. Injection was with a 27G needle and the injection
volume was 20pl. A needle guard was used for these injections to limit the depth of
penetration to 4mm, this was to prevent damage to the bones of the leg and helped
avoid damage to blood vessels in the leg. It was found that extending the leg slightly
made it easier to inject into the muscle and avoid scratching the bone. In order to
ensure consistent injection site, a group of test mice were injected with a small
amount of trypan blue immediately before being sacrificed by rapid cervical
dislocation, and the location of the dye in the muscle of the leg was noted. Only
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when consistency was achieved did the experimental animals receive their injections.
On recovery from anaesthesia the animals appeared to reluctant to place weight on
the injected limb but this behaviour disappeared after 1-2 days, otherwise the animals
showed no ill-effects.
2.5.5 Oral
Successful oral dosing was achieved by adsorption of the inoculum to food
pellets. lOOpl of inoculum was dropped onto a single food pellet. The mice were
then put into individual cages. Usual bedding was replaced with torn tissue paper
which made it easier to determine that the whole dosed pellet had been ingested and
not merely broken up and camouflaged by the standard bedding material. Water was
given ad libitum and food was withdrawn except for two mouse pellets, the dosed
one and an undosed one. The mice were observed until they had eaten both pellets,
in all cases within 48 hours of dosing, and then they were recaged in groups of six as
before with unrestricted food and water.
Previous attempts at oral dosing by dropping brain homogenate directly into
the open mouth of each mouse were felt to be too variable. In this case the intended
volume of inoculum to be administered was lOOpl. However, in many cases the
mice were uncooperative and best estimates are that on average between 60-70pl of
the inoculum were actually ingested. Because individual animals received different
amounts of inoculum it was decided that the value of information gathered from
these animals might be reduced. For this reason a second group of animals were
dosed via food pellets as described above, this gave more control of dosing. The
animals from the initial experiment were maintained until they succumbed to disease.
The incubation period data from this set of animals will be presented and discussed
later in this thesis.
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2.6 Harvest of Murine Tissues.
All of the animals used in the work described in this thesis were sacrificed in
a serial fashion. The method of sacrifice, number of animals per group and the
number and spacing of serial sacrifice time points in an experiment were determined
in order to best suit the needs of the given experiment.
In the case of the study of the effect that route of infection has on the
development of pathology in the murine CNS Following infection with the scrapie
agent groups of animals were selected at various times after infection and sacrificed
by carbon dioxide inhalation so that the brains and spinal cords might be removed
intact. In the case of the animals involved in the investigation of possible transport
of infectivity in PrP7" mice rapid cervical dislocation was the method of euthanasia
employed; in all cases euthanasia of animals was carried out in accordance with
home office regulations.
Serial sacrifice time points were selected to ensure that the best possible
chance of detecting early, middle and late pathological changes could be identified.
Although the numbers of mice employed for the route study were quite high the
necessity of harvesting tissues from each of the three groups (i.m. infected , i.p.
infected and orally infected) at a sufficient number of time points such that the entire
incubation period was covered, meant that the number of animals available for
sacrifice from any given group at any given time point was small; in this case each
serial sacrifice group consisted of four animals.
For this experiment animals were sacrificed at either six (i.m. and i.p.) or
seven (oral) time points. These time points were assigned arbitrarily by the author
and were selected with the intention that the last time point would coincide with the
terminal stage of the disease. In all cases the first serial kill was made at a time point
relating to a point approximately halfway through the expected incubation period.
Estimation of the incubation periods were made for the i.m. and oral route based on
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previous experiments conducted at the Neuropathogenesis Unit using similar, though
not the same, model systems. Following sacrifice of the animal the spinal column
and brain were removed and stored in 10% formal saline until processing. The
length of fixation was approximately one week for the brain and two weeks for the
spinal column.
In the case of the animals for the infectivity transport study animals were not
sacrificed by CO2 inhalation because the spinal cord was not required for this
experiment. In this experiment two parallel groups of PrP7" and PrP wild-type mice,
36 mice in each group, were infected intraocularly with ME7 scrapie. At each of six
time points six animals from each group were sacrificed and the brain and injected
eye removed. The superior colliculus and dorsal lateral geniculate nucleus from the
side of the brain contralateral to the injected eye, and the optic nerve attached to the
injected eye were dissected and used to produce inoculum for bioassay as detailed
above. The time points ranged from 24 hours post injection up to 72 days post
injection. This window was selected based on published information regarding the
movement of scrapie infectivity through the visual system ofC57BL mice that have
normal PrP expression (Scott and Fraser, 1987). A larger number of animals were
sacrificed at each timepoint than in the larger, route of infection, study in order to
produce sufficient tissue, especially optic nerve, for the subsequent inoculation into
the bioassay C57BL mice.
For the bioassay individual groups of nine C57BL mice were injected
intracerebrally with inoculum produced from pools of each of the tissues harvested at
each individual time point from either the PrP7" mice or the wild-type 129 mice.
Therefore for each serial sacrifice point 54 bioassay animals were injected. Unlike
the larger study into route of infection where tissues were harvested, processed and
analysed as they became available all of the tissues for bioassay were stored, frozen,
until the end of the serial sacrifice schedule and all the bioassay animals were
injecetd on the same day. Bioassay animals were monitored twice weekly for signs
of neurodegenerative disease.
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2.7 Determination of Incubation Period.
Incubation period is defined as the time elapsed, in days, between the day of
infection and the clinical end point of the disease (Dickinson et al., 1968). In the
case of the orally challenged mice the day of infection is taken to be the day of dosing
although it is acknowledged that the mice could take up to two days to consume the
full dose given (as mentioned above).
Infected mice are assessed by experienced animal technicians and each mouse
(as identified by ear-punch and experimental number) is given a rating of 'unaffected',
'possibly affected' or 'definitely affected'. Calculation of incubation period is
determined by the end-point which is defined in one of four ways: (1) end-point is
the day on which the mouse receives a third consecutive weekly 'definite' rating. (2)
The day on which a fourth 'definite' rating is given within five consecutive weeks.
(3) The day on which the animal is killed in extremis, or (4) the animal is found dead
in the cage having received a 'definite' rating at time of scoring in the previous week.
In Chapter 3, unless otherwise stated, the incubation periods referred to are means.
These are the mean incubation periods for a group of mice, (± the standard error of
that mean).
2.8 Histological Preparation.
Mice were generally sacrificed by carbon dioxide inhalation as this made
recovery of the whole spinal cord easier than if cervical dislocation was used. All
tissues taken for histological examination were immersion fixed in 10% formal saline
at room temperature prior to trimming and processing. In the case of brains and
spleens this was for between 24 and 48 hours. For spinal cords the initial fixation
was from 10 to 14 days. This was considered sufficient to ensure complete
penetration of the fixative through the bone of the spinal column.
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Fixed brains were trimmed sagittally, into two pieces. The bisection was
made just to the left ofmidline at a level corresponding to sagittal level 107 in
Sidmans mouse brain atlas (see figure 6 for line of incision). This ensured that it was
possible to retrieve the maximum sagittal area of the brain. If the brain had been
bisected along the midline then the areas exposed at the cut face would be lost when
the tissue was trimmed on the microtome prior to cutting of tissue sections for
immunocytochemistry and haematoxylin and eosin (H&E) staining. Saggital sections
were chosen for use so that mapping of the spread of pathology from the brainstem to
the forebrain could be conducted as far as possible given the limitations of an
investigation in a single planar section.
Figure 6. Illustrates the line of bisection made in the brain prior to processing and embedding. This
corresponds to level 107 Sidman's mouse brain atlas.
Spinal columns were removed after the brains although it should be noted that
all tissues were removed as soon after death as possible to minimise any autolytic
damage. Following euthanasia with CO2, the skin and muscle on the back of the
mouse's neck was pared back to expose the cisterna magna. Decapitation was
performed with scissors along the line of the cisterna magnum, this made it possible
to retrieve the cervical sections of the spinal cord. The spinal cord was fixed and
trimmed in situ within the spinal column. It is possible to remove the cord from the
column following fixation of the tissue; however, initial trials of this procedure
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determined that there was a likelihood of damage being caused to the cord in some
cases during removal. Following fixation of the spinal cord it was necessary to
decalcify the columns, this was done by incubating the column for 12 hours in Rapid
Decal solution. Following decalcification the columns were returned to fixative for a
further 24 hours before trimming and processing.
Each spinal cord was trimmed into nine transverse sections; 2 cervical, 4
thoracic and 3 lumbar. One side of each trimmed section of spinal cord was marked
with Indian ink to enable accurate orientation of the sections for embedding. The
spinal cord blocks were embedded with the rostral face down and marked on the
caudal face so as to ensure uniform orientation prior to immunohistochemical
staining..
Spleens were taken from some animals at a late stage in the disease
incubation time, these were also fixed in 10% formal saline solution. These spleens
were embedded whole with the exception of a small transverse section taken from
one end of the organ, the standard practice for routine embedding ofmouse spleens at
the Neuropathogenesis Unit.
All tissues were processed into paraffin wax. This was done on one of the
Neuropathogenesis' Units two processing centres, either a Shandon Hypercentre II
(Shandon) or the TP 1050 (Reichart Jung/Leica). Although the reagents used for
processing the tissues were the same as would be used for the routine work carried
out at the Neuropathogenesis Unit it was necessary to increase the time of the
processing in most cases (spleens could be processed using routine programs). This
is because the saggital sections chosen for this study are thicker than the coronal
sections used for routine diagnosis and study at the Neuropathogenesis Unit. This
routine sectioning is necessary so that lesion profiling/scoring may be carried out at
specific levels (as described in Chapter 1) however, this study is not concerned with
the production of classical lesion profiles. Instead the brains that were used in these
studies were cut on the sagittal plane for reasons described above. Trimming the
31
brain into five coronal pieces means that there is a quicker penetration of the
processing reagents through the tissue than occurs when there are two large pieces of
brain (the sagittal sections) as were used for this investigation, for this reason
processing times were increased. The spinal cord sections, although not especially
thick, take longer to process due to the presence of residual spinal column material.
The general program that was used for tissue processing is given below in Table 3;
the stages at which differences were necessary have been noted.
Reagent Time Temp/Pressure
10% Formal Saline 5 minutes Amb/Amb
70% Alcohol (Ethanol) 45 minutes Amb/P
80% Alcohol 45 minutes Amb/P
95% Alcohol 45 minutes Amb/P
99% Alcohol 45 minutes Amb/P
99% Alcohol 45 minutes Amb/P
Xyl/Abs 45 minutes Amb/P
Xyl/Abs 45 minutes2 Amb/P
Xylene 45 minutes Amb/P
Xylene 45 mmutes Amb/P
Paraffin Wax 25 minutes 62°C/Vac
Paraffin Wax 25 minutes3 62°C/Vac
Paraffin Wax 25 minutes3 62°C/Vac
Table 3: Tissue Embedding Program (Routine; suitable for coronal sections of brain and spleen)
Key. Xyl/Abs - Equal parts xylene and absolute alcohol; IThese steps take 50 minutes when
processing spinal cord and sagittal brain sections; 2These steps take 35 minutes when processing
spinal cord and sagittal brain sections; 3 These steps take 30 minutes when processing spinal cord and
sagittal brain sections; Amb - ambient temperature/pressure; P - processed under positive pressure;
Vac - processed under vacuum.
Once processed the tissues are embedded in paraffin wax into metal moulds
(Tissue Tek). The embedded tissues are then cut into 6pm thick sections on a
microtome. The cut sections are floated out on a water bath and picked up onto
electrostatically charged microscope slides (SuperFrost*/Plus, Menzel-Glaser).
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These slides were chosen in preference to conventional glass slides as the tissues
adhere more strongly to them, this makes them especially suitable for
immunocytochemistry. Seven serial sections were taken from each tissue. These
sections were numbered 1 - 7. Section number 1 from each tissue was stained with
H&E, automatically on a Jung Autostainer XL (Leica) with the other six sections
being set aside for immunocytochemistry.
2.9 Immunocytochemical Techniques.
Brain and spinal cord were immunostained using antibodies raised against the prion
protein (PrP) and glial fibrillary acidic protein. Spleens, when they were taken, were
immunostained using only anti-PrP antibodies.
The identity, specificity, source and working concentration of the primary antibodies
used are given in table 4
Antibody. Specificity. Source. Working
Dilution.
1A8 Rabbit Anti-PrP C.F. Farquhar (NPU)
(Farquhar et al., 1994)
1:1500





Table 4: Source and specificity of primary antibodies used in this project.
As mentioned above, the tissues were fixed in a solution of 10% formal
saline. The fixative works by denaturing and then cross-linking protein chains within
the tissue. Because of this mode of action it is a good fixative to use when
preservation of tissue morphology is a concern, as is the case in histopathological
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scoring. However, this type of fixation can in some cases reduce antigenicity of a
tissue by masking certain epitopes. This is the case with PrP immunostaining, and so
certain methods of antigen retrieval must be employed to ensure effective
immunostaining. To this end there are a variety ofmethods which can be used. In
the case of the work described in this thesis the tissues were autoclaved in distilled
water and then treated with formic (methanoic) acid (Haritani et. al., 1994). On the
basis of this work, autoclaving has now become a routine step in PrP immunostaining
at the Neuropathogenesis Unit.
These antigen retrieval steps are not necessary in the case ofGFAP
immunostaining, facilitating the automation of the process in these cases. A Cadenza
Automated Immunostainer (Shandon) was programmed to immunostain tissue
sections with antibodies against GFAP. This ensured consistency of immunostaining
and kept between run differences to a minimum. The Cadenza can be used for PrP
immunostaining but previous experience [of poor results] and a reluctance to expose
the machine to formic acid meant that all PrP immunostaining was done on the bench
following the protocol below. The protocol employed by the Cadenza is virtually
identical from step 5 onwards. Any differences are noted:
1). Sections are dewaxed and rehydrated through a series of alcohols into water.
(Xylene; 99% alcohol; 94% alcohol; 70% alcohol; Water)
2). Sections are autoclaved (Little Sister2 benchtop autoclave, SES) for 15
minutes at 121oC. Sections are cooled rapidly in buffer or more distilled
water.
3). Sections are incubated in 98% formic acid for 10 minutes, then washed in
distilled water.
4). Sections are incubated in 3% Hydrogen Peroxide/Methanol for a further 10
minutes. This step blocks the action of endogenous peroxidases.
34
5). Wash sections in buffer, 3x5 minutes. Buffer is PBS/BSA (5g BSA/2500ml
PBS).
6). Block sections with normal donkey serum (NDS) 1:20 for 30 minutes.
7). Apply primary antibody to sections at required working dilution (see table).
Incubate at room temperature overnight. (One hour on the Cadenza).
8). Wash sections in buffer, 3x5 minutes.
9). Incubate sections with secondary antibody, donkey anti-rabbit IgG for 1 hour.
Working dilution of secondary antibody is 1:40.
10). Wash sections in buffer, 3x5 minutes.
11). Incubate sections with rabbit PAP (peroxidase-anti-peroxidase) for 30
minutes. Working dilution of PAP is 1:100.
12). Wash sections in buffer, 3x5 minutes.
13). Incubate sections with chromagen, DAB (BDH, Poole, Dorset), for 6 minutes.
14). Wash sections in water; counterstain with haematoxylin (2 minutes); wash in
water; "Blue" sections in Scott's Tap Water solution; dehydrate, clear and
mount.
Step 14 cannot be performed by the Cadenza and must be done by hand.
When immunostaining spleens a different chromagen is used. DAB gives a brown
precipitate and this can be confused with haemosiderin, a brown pigment found in
the spleen derived from damaged blood cells. For this reason a red chromagen
(Vector Red, Vector Laboratories) is used when looking at spleen sections. This
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chromagen does not react with peroxidase enzymes and requires an alkaline
phosphatase molecule for the precipitate to form. It is therefore necessary to use a
secondary antibody that is conjugated to alkaline phosphatase. Alternatively it is
possible to take advantage of streptavidin's (or avidin) affinity for the vitamin
molecule biotin by using a biotinylated secondary antibody. This can then be linked
to a streptavidin-alkaline phosphatase conjugate before addition of the chromagen.
When using this system a Tris based buffer (TBS) is used instead ofPBS. This
prevents interference with the phosphatase reaction of the chromagen.
2.9.1 Immunohistochemical Controls.
Due to the long incubation period associated with TSE infections, which
accounts for the protracted nature of the experiments described in this thesis, and the
large number of tissue to be immunostained and examined it was not possible to
carry out all the immunostaining in a single run. For this reason certain controls had
to be put in place to ensure that the quality of immunostaining observed from one run
to the next was maintained.
Prior to the outset of the serial kill schedule for this project a mouse, from the
Neuropathogenesis Unit general use animal population and infected with the 87V
strain of scrapie was sacrificed and it's brain was taken. This mouse brain was
trimmed at four coronal levels as is the normal procedure at the Neuropathogenesis
Unit to produce the five standard brain segments mentioned above. This material
was processed and embedded in paraffin wax as described previously. 6pm sections
were cut from this block and these sections were then used as a source of positive
control material. By including sections from this single animal in all the susequent
immunohistochemical analyses of the experiemtnal tissues and comparing the
staining seen in the equivalent material used between runs it was possible to
determine that the staining seen in the experimental tissues was result of genuine
antibody/antigen interactions and not a consequence of non-specific reactions. The
use of this control material also served as a means ofmonitoring the between run
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quality of the immunostaining. In an attempt to minimise the variation of the quality
of staining between immunoruns as many variables as possible were controlled and
kept constant. Most significantly this meant that single batches of the primary and
secondary antibodies were used for all the immunohistochemistry. Other aspects of
the immunostaining that were fairly easily controlled were the chromagen and the
third stage, peroxidase-anti-peroxidase, reagents were also from a single batch or kit.
Despite these controls it is however, inevitable that there will be some variation in
the quality and intensity of the immunostaining seen between runs. The reasons for
this are unclear but may be influenced by factors such as the quality of the tissue
fixation or processing or the quality of the counterstain. These were outwith the
control of the author as the equipment used to fix and process the material and the
counterstain are communal resources that are heavily used and consequently the
reagents involved have to be changed regularly.
Because there was observed variation between immunoruns it was apparent
that some form of operator intervention would be required in order to produce the
most meaningful results from the image analysis system (described below). The
degree of inter run variation, whilst not suggestive of false results, was sufficient to
mean that a single set of parameters regarding the appearance of immunopositivity to
the computer system would not be adequate to carry out a full and detailed analysis.
The nature of this operator intervention is described below.
2.10 Image Analysis.
Within the bounds of this thesis image analysis can be defined as the
extraction of quantitative information from an image. In the terms of a conventional
computer system the image merely represents a set of data like a number set in a
statistical program. In this thesis the purpose of extracting the data is to allow for an
objective (or minimally subjective) and reproducible interpretation of the content of
an image.
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2.10.1 Elements of the system.
Image analysis systems comprise four general elements:
1. Image capture (Input)
2. Image storage
3. Image manipulation (Processing capability)
4. Image display (output)
A JVC KY-F55B 3-CCD (Charge Coupled Device) colour video camera,
with an RM-LP55U remote control unit, connected via a C-mount to a Nikon E400
light microscope,was used for the image input stage, this allows real time capture of
images. The captured image has to be converted from an analogue signal to a digital
one; this is done using a frame grabber, Snapper-24 (Active Imaging (UK) Ltd). It is
the frame grabber that produces an image that is suitable for analysis. This image
capture stage is also referred to as image acquisition.
2.10,2 Image manipulation.
A commercially available image analysis package, Image-Pro Plus v3.0
(Media Cybernetics, Maryland, USA), was used for all analyses. This is run under
WindowsNT Workstation 4 (Microsoft) on a Viglen Genie 2/266 PC (Viglen Ltd,
Middlesex) with 64Mb RAM and 4Gb SCSI hard disk. The PC also has a 2Mb
graphics card. This level of specification is sufficient for rapid analysis of images.
The capacity of the hard disk makes it possible to store images on the
computer. However, because storing colour images requires so much memory, in
practice images were stored on the hard disk for a short time whilst the analyses were
carried out. The images were then transferred to Zip Disk (Iomega) for long term
storage. Each Zip Disk can hold up to 70 full colour images and these form the basis
of an image archive.
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Images are displayed on a 17-inch Viglen Envy colour monitor. The images
captured by the camera and frame grabber are displayed at a resolution of 568 x 768
picture elements (Pixels) this is a suitable level of resolution for histological work
(Wootton, 1995).
2.10.3 Processing of Images.
A standard protocol was devised to ensure minimal variation between
samples. This standard analysis is described below.
Image capture has been described previously under the banner of image input.
Image preparation involved processes of background correction and conversion of
the colour image to a greyscale or black and white image. Processing of a black and
white image is quicker than in colour and background correction eliminates aberrant
illumination that may occur between sections although this should be minimal due to
a stabilised light source. In order to accurately assess the degree of vacuolar
pathology within a tissue section it is necessary to firstly define a vacuole in terms
that the computer can interpret. This enables the system to differentiate between
pathological vacuolation and non disease specific tissue cavitation which may occur
as a result of the collapse of blood vessels or general tissue damage that occurs as a
result of knife 'chatter' when sectioning. For the purposes of this study this meant
that the shape (roundness; determined by the ratio of the two longest perpindicular
diameters so that a perfect circle has a roundness value of 1), size (area) and
transparancy of a vacuole (a measurement of the amount of transmitted light that
passes through the section) had to be defined in such a way that these non-specific
tissue aberrations were not included in any measurements. The values for these
parameterswere determined with the assistance of experienced histopathology
technicians and a series of archive tissues that exhibited varying degrees of
vacuolation. When satsfactory identification of vacuolation could be assured the
experimental tissues were assessed for pathological damage.
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The experimental tissues were examined at nine distinct regions these were:-
1. Frontal cortex, 2.Caudate Putamen, 3. Hippocampus (especially CA4), 4.
Thalamus (including laterodorsal, angular, lateral posterior and anteroventral) nuclei,
5. Retrorubral fields, 6. Superior/inferior colliculi, 7. Parietal cortex, 8. Parvocellular
reticular nucleus/motor trigeminal nucleus and 9. Interposed cerbellar nuclei. These
regions were chosen because they represent the whole of the sagittal plane from the
region of the olfactory system to the brainstem area thus providing a complete,
though planar, series of results. It is extremely important that the nature of the
measurements being made is understood.
For the quantitative analysis of vacuolation and PrP and GFAP accumulation
what is actually being measured is the area of a given region of the brain that is
occupied by the lesion or by the marker. Because the measurement is of an area
within an area; it is critical that all the measurements are done at a single
magnification or the parameters defining pathology are re-calibrated for each
different magnification used in the study. Calibration of the image analysis system is
done with an internal 'line-measure' tool which is a feature of the software and a
microscopic scale. To calibrate the system for distance, and consequently area, a line
of known length is drawn between two points and the details of the line are stored by
the computer. This provides the computer with the necessary reference measurement
to calculate areas in the experimental sections. As mentioned above, calibration must
be carried out for each different power ofmagnification that is to be used.
Having determined the parameters for a vacuole and decided upon the areas
that are to be examined the actual measurements were made by capturing an image of
the brain area of interest and using a series of operations to optimise the image and
extract the information that is of interest to this study. In order to ensure uniform
treatment of the sections during the count a macro, a short program containing a set
of instructions that can be carried out automatically, was written. This overcame
potential problems that may have otherwise arisen on account of the analyses being
performed over a period ofweeks and not all at the same time.
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The instructions contained in the macro were designed to make the analysis as
quick and as constant as possible. However, the macro could not locate the initial
area of interest on a tissue section, this required operator input. Having located the
area of interest and acquired the image the macro instructs the computer to convert
the image from full colour into a greyscale. The net result of this conversion is a
black and white version of the initial image which is approximately one-third of the
size (in terms of computer file size, not physical size) of the starting image. This
makes the image easier to work with and subsequently the analyses proceed more
quickly.
The next step of the analysis is the application of visual filters, in this case the
images are sharpened to enhance the edges of the vacuoles. This edge enhancement
is achieved by the application of the paradoxically named 'unsharpen' filter. This
filter, and others, are features of the image analysis software. They work by
performing complex calculations based on the grayscale value of any given pixel and
the values of those immediately surrounding it further details of filter function can be
found in the manual accompanying the image analysis software.
Having sharpened the image the macro then uses the predetermined
parameters to threshold the image, that is identify regions of the image that are
occupied by vacuolation, and isolate them from the surrounding tissue. The system
then measures the area of each of these vacuoles and displays the cumulative total of
these areas. This operation is performed for each of the tissues harvested from each
serial kill timepoint and a mean value and standard error are calculated.
In the case of the immunostained slides, those for GFAP and PrP analyses, it
became apparent that differences in staining quality that occur between runs and the
types of staining that are produced meant that a single set of instructions such as
those contained in a macro were not going to be sufficient to perform an accurate
analysis. Consequently it was decided that it was necessary to manually threshold
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each image in order to extract the maximum information from each section. This
operation was carried out on colour images, not grayscale, and the immunostained
product was isolated from the image background by using a pixel selection tool that
is a feature of the image analysis software. This tool allows the operator to select a
pixel which corresponds to an area of positive immunostaining, the computer will
determine the value of this pixel and isolate all of the other pixels of that value in the
image. In this way it is possible to separate the pixels that represent the chromagen
from the rest of the image. The area occupied by the immunostaining is then
determined by summing the areas of the individual pixels. As in the case of the
vacuolation assessment this operation is performed on equivalent sections from the
other animals sacrificed at the same timepoint and a mean value and standard errors
are calculated for each of the nine brain regions in the study.
Although this manual thresholding of the immunostained sections is
acknowledged as a source of bias and error the fact that all the thresholding
operations were carried out by a single operator ensures that the bias across the range
of sections is uniform and therefore does not affect the overall result.
The standard analysis protocol can be divided into four principal steps, as
summarised in Table 5.
Step Operation Considerations Tools Employed












4 Measurements Defined area of Interest AOI tool. Measure tool
Table 5. Outlines the principal steps involved in semi-quantitative image analysis and details some of
the procedures employed.
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2.10.4 Validation Image Analysis System.
In order to qualify the use of a computerised system of pathological
measurement it was necessary to assess its accuracy when compared to experienced
histopathology screeners. As described above, routine scrapie histopathology is
scored on a scale of 0-5 depending on the severity of the lesion. The method of
validating the computerised system is detailed in Chapter 2. Briefly, a series of
pathological specimens, representing all categories of severity, were captured and
transformed into digital (computerised) images. These images were then scored from
0-5 by three independent screeners. The averages were calculated and assigned to the
respective image. The degree of vacuolation was then measured in each of the
images using the system and macro outlined above. The extent of vacuolation in
each section was measure as an area (pm2). These measurements were then assigned
a score of between 0-5 depending on the assessment of the screener. An average area
of vacuolation for each score was calculated and a graph of 'average area of
vacuolation' against 'pathological score' was plotted in order to demonstrate how
well the computerised system could differentiate between different degrees of
pathology.
2.11 Kinetics of Pathology.
In an attempt to make a meaningful comparison between the different
experimental groups a method of examining the way in which the pathology in a
given region changes with time was developed. In order to do this a way of
standardising the non-uniform incubation periods had to be devised. This was done
by converting the incubation period in to a linear scale of 100 divisions for each
model. The day of injection is day zero (0) and the terminal stage is 100. In this way
percentages of incubation periods and the amount of pathology present at the times
relating to those percentages can be directly compared. Three regions were chosen
for this examination, the thalamus, the hippocampus and the frontal cortex and
'kinetic curves' for each region were constructed.
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2.12 Comparison with Human Tissue.
In conjunction with the National CJD Surveillance Unit it has been possible
to study examples of sporadic, iatrogenic (as a result of growth hormone therapy) and
new variant CJD. A qualitative study of similarities and differences in the patterns of
lesion distribution and type of lesion (especially in the case of PrP deposits) that are
seen in these different human diseases and the animal models under investigation
was carried out. The human tissues were obtained from the National CJD
Surveillance Unit in Edinburgh where the sections are routinely stained with





The results of this work are presented in such a way as to make comparisons
between different routes of infection more straightforward. For this reason each of the
three pathological markers of TSE infection that are under investigation (vacuolation,
PrP accumulation and GFAP accumulation) will be dealt with individually. The
significance of the results and the profiles they form as a whole will be discussed in
Chapter 4. Unfortunately no valuable information could be extracted from the spinal
cords of these animals. Because the cords were fixed, processed in situ (that is still
enclosed in the spinal column) it was necessary to decalcify in order to make the
sectioning easier. It appears that the decalcification agent used damaged the tissue as
well as demineralising the bony column. The result was that all the spinal cord
sections exhibited high levels of background making the detection of PrP by
immunohistochemistry impossible. This was unfortunate and with hindsight it is
now apparent that removal of the cord from the column, prior to processing, thus
negating the need for decalcification, would have been a better course of action.
3.1 Examination of the Role of Route of Infection on Disease Pathogenesis.
3.1.1 Incubation Periods.
The main purpose of the work described in this thesis was to determine the
influence that route of infection has on the eventual disease phenotype. For the
purposes of presenting the data generated by these experiments, phenotype can be
described as the combination of incubation period, degree of vacuolar degeneration,
hypertrophy/hyperplasia of astrocytes (as indicated by increased GFAP production)
and accumulation of the PrP protein. These four indices of pathogenesis and
pathology will be considered below. Each of the four markers will be presented
separately so that any route dependant differences can be more readily determined.
The results from each section will be combined to provide a more complete picture.
This will be discussed in Chapter 4.
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The simplest of these indices to measure is the incubation period. In Table 6
the incubation periods for each of the chosen routes of infection are given. These are
expressed as 'Mean ± Standard Error' number of days. The number of animals in
each group that the means are calculated from is also given.





Intracerebral (i.e.) 160±2 10/10 bo<N
Intraperitoneal (i.p.) 251±9 13/13 20/10"2
Intramuscular (i.m.) 238±10 10/10 20/10"2
Oral 307±2 15/15 100/10"2
Table 6 : Incubation period data from experiment 531B-1C
The animals used in this study were C57BL mice there were approximately equal numbers ofmale and
female mice.
Of particular interest in this case is the very small standard error associated
with the incubation period of those animals which were infected by the oral route.
This is especially interesting when considered next to the data from the
intraperitoneally infected series. The data from these experiments suggests that the
oral route of infection is potentially as efficient at establishing disease as the other
routes under investigation and may provide a more 'natural' model for examining
acquired disease in cattle and humans. This is discussed in further detail in Chapter 4.
Prior to the experiment described above, a similar project was undertaken
using SV mice. This experiment had to be disregarded at the time due to fears of
accidental contamination of the animals with the 301V (mouse-passaged BSE) strain
of scrapie. The possibility of a contaminating event came to light when two of the
animals in the experimental group developed signs of neurological illness shortly,
within 21 days, of being injected with ME7 scrapie. The histopathology on the brains
of these animals showed signs of TSE infection and the distribution of lesions
indicated that the infecting strain was 301V. It appears that an error in the animal unit
led to the introduction of previously infected animals into the population that was
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used in this study. Because of this error there was no way to be sure that some or all
of the other animals might also have been infected with 301V. Therefore, it was felt
that the result of this study may be compromised and the experiment should be
restarted with a population of animals that could not have been accidentally infected.
The remaining animals in the original experimental group were allowed to develop
disease and progress to the terminal stages without any serial culling for tissues. Post¬
mortem examination of the brains from these animals, including lesion profiling,
determined that there had been no contamination and that the animals had succumbed
to ME7 scrapie and not 301V. Although this experiment was not valuable in terms of
a complete pathogenesis study, the incubation period data gained from it support the
contention that the oral route of infection is more efficient than was once thought and
may be worth considering as a routine method of establishing a 'natural-experimental'
disease. The incubation period data from that experiment, designated 53IB-IB are
shown in Table 7.





Intracerebral (i.e.) 213±21 4/4 20/10"2
Intraperitoneal (i.p.) 287±4 42/42 to o o
to
Intramuscular (i.m.) 245±6 37/37 20/10"2
Oral 312±9 36/36 <Nooo
Table 7: Incubation period data from experiment 531B-1B
The animals used in this experiment were SV mice. These have the same Sine genotype (s7) as the
C57BL mice used in experiment 531B-1C.
A number of intercurrent deaths in the intracerebral group has restricted the
population size and possibly skewed the statistic. It is interesting that that the Oral
incubation period does not differ greatly between the two experiments as in
experiment 53IB-IB the orally challenged mice were dosed with a chilled brain
homogenate which was dropped from a syringe into their mouths. This is in contrast
to experiment 531B-1C where the mice were dosed with inoculum that had been
absorbed onto the surface of a standard mouse food pellet. In the case of experiment
53 IB-IB it was not possible to ensure that each animals received an identical dose of
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scrapie infectivity, this was due to some animals refusing to drink the full amount
(lOOpl) of inoculum. The implications of this will be discussed later.
3.1.2 Sequence of Appearance of Pathological Markers.
It has been shown that the terminal stage signature of pathological lesions for a
given agent/rodent strain model is effectively preserved upon passage to mice of the
same strain as long as the route of infection is kept constant. It is therefore possible to
determine the strain of agent if the strain ofmouse infected and the route of infection
are known it is worth noting that generally this type of analysis is done in mice
infected by the intracerebral (i.e.) route.
One of the noted features of the lesion profile system is that the signature
profile is only found at times close to the clinical phase of the infection. Before this
time the dynamics of vacuolar degeneration are different in different parts of the brain.
This may be a result of the length of time that the lesion has to develop prior to onset
of the clinical phase. This in turn is a function of the distribution of infectivity which
can be affected by the route of infection (Cole and Kimberlin, 1984).
What is often evident where different routes of infection are employed to
infect a uniform strain ofmouse with a uniform strain of scrapie are differences in the
height and shape of the lesion profiles. For example, a given strain ofmouse that is
infected by the i.e. route exhibits more pronounced pathology than a mouse that is
infected by the i.p. route. Furthermore the profile of the pathological lesion in the i.e.
infected animal is stable from approximately halfway through the incubation period
(Fraser and Dickinson, 1968) with no significant changes in the shape of the profile
between that point and the clinical phase. This is thought to be due to the extended
duration of agent replication in the brain (as a result of direct injection) and the
consequent widespread infectivity. In an i.p. system the lesion profile will be
different to the i.e. profile and will be dynamic for longer as the infectivity spreads. In
these cases the shapes of the terminal lesion profiles are generally similar but the
preterminal profiles are not. It was the intention of this project to examine these
48
preterminal events in order to determine the extent that the route of infection can
influence the early pathological events.
It was thought that these route dependant differences would be most apparent
early in the incubation period of the disease, therefore, with the aim of identifying any
route-dependant early pathological changes, a sequential identification and mapping
of PrP deposition and GFAP upregulation was undertaken. These two markers were
used as they traditionally appear prior to the first vacuolar changes (at least in the
case ofME7 scrapie), and there are good immunohistochemical protocols in place to
specifically identify them.
Table 8 below shows when the first detection of these markers was made for
each of the routes under investigation and how this timepoint related to the eventual
incubation period for that particular model.
Route of
Infection First PrP(dpi) % incubation First GFAP(dpi) % incubation
intramuscular 140 58 166 70
intraperitoneal 140 56 140 56
oral 221 72 221 72
Table 8: Details of when the first pathological markers (PrP and GFAP) can be detected following
peripheral infection with ME7 scrapie. Information displayed as time post injection and percentage of
total incubation period. Percentages based on incubation periods displayed in table 6 above.
Figures 10-15 below illustrate the sequential appearance of PrP and GFAP in
each of these cases. These figures are representations of the appearance and
subsequent accumulation of PrP and GFAP in the CNS following experimental
infection. Lists of brain areas affected are given in Appendix III. Although these
maps are accurate, based on experimental observations, due to the constraints of the
experimental design they cannot be assumed to be totally comprehensive. There is no
doubt that other nuclei in the brain are affected. However, constraints of time did not
allow for a more detailed investigation of the whole of the central nervous system. It
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Figure lO(a-f): Sequential deposition ofPrP in
the brains ofmice infected by the i .p. route.
(a) 140 days post injection (dpi)
(b) 166 dpi; (c) 189 dpi; (d) 221 dpi
(e) 231 dpi; (f) 246 dpi.
Figure ll(a-f): Sequential deposition ofGFAP
in the brains ofmice infected by the i .p. route.
(a) 140 days post injection (dpi)
(b) 166 dpi; (c) 189 dpi; (d) 221 dpi
(e) 231 dpi; (f) 246 dpi.
Figure 12 (a-f): Sequential deposition ofPrP in
the brains ofmice infected by the i.m. route.
(a) 140 days post injection (dpi)
(b) 166 dpi; (c) 189 dpi; (d) 221 dpi
(e) 231 dpi; (f) 250 dpi.
Figure 13(a-e): Sequential deposition ofGFAP
in the brains ofmice infected by the i.m. route.
(a) 166 days post injection (dpi)
(b) 189 dpi; (e) 221 dpi; (d) 231 dpi
(e) 250 dpi.
(a) (b)
Figure 14 (a-d): Sequential deposition ofPrP in
the brains ofmice infected by the oral route.
(a) 221 days post injection (dpi)
(b) 250 dpi; (c) 279 dpi; (d) 302 dpi/terminal
stage.
Figure 15 (a-d): Sequential deposition ofGFAP
in the brains ofmice infected by the oral route.
(a) 221 days post injection (dpi)
(b) 250 dpi; (c) 279 dpi; (d) 302 dpi/terminal
stage.
is assumed that the results and trends observed in the regions of the brain that were
examined can be broadly applied to the CNS as a whole.
3.1.3 Assessment and Comparison ofVacuolar
Pathology using Computerised Image Analysis.
In an attempt to identify specific pathological differences between
experimental groups that could be attributed to route of infection, computerised
image analysis was employed to measure the amount of 'pathology' in nine
predetermined areas of the mouse brain. Details of the procedure employed to make
these measurements can be found in Chapter 2. The results for each experimental
group could then be compared and any route specific differences isolated. Figure 16
shows that the system can be used to detect varying degrees of vacuolar pathology in
the validation images and that these differences correspond with the pathological




















Figure 16: Demonstration that computerised image analysis can clearly differentiate between different
severity's ofvacuolar pathology.
The graph illustrates clearly the ability of the computerised image analysis
system to differentiate between differing severity ofvacuolar pathology. There no
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Figure 20.
Figures 17-20. These figures illustrate the capacity of the computerised image analysis system to
recognise and measure markers of pathology in scrapie infected mouse brains. Figures 17 and 18
show how vacuolation in the neuropil is detected. Figure 17 is a brain section before the image
analysis system is employed. Figure 18 shows the detection of vacuolation in the same section by
overlaying the image with black. Arrow heads indicate the same vacuole in both sections. (xlOO
magnification). Figures 19 and 20 show the system being used to measure immunohistochemical
product in a section stained for reactive astrocytes. Arrow heads indicate the same astrocyte in both
figures. This method of detecting immunohistochemical product can also be used to measure PrP in
scrapie infected brains. (x200 magnification).
almost inconsequential as a score of 1 is not considered sufficient to deliver a
diagnosis of scrapie.
Figures 17-20 illustrate the type of result that the image analysis system
produces. They also serve to illustrate that the system does not count non-scrapie
associated spaces in the tissue such as blood vessels.
Having determined that the computerised image analysis system was able to
differentiate the recognised degrees of vacuolar pathology, at least to the same degree
as the three histological screeners who also scored the images, tissues from the
experimental animals were examined.
Using the computerised system vacuolar pathology was assessed in the nine
brain areas mentioned in Chapter 2.
3.1.3.1 Establishing a Baseline for Quantifying Vacuolation.
The first group of brains that were examined were from the control animals.
These animals were injected i.e. with a preparation of non-infected brain and
consequently do not develop scrapie. Quantifying the amount of 'vacuolation' in
these brains provides a baseline with which to compare infected animals. In the case
of these uninfected animals 'vacuolation' is used to describe the spaces in the tissue
that can occur naturally, as a result of ageing, or as artefact, for example cracking of
the tissue due to knife 'chatter'. It does not specifically denote disease associated
degradation of the neuropil.
Groups of three animals were sacrificed at each of four timepoints. The
timepoints were selected to cover the expected incubation periods of all the infected
groups and are consequently relatively widely spaced.
Figure 21 shows the degree of tissue damage in each of the nine predetermined
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Figure 21: Shows the degree of non-specific 'vacuolation', or microcavitation, in the brain of
uninfected animals. This does not change significantly during the course of these experiments.
As can be seen for the graph the amount of vacuolar-type microcavitation in
an uninfected brain varies very little with time. The graphs are reasonably flat
although there is some variation between brain regions. In particular region 2 and 9
show relatively high amounts of vacuolation This can be explained in terms of the
amount ofwhite matter in each of these regions. Region 2 corresponds to the caudate
putamen and region 9 to the white matter of the cerebellum. Both of these regions as
well as region 8, the brainstem, have a naturally vacuolar appearance on account of
the high levels ofwhite matter tracts and fibre bundles in these regions . This is not a
disease associated feature and as such illustrates one of the limitations of the
experimental design.
The graph shows that at 166 days post-injection there is significantly more
vacuolation in certain regions than at any of the other timepoints. This is probably a
reflection of the small numbers of animals involved it does not represent a real
phenomenon. Occasionally one animal in a serial kill group will exhibit abnormally
high level of pathology compared to its group mates and this will greatly influence the
mean value obtained for that serial kill group. A table containing the actual
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measurements of tissue damage in the brains of the control animals can be found in
Appendix IV.
3.1.3.2 Vacuolation in Brains ofOrally Infected Mice.
Groups of four orally infected animals were sacrificed at each of seven
timepoints and the brains were taken for examination. Each brain was fixed and
processed as described in Chapter 2. Figure 22 shows the mean area of vacuolation in
each of the nine brain areas at each of the seven timepoints. The seven timepoints


























Figure 22: Shows the levels ofvacuolation observed in the brain of orally infected animals throughout
the incubation period.
As can be seen from the graph at each of the first four timepoints (140 days
post injection - 250 days post injection) there is a considerable degree of similarity in
the shape and height of the traces. This is especially apparent in areas 1,3,4 and 7
(frontal cortex, hippocampus, thalamus and parietal cortex respectively). This could
be interpreted as a form of lag phase in the development of the disease. This will be
discussed in Chapter 4.
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Other findings are the overlapping standard errors and the fact that for the
most part the most severe vacuolation is detected at 306 days post injection. Indeed
with the exception of the thalamus and the superior colliculus every other region of
the brain that was examined returned a more severe assessment of vacuolar pathology
at 306 dpi. than at 320 dpi, there is however the caveat that the differences were not
significant except in the case of area 3 (the hippocampus). Indeed at 306 dpi the
degree of vacuolation is markedly higher than at 279 dpi in all the brain areas
examined with the exception of the superior colliculus (area 6). Whether or not this is
an actual result or a consequence of the small sample size, and therefore the
experimental design., is unclear.
A further feature is the very high degree of vacuolation that was detected in
area 2 (the Caudate Putamen) at 221 dpi. There is a similar, though not as
pronounced, result at 250 dpi. The caudate is rich in white matter and it is
conceivable that this can produce falsely elevated results. Another explanation might
be the small sample size which has the effect of magnifying the importance of one
unusually high result.
3.1.3.3 Vacuolation in the Brains of Mice Infected by the Intramuscular Route
Figure 23 shows the degree of vacuolation in each of the nine pre-selected
brain areas during the course of infection. As can be seen from the traces on the
graph, following intramuscular infection there is what could be considered a broadly
linear increase in vacuolation levels at each of the brain areas examined. There is very
little difference in the levels of detectable vacuolation between 140 dpi and 166 dpi

























Figure 23: Illustrates the level ofvacuolation throughout the brains of animals infected by the i.m.
route.
In comparison with the result from the orally infected animals the severity of
vacuolation (as evidenced by the height of the trace) does not appear to be as great in
the mice infected intramuscularly. Furthermore, with the exception of the result
relating to the thalamus at 279 dpi, the results from the intramuscular study indicate
an qlmosjuniform development of vacuolation . The evidence for this is in the
broadly similar shapes of each trace and the way in which they more or less fit on top
of each other. This is borne out by the results for PrP and GFAP accumulation
following intramuscular challenge which are presented below. This tendency towards
regularity between traces is not apparent, at least certainly not to the same degree, in
either the orally or intraperitoneally infected mice. This poses questions about
differences in peripheral processing of infectivity following route specific challenge
with the scrapie agent, this is a point which will be addressed in Chapter 4.
One result which cannot be readily explained is that the degree of pathology
(vacuolation, PrP accumulation and GFAP accumulation) at 231 dpi is less (with one
exception, the GFAP levels in the superior colliculus) throughout the brain than at the
previous timepoint, 221 dpi (189 dpi in the case ofGFAP) This is apparently the case
for all three markers of disease that have been examined in the course of this work.
Again this observation will be discussed further in Chapter 4.
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3.1.3.4 Vacuolation in the Brains ofMice Infected by the Intraperitoneal Route.
Figure 24 shows the progressive development of vacuolation in mouse brains
following intraperitoneal infection with the ME7 strain of scrapie.
As can be seen from the traces early in relating to the earlier part of the incubation
period there is generally little real difference in the height and shape of the graph (and
by consequence the severity and distribution of vacuolar pathology) and certainly
there is no evidence of any statistically significant differences. This is similar to what
is seen in the vacuolar profile of the mice infected orally and could also represent a
lag-phase of infection.
As can be seen from the graph the traces relating to the two latest time points
are very similar. This is not unexpected as the two traces in question represent a
period of only four days. However, the fact that there are differences is interesting,
and probably the result of variables in sampling and incubation period range. The
especially interesting feature of this result is the way than the trace relating to 231 dpi
is very much higher than the trace relating to the terminal stage of the infection in
certain areas of the brain. This is not a phenomenon observed in either PrP or GFAP
accumulation (See figures 27 and 31 below). This will be discussed in Chapter 4.
Also, on the whole, the level of vacuolation in the brain following intraperitoneal
infection is less than is observed following oral infection. This is a similar trend to



























Figure 24: Illustrates the level of vacuolation following i.p. infection.
3.1.4 Comparison of PrP Accumulation
Identification of Route Specific Differences.
Measurement of the amount of PrP in each of the brain sections studied was
performed using a similar approach as that employed for assessment of vacuolation.
There was however one significant difference in the protocols employed. Whereas
the parameters defining a vacuole (in terms of its' size and shape) were constant, and
consequently amenable to automation, the definition of positive immunostaining is
not as straightforward. For each section that was assessed, individual thresholds had
to be set. These thresholds varied between areas within a section as well as between
sections and as such are recognised as a source of potential experimental errors.
However, it was considered that this method enabled more information to be
extracted from each section than if a constant, but subsequently low, threshold had
been set. There was no detectable level ofPrP in the brains ofmice that had been
injected with non-infective material.
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3.1.4.1 PrP in the Brains ofOrally Infected Mice
Figure 25 illustrates the temporal and spatial accumulation ofPrP in the brains
ofmice infected orally with ME7 scrapie at each of five timepoints spanning
approximately the final 100 days of the incubation period. At timepoints prior to





















Figure 25: Progressive PrP accumulation throughout the brain following oral infection.
From this figure it can be seen that there is a progressive increase in the
amount ofPrP that accumulates in the brain and that certain areas of the brain are
more susceptible to PrP accumulation than others. In particular the thalamus, area 4,
displays not only a very high level ofPrP at the terminal stage of the disease (when
compared to the other routes of infection that were investigated) but also
demonstrates a much quicker accumulation of the protein - when compared to the
other brain regions studied - as indicated by the steepness of the trace.
The level ofPrP seen in the hippocampus (area 3) at 306 dpi is elevated over
the level seen at the terminal stage, 320 dpi. This is not in keeping with the general
trends that can be extracted from the result. As mentioned above there was no
detectable PrP prior to 221 dpi. However between 221 dpi and 250 dpi there is very
little difference in the measurable amounts of the protein that are present in any of the
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brain areas. At 279 dpi there is a marked increase and this represents the start of a
significant build up ofPrP in the brain. The pattern of deposition of the protein (as
shown by the overall shape of each trace) is similar over the final three timepoints.
This is suggestive of a steady increase in protein deposition over these brain areas.
3.1.4.2 PrP in the Brains of Mice Infected by the Intramuscular Route.
Figure 26 shows the result of the measurement ofPrP levels in the brains of























Figure 26: Progressive PrP accumulation in the brains of animals infected by the i.m. route.
This clearly illustrates that the maximum amount ofPrP detectable in these
brains is in the thalamus (area 4). This is the same as was seen in the brains of the
orally infected animals. However, the actual amount ofPrP that could be measured in
these animals was approximately half the amount that was detected in the orally
challenged mice.
For the most part the PrP detected in these brains follows a pattern where the
levels in a given area relative to any other area follow a similar trend. The exceptions
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to this are i) areas 7, 8 and 9 where at 189 dpi the level of detectable protein does not
follow this trend and ii) The level ofPrP that can be detected at 189 dpi throughout
the brain is higher than at any other point during the incubation period. This result is
illustrated below and appears to be real. Possible reasons for this will be discussed in
Chapter 4.
3.1.4.3 PrP in the Brains of Mice infected by the Intraperitoneal Route.
The intraperitoneal route of infection has been widely used to establish
disease in experimental animals, especially when questions regarding peripheral
processing of infectivity have been asked. Figure 27 shows the progressive deposition
of PrP in the CNS following intraperitoneal challenge.
The figure clearly shows that the progressive deposition of the pathognomonic
protein is not as irregular as is the case following oral challenge. This figure also
highlights the differences that are seen in the actual detectable amounts of protein
between the three routes examined. Following intramuscular or intraperitoneal
infection the peak amount of detectable PrP occupies an area of approximately
40,000pm2. Following oral challenge the peak amount ofPrP that can be measured
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occupies an area of nearly 80,000|im2. In all three cases these peak measurements
relate to the amounts ofPrP found in the thalamus (area 4).
As with the previous results there appears to be a lag phase in the deposition of
the protein. This is indicated by the low levels ofPrP detected throughout the brain
during the early stages of the investigation and by the roughly similar pattern of
deposition that is seen. For the most part, the detectable levels ofPrP in the brain are
virtually the same until 231 dpi. At this time there is a noticeable increase in the
hippocampus and in the thalamus (areas 3 and 4 respectively). There is also an
observed increase at 189 dpi in the thalamus. The reason for this is not clear although
the small numbers of experimental subjects are likely to produce some unusual
results.
By far the most significant increase that is seen in these cases is in the
thalamus between 231 dpi and the terminal stages of the disease at 246/250 dpi. Over
this period a large increase is observed in the thalamus. There are also less striking
increases in the hippocampus, superior colliculus (area 6), brainstem (area 8) and the
cerebellum (area 9). The differences seen in the frontal cortex (area 1) between 246
dpi and 250 dpi are thought to be a function of the small sample size. These unusual
results that have been attributed to the small sample size illustrate one of the
shortcomings of the experimental design and the difficulty of carrying out a large
study of this type.
3.1.5 Comparison of GFAP Accumulation:
Identification of Route Specific Differences.
The degree of astrocytosis in the CNS of animals infected with scrapie, or any
of the related TSEs, is indicated by the amount ofGFAP produced by the astrocyte
population. However, not all astrocytes that produce GFAP are activated as a result of
scrapie infection.
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3.1.5.1 GFAP in the Brains ofNon-Infected Mice.
There is a detectable , though comparatively low, level ofGFAP throughout
the brain. This is not associated with reactive astrocytes such as those seen in TSE
infections. Consequently this protein is not an index of pathology. However because
the methods used to detect and measure GFAP in the brains of diseased animals will
also detect GFAP produced by non-reactive astrocytes it was necessary to establish a



















Figure 28: Shows the levels ofGFAP that can be observed in the uninfected brain. This signifies the
resting state for astrocytes.
Figure 28 shows the levels of GFAP that can be detected in non-infected,
normal, mouse brains. As can be seen from the figure the levels are virtually constant
within a given area of the brain over a period of 166 days. There are two small peaks
, one in the caudate (area 2) and the other in the cerebellum (area 9), but these do not
represent any statistically significant differences in the levels ofGFAP at any
particular timepoint in any particular region of the brain. This clearly illustrates that
the level of GFAP normally found in the brain is very low when compared to the






3.1.5.2 GFAP in the Brains ofOrally Infected Mice.
Figure 29 illustrates the accumulation, over a period of time, ofGFAP in the
brains of animals infected orally with the scrapie agent. Clearly there is a much
greater amount ofGFAP in these animals than was seen previously in the brains of
uninfected control animals. There is an apparently rapid increase in GFAP levels
between 250 dpi and 279 dpi. This is especially apparent in areas 1, 3,4 and 7; and is
indicated by the distances between the two traces relating to those timepoints in those

















Figure 29: Levels of disease specific GFAP seen in the brain of orally infected mice during the
incubation period.
From this figure it can be seen that, as in the case ofPrP accumulation (and
vacuolation although that result is more confused), the thalamus is the most seriously
affected region of the brain (at least within the parameters of this experimental
design). Thalamic levels ofGFAP in the brains oforally challenged mice is higher
than is seen in the brains of mice infected by the other routes under investigation.
This observation also holds for PrP accumulation and development of vacuolation. In
general animals infected by the oral route have developed more severe pathology than
those infected intramuscularly or intraperitoneally.
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3.1.5.3 GFAP in the Brains of Animals Infected Intramuscularly.
Figure 30 shows the levels of detectable GFAP at each of six timepoints
ranging from very early in the disease incubation period (102 dpi) up to the terminal
stages (279 dpi). From this figure it can be seen that the peak levels ofGFAP that
accumulates following intramuscular infection are much lower, <50% of the peak
amount seen following oral infection, yet considerably higher than the peak amount
found following intraperitoneal challenge (see below).
scrapie.
What is also apparent from this figure is the marked increase seen throughout
the brain, with the exception of region 9, between the penultimate and final
timepoints. The levels of detectable GFAP at 102 and 140dpi are comparable with
those observed in the non-infected control animals. Furthermore the levels ofGFAP
at the next three timepoints (relating to a period of 57 days) in all regions of the brain
are very close together. This is similar Tag-phase' that is seen in the accumulation of
PrP following intramuscular and intraperitoneal challenge. The Tag-phase'
phenomenon will be discussed in Chapter 4.
64
Another feature of this result that is completely different from the result
obtained following oral challenge is the gradient of the traces. Concentrating solely
on the final trace in this figure and comparing it with the final trace in figure 29
above it is obvious that the gradients of the respective traces are very different. This
suggests that the accumulation ofGFAP in the brain following intramuscular infection
is a much more widespread event than is the case in orally infected animals where the
thalamus is by far the most affected region of the brain.
3.1.5.4 GFAP in the Brains of Intraperitoneally Infected Animals.
Following intraperitoneal challenge with the scrapie agent, the amount of
GFAP that accumulates in the brain is less than is seen following either oral or
intramuscular infection. Figure 31 illustrates this point. The highest peak in this
figure relates to an amount ofGFAP in the thalamus that occupies an area of less than
20,000pm . This compares to peaks of approximately 22,000pm2 (intramuscular
infection) and greater than 50,000pm (oral infection). The overall shape of the
traces are very similar to those relating to GFAP following intramuscular infection.
However, from this trace it appears that only the thalamus and hippocampus are
especially involved in the development of astrocytic pathology in the late stages of the
disease. This is demonstrated by the relatively greater increases in amount ofGFAP
detected in these regions, between 231dpi and 250dpi. This level of increase is not
observed in other regions of the brain. This contrasts with the intramuscular infection
where at the late/end stage of the disease all of the regions examined, with the
exception of the cerebellum (area 9) show a marked increase in the amount ofGFAP
over the levels detected at the penultimate timepoint.
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The reported increase in the amount ofGFAP detected between 246dpi and
250dpi appears to be large, especially in the hippocampus and the thalamus.
However given the very small time interval involved it seems unlikely that this
represents a true pathological event. Small sample size has probably contributed to
this, however this will be discussed further in Chapter 4.
3.2 Kinetics of Disease
The kinetics of the development of pathology were investigated so that it
would be possible to directly compare any differences in pathogenesis that might
occur as a function of the route of infection. In order to do this a way of standardising
the non-uniform incubation periods had to be devised this is described in Chapter 2.
For each of the three routes of infection that were studied the amount ofPrP
and GFAP in each of three regions of the brain (frontal cortex, hippocampus and
thalamus) were plotted against the percentage of the total incubation period that each
serial kill date fell on. The hippocampus and thalamus especially were chosen
because they appear to be the most significantly involved with regards to PrP
accumulation and GFAP expression in each of the three routes examined; the frontal
cortex was chosen as less variability was demonstrated in that region when comparing
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intraperitoneal routes of infection. The expected similarity in the results of this region
will validate this approach for comparing the other areas of interest.
In each of the figures below the rate of accumulation ofPrP or GFAP is related
to the gradient or steepness of the slope.
3.2.1 Kinetics of Disease in Orally Infected Mice.
Figures 32 (a-f) show the rate of change curves relating to the accumulation of
PrP (a-c) and GFAP (d-f) in the thalamus, hippocampus and frontal cortex
respectively.
In the orally infected animals the first PrP was detected at a time corresponding
to approximately 70% of the total incubation period. Figure 32a maps the progressive
deposition ofPrP in the thalamus of an orally infected animals from this point through
to the terminal stage of the disease. The development of pathology exhibits almost
exponential behaviour as can be seen from the shape of the curve. The curve is based
on the information gathered from five timepoints where pathology was evident.
Figures 32a(i-iv) are graphic examples of the degree ofPrP pathology seen in the
thalamus at each of those timepoints and clearly illustrate the type of increases
signified by the shape of the curve.
Figure 32b shows the way that PrP accumulated in the hippocampus of orally
infected mice during the course of the incubation period. Clearly this figure shows that
the amount ofPrP accumulation is not as great as is seen in the thalamus although the
rate of accumulation seems to be quicker. A particularly interesting feature and one
that is also seen in the frontal cortex, though not in the thalamus, is the way that the
graph peaks before the end point of the disease at which point the amount ofPrP
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Figure 32 (a-c): Curves illustrate how the amount of detectable PrP changes with time during
incubation in the thalamus (a), hippocampus (b) and frontal cortex (c) of C57B1 mice following oral
infection with ME7 scrapie.
Figure32a(i). Figure 32a(ii).
Figure 32a(iii). Figure 32a(iv).
Figures 32a (i-iv). Illustration of the changes in PrP pathology seen in the thalamus of orally infected
mice during the incubation period. 32a(i) Thalamus at 75% of total incubation period. 32a(ii)
Thalamus at 87% of total incubation period. 32a(iii) Thalamus at 95% of total incubation period.
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Figure 32b(iv).
Figures 32b (i-iv). Illustration of the changes in PrP pathology seen in the hippocampus of orally
infected mice during the incubation period. 32b(i) Hippocampus at 75% of total incubation period.
32b(ii) Hippocampus at 87% of total incubation period. 32b(iii) Hippocampus at 95% of total
incubation period. 32b(iv) Hippocampus at terminal stage of disease (100% of incubation period). All
figures at x200 magnification.
Figure32c(i). Figure 32c(ii).
Figures 32c (i-iv). Illustration of the changes in PRP pathology seen in the Frontal cortex of orally
infected mice during the incubation period. 32c(i) Frontal cortex at 75% of total incubation period.
32c(ii) Frontal cortex at 87% of total incubation period. 32c(iii) Frontal cortex at 95% of total
incubation period. 32c(iv) Frontal cortex at terminal stage of disease (100% of incubation period). All
figures at x200 magnification.
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Figure 32 (d-f): Curves illustrate how the amount of detectable GFAP changes with time during
incubation in the thalamus (a), hippocampus (b) and frontal cortex (c) of C57B1 mice following oral
infection with ME7 scrapie.
Figure32d(i). Figure 32d(ii).
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Figure 32d(iv).
Figures 32d (i-iv). Illustration of the changes in GFAP pathology seen in the thalamus of orally
infected mice during the incubation period. 32d(i) Thalamus at 75% of total incubation period. 32d(ii)
Thalamus at 87% of total incubation period. 32d(iii) Thalamus at 95% of total incubation period.
32d(iv) Thalamus at terminal stage of disease (100% of incubation period). All figures at x200
magnification.
Figure32e(i). Figure 32e(ii).
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Figure 32e(iv).
Figures 32e (i-iv). Illustration of the changes in GFAP pathology seen in the hippocampus of orally
infected mice during the incubation period. 32e(i) Hippocampus at 75% of total incubation period.
32e(ii) Hippocampus at 87% of total incubation period. 32e(iii) Hippocampus at 95% of total
incubation period. 32e(iv) Hippocampus at terminal stage of disease (100% of incubation period). All
figures at x200 magnification.
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Figure 32f(iii).
Figures 32f (i-iii). Illustration of the changes in GFAP pathology seen in the frontal cortex of orally
infected mice during the incubation period. 32f(i) Frontal cortex at 75% of total incubation period.
32f(ii) Frontal cortex at 95% of total incubation period. 32f(iii) Frontal cortex at 100% of total
incubation period. All Figures at x200 magnification.
that can be detected in this region seems to decrease. Figures 32b(i-iv) illustrate this
observation.
The rate at which PrP accumulates in the frontal cortex of the orally infected
animals is represented by figure 32c. This figure shares a broadly similar shape with
figure 32b above although the maximum value reached is much higher and the rate at
which this maximum is reached is also much higher. This is shown by the gradient of
the curve between 85% and 100% of the incubation period. This figure also illustrates
a drop-off in the amount of detectable PrP prior to the last timepoint. Figures 32c(i-
iv) show this decrease. Possible reasons for this will be discussed in Chapter 4.
Figure 32d shows the progressive accumulation of GFAP in the thalamus of
the orally infected animals. The shape of the trace is broadly the same as was
obtained for the kinetics of PrP accumulation although the gradient of the curve is
not as steep. This result is not unexpected as colocalisation of PrP with reactive
astrocytes has been seen in cases ofME7 scrapie. Figures 32d(i-iv) show the
progressive accumulation ofGFAP in this region.
Figure 32e illustrates the changes through time in the levels ofGFAP that can
be detected in the hippocampus. Compared to the accumulation of PrP there is an
increased initial rate ofGFAP accumulation although the peak level achieved is far
below peak level ofPrP detected. Also, in further contrast with the PrP result is the
much more linear appearance of the graph. This suggests that the rate of
accumulation ofGFAP in the hippocampus occurs at a steady rate after a certain point
in the incubation period. It seems unlikely that the difference observed between with
GFAP result and that of PrP is a result of the small sample size upon which the results
are based; instead this probably reflects a true phenomenon that occurs as a result of
oral infection. This pattern is not seen in i.m. or i.p. infection. Figures 32e(i-iv)
illustrate the information extracted from this graph.
Figure 32f shows the way in which GFAP accumulates in the frontal cortex
following oral infection. Compared to the hippocampus and the thalamus GFAP
accumulation in the frontal cortex occurs later and more slowly. However, when the
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protein starts to accumulate, it does so fairly steadily (as seen by the almost linear
progression between 75-95% of incubation) until the very late stages (>95%) where
there is a slight decrease. This is not as marked a decrease as is seen the cases of PrP
accumulation in orally infected mice and it is likely to be a function of the small
number of observations that the result is based on. This will be discussed further in
Chapter 4. Figures 32f (i-iii) are representative of the levels ofGFAP seen in the
frontal cortex at each of the five timepoints examined.
3.2.2 Kinetics of Disease in Intramuscularly Infected Mice.
Figures 33(a-f) are the rate of change curves relating to PrP and GFAP
accumulation following intramuscular infection. As above figures (a-c) relate to PrP
accumulation and figures (d-f) are concerned with GFAP build up.
Figure 33 a illustrate the amount of PrP detectable, and the rate at which it
accumulates in the thalamus during the incubation period. Figures 33b and 33c show
similar information for the hippocampus and the frontal cortex respectively.
What is immediately apparent from these three figures is their remarkable
similarity with respect to overall shape and behaviour. This contrasts with the results
obtained from the orally infected animals, above, where the pattern and rate of
accumulation varies greatly from one area to another. The overall picture of PrP
accumulation following intramuscular is shown as one that begins earlier in the
incubation period (50% of total incubation) than in the case of orally infected animals
(-70%). In all three areas examined the level of PrP increases at a steady rate until
about 70% of the incubation period is reached. There is then an apparent drop off in
the amount of detectable PrP before a second stage of increased PrP deposition which
continues until the end point of the incubation period.
Figures 33a(i-iv), 33b(i-iv) and 33c(i-iii) show the levels of detectable PrP in
the thalamus, hippocampus and frontal cortex, respectively, during the incubation
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Figure 33 (a-c): Show changes in PrP levels with time during incubation in the thalamus (a),
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Figure 33a(iv).
Figures 33a (i-iv). Illustration of the changes in PrP pathology seen in the thalamus of i.m. infected
mice during the incubation period. 33a(i) Thalamus at 50% of total incubation period. 33a(ii)
Thalamus at 67% of total incubation period. 33a(iii) Thalamus at 79% of total incubation period.
33a(iv) Thalamus at terminal stage of disease (100% of incubation period). All figures at x200
magnification.
Figure33b(i). Figure 33b(ii).
Figure 33b(iii). Figure 33b(iv).
Figures 33b (i-iv). Illustration of the changes in PrP pathology seen in the hippocampus of i.m.
infected mice during the incubation period. 33b(i) Hippocampus at 50% of total incubation period.
33b(ii) Hippocampus at 67% of total incubation period. 33b(iii) Hippocampus at 79% of total
incubation period. 33b(iv) Hippocampus at terminal stage of disease (100% of incubation period). All









Figures 33c (i-iii). Illustration of the changes in PrP pathology seen in the frontal cortex of i.m.
infected mice during the incubation period. 33c(i) Frontal cortex at 50% of total incubation period.
33c(ii) Frontal cortex at 67% of total incubation period. 33c(iii) Frontal cortex at 100% of total
incubation period. All figures at x200 magnification.
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Figure 33 (d-f): Show changes in GFAP levels during the incubation period in the thalamus (a),
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Figure 33d(iv).
Figures 33d (i-iv). Illustration of the changes in GFAP pathology seen in the Thalamus of i.m.
infected mice during the incubation period. 33d(i) Thalamus at 67% of total incubation period. 33d(ii)
Thalamus at 79% of total incubation period. 33d(iii) Thalamus at 83% of total incubation period.
33d(iv) Thalamus at terminal stage of disease (100% of incubation period). All figures at x200
magnification.
Figure33e(i). Figure 33e(ii).
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Figure 33e(iii). Figure 33e(iv).
Figures 33e (i-iv). Illustration of the changes in GFAP pathology seen in the hippocampus of i.m.
infected mice during the incubation period. 33e(i) Hippocampus at 67% of total incubation period.
33e(ii) Hippocampus at 79% of total incubation period. 33e(iii) Hippocampus at 83% of total
incubation period. 33e(iv) Hippocampus at terminal stage of disease (100% of incubation period). All
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Figure 33f(iii). Figure 33f(iv).
Figures 33f (i-iv). Illustration of the changes in GFAP pathology seen in the frontal cortex of i.m.
infected mice during the incubation period. 33f(i) Frontal cortex at 67% of total incubation period.
33f(ii) Frontal cortex at 79% of total incubation period. 33f(iii) Frontal cortex at 83% of total
incubation period. 33f(iv) Frontal cortex at terminal stage of disease (100% of incubation period). All
figures at x200 magnification.
period of the disease. From these images the peaks and troughs of the kinetics curves
can be seen.
Figures 33 d - 33f represent the kinetics of the disease with respect to the
sequential accumulation ofGFAP following intramuscular infection. These figures
exhibit very similar characteristics as the figures for PrP kinetics, above.
The overall shape of these three figures is very similar, more so than the previous
examples (PrP).
Again these figures show that the level ofGFAP reaches a peak, troughs
between 80 and 85% of the way through the incubation period before surging to even
higher levels during the latest stages of the incubation period. Accounting for the
differences in actual levels of protein detected in each of the three brain areas, the rate
of accumulation (indicated by the steepness of the curve at a given point) appears to
be very similar. This is certainly not the case in the orally infected animals. Figures
33d(i-iv), 33e(i-iv) and 33f(i-iv) illustrate the presence and the levels ofGFAP in the
thalamus, hippocampus and frontal cortex, respectively, of animals that were
experimentally infected with scrapie by the intramuscular route.
3.2.3 Kinetics of Disease in Intraperitoneallv Infected Mice.
Figures 34(a-f) represent the kinetics of PrP and GFAP accumulation in mice
experimentally infected with scrapie by the intraperitoneal route. As in the cases of
oral and intramuscular infection, above, the brain regions under investigation are the
thalamus, hippocampus and the frontal cortex of the cerebrum.
Unlike the intramuscularly infected mice the patterns and rates of PrP
accumulation in the three areas under investigation, Figures 34a - 34c, are quite
different. They are also very different to the result seen in the orally infected animals.
In the thalamus the levels of PrP, which is detectable at a time corresponding
to around 56% of the total incubation period, are reasonably constant as seen by the
flatness of the early portion of the graph. There is a slight increase towards 70% of
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Figure 34 (a-c): Show changes in the detectable levels of PrP during the incubation period in the




Figures 34a (i-iii). Illustration of the changes in PRP pathology seen in the thalamus of i.p. infected
mice during the incubation period. 34a(i) Thalamus at 56% of total incubation period. 34a(ii)
Thalamus at 75% of total incubation period. 34a(iii) Thalamus at 100% of total incubation period. All
figures at x200 magnification.
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Figure34b(i). Figure 34b(ii).
Figure 34b(iii).
Figures 34b (i-iii). Illustration of the changes in PRP pathology seen in the hippocampus of i.p.
infected mice during the incubation period. 34b(i) Hippocampus at 75% of total incubation period.
34b(ii) Hippocampus at 92% of total incubation period. 34b(iii) Hippocampus at 100% of total
incubation period. All figures at x200 magnification.
Figure34c(i). Figure 34c(ii).
Figure 34c(iii).
Figures 34c (i-iii). Illustration of the changes in PRP pathology seen in the frontal cortex of i.p.
infected mice during the incubation period. 34c(i) Frontal cortex at 88% of total incubation period.
34c(ii) Frontal cortex at 92% of total incubation period. 34c(iii) Frontal cortex at 100% of total
incubation period. All figures at x200 magnification.
the incubation period. However, this could be as a result of the small sample size.
The major increase in the amount of PrP is seen between 90 and 98% of the
incubation period where there is a rapid increase in the amount of PrP that can be
detected. The speed of this increase is indicated by the steepness of the curve. Just
prior to the end of the incubation period there appears to be a plateau, where there is
no more PrP being deposited.
This is similar to the hippocampus where the level of PrP increases very
slowly, almost imperceptibly until just before 90% of the incubation period has
passes. At this time there is an increase in the rate of deposition towards the end
point. Between 98 and 100% of the incubation period there is a small decrease in the
level of PrP that can be detected, this is due to experimental variation and doesn't
constitute an actual phenomenon. In the frontal cortex, the level of PrP is virtually
constant from the time when it can be first detected until almost the end of the
incubation period. At the end of the incubation period there is an increase in the rate
at which PrP is deposited. This results in an increase in the amount of detectable
protein. This trend of very late, very sudden increase in the area occupied by the
accumulated PrP is only in the i.p. infected animals. A similar [late] observation can
be made in the case of i.m. infected mice, However, the increase in rate does not
occur as late and the resulting shift leads to a relatively greater deposition of PrP than
is seen in the i.p cases.
Figures 34a(i-iii), 34b(i-iii) and 34c(i-iii) show the consistency between
timepoints of the amount of PrP that can be detected.
Figures 34d - 34f show the results of assessing the kinetics ofGFAP
deposition in i.p. infected mice. In the thalamus (Fig. 34d) the gradient of the curve is
shallow indicating a low rate of deposition. There is a sharp upturn in the curve
between 98 and 100% of the incubation period but this is most likely a result of
variation between animals and the small sample size.
Similar graphs are produced from the results gathered in the hippocampus and
frontal cortex (Figures 34e and 34f respectively). Figures 34d(i-iii), 34e(i-iii) and
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Figure 34 (d-f): Shows progressive Changes in GFAP levels in thalamus (a), hippocampus (b), and
frontal cortex (c) of C57B1 mice infected with ME7 scrapie.
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Figure 34d(iii).
Figures 34d (i-iii). Illustration of the changes in GFAP pathology seen in the thalamus of i.p. infected
mice during the incubation period. 34d(i) Thalamus at 67% of total incubation period. 34d(ii)
Thalamus at 79% of total incubation period. 34d(iii) Thalamus at 100% of total incubation period. All
figures at x200 magnification.
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Figure 34e(ii).Figure34e(i).
Figure 34e(iii).
Figures 34e (i-iii). Illustration of the changes in GFAP pathology seen in the hippocampus of i.p.
infected mice during the incubation period. 34e(i) Hippocampus at 79% of total incubation period.
34e(ii) Hippocampus at 83% of total incubation period. 34e(iii) Hippocampus at 100% of total
incubation period. All figures at x200 magnification.
Figure 34f(iii).
Figures 34f (i-iii). Illustration of the changes in GFAP pathology seen in the frontal cortex of i.p.
infected mice during the incubation period. 34f(i) Frontal cortex at 67% of total incubation period.
34f(ii) Frontal cortex at 79% of total incubation period. 34f(iii) Frontal cortex at 100% of total
incubation period. All figures at x200 magnification.
34f(i-iii) show the detectable levels ofGFAP seen in these areas of the brain
throughout the course of the incubation period.
These results indicate potential differences in the pathogenesis of experimental
scrapie which may be attributable to differences in the route of infection. This will be
discussed in further detail in Chapter 4.
3.3 Identification of PrP in Lvmphoreticular System
Following Experimental Challenge.
Figures 35 -37 show clearly that PrP is detectable in the spleen following
challenge by the three routes under investigation here. PrP is identified by the red
immunohistochemical product. The brown pigment that is visible in some of the
images is haemosiderin, an iron-containing pigment that occurs in ageing animals as a
result of red blood cell breakdown. It has no relevance to scrapie infection.
In all cases where PrP can be detected the distribution of the protein in the
spleen is restricted to the germinal centres of the splenic follicles. However, PrP is
not necessarily detected in every follicle.
These figures are all taken from the spleens of animals at the late stages of the
disease. Figures 35(a-c) show the spleens of animals infected orally and sacrificed at
250, 279 and 320dpi respectively. From this result there appears to be a diminution in
the amount of PrP located in the spleen as the disease progresses towards the terminal
stages. There is also a noticeably higher amount of haemosiderin present in Figure
35c than in Figures 35(a or b). Whether or not this represents a genuine decrease with
time, of the amount of PrP, is not clear. It may represent a period of replication prior
to transport of the protein to the CNS.
Figures 36(a and b) show PrP in the spleens of animals that had been infected
by the intramuscular route. As for the orally infected animals these spleens were
harvested at the late stages of the disease, 246 and 279dpi respectively. In these




Figures 35a-c. Demonstrate the presence of PrP (shown here as red precipitate) in the spleens of
animals infected with ME7 scrapie by the oral route. Fig. 35a spleen from animal sacrificed at
250dpi. Fig. 35b spleen from animal sacrificed at 279dpi. Fig. 35c spleen from orally infected animal
sacrificed at terminal stage of infection, 320dpi. All figures at x200 magnification.
Unfortunately there are no available photographs of the uninfected controls. However the spleens of
uninfected animals demonstrated no detectable PrP.
Figure36a. Figure 36b.
Figure 36 a-b. Illustrate the presence ofPrP (red precipitate) in the spleens of animals infected with
ME7 scrapie by the i.m. route. Fig. 36a animal sacrificed at 246dpi. Fig. 36b animal sacrificed at end
stage of disease, 279dpi. X200 magnification.
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Figure 37a. Figure 37b.
Figures 37a-b. Demonstrates the presence of PrP in the spleens of animals infected with ME7 scrapie
by the i.p. route. Fig. 37a animal sacrificed at 231dpi. Fig. 37b animal sacrificed at terminal stage of
infection, 250dpi. x200 magnification.
earlier. This could be suggestive of an accumulation of PrP in the spleen that
continues until the terminal stage of the disease. The PrP in the spleen at 246 dpi is
not especially concentrated and appears as a pale pink product when detected
immunohistochemically. In contrast, at the end stage of the disease, the PrP is clearly
identified as an intense red product in the germinal centre of the follicle.
Figures 37(a and b) illustrate PrP in the spleens of animals infected by the
intraperitoneal route. As with the previous examples, these figures represent the late
stages of the infection, 231 and 250dpi respectively. This result differs from the
previous two examples with respect to the relative amounts ofPrP detected. In these
intraperitoneal cases there are no readily apparent differences with respect to the
amount of protein detected. In both of these figures the PrP appears as a diffuse pink
coloured product in the germinal centre. Non-infected spleens, from non-infected
mice were also stained as a means of control but did not exhibit visible PrP. These
tissues are not shown here, however all results were confirmed in conference with Dr
Martin Jeffrey.
These results appear to suggest that the involvement of the spleen and, by
extrapolation, other components of the lymphoreticular system is variable depending
on the initial route of infection. The obvious caveat to this observation is that it is
based on a very small sample size. Further experiments would be required before any
true conclusions can be reached. This will be discussed in Chapter 4.
3.4 Comparison with Human Acquired TSE.
The rationale behind much of the work presented in this thesis was an attempt
to elucidate the events of infection in humans, especially with the agents of
Creutzfeldt-Jakob disease and the recently identified new variant. It was intended that
by choosing the oral and intramuscular routes of infection it would be possible to
model new variant CJD and iatrogenic CJD infection. These diseases share common
pathological characteristics, both with sporadic CJD and each other, although in the
case of variant CJD the clinical presentation is markedly different. However, there are
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also differences in terms of the appearance and distribution of the established
pathological markers of vacuolation and PrP. These differences enable an
experienced pathologist to make an accurate diagnosis. It is acknowledged by the
author that this may have been an over ambitious course of action given the
limitations of the experimental model and the complexity of naturally acquired human
TSEs. However in light of the MRC funding for this work, and the otherwise overtly
veterinary nature of the studies presented in this thesis, it was felt by the author that
some attempt to integrate aspects of human TSE infection into this study was
required. Unfortunately the results of this particular study serve only to illustrate the
difficulty of translating results from animal systems to human diseases. The
limitations of this study are described in greater detail in Chapter 4.
Tissues from cases of sporadic, iatrogenic and new variant CJD were obtained
from the National CJD Surveillance Unit in Edinburgh. The tissues were taken from
the CJD unit archive and had been immunostained to detect PrP. Parallel sections
were stained with haematoxylin and eosin for the purpose of detecting vacuolar
change. Most of the comparisons are based on the pathology in the cerebellum as this
particular region is known to produce striking differences between the different
human CJD types.
An important consideration when making these comparisons is the size of the
human brain versus that of the mouse brain. Due to the extreme differences in size
the relative areas that can be examined for comparative purposes are much greater in
the mouse brain. This is a potential source of error in this type of study. However as
the most easily identifiable differences relate to the morphology of the PrP deposits,
and not necessarily the overall pattern of distribution of the lesion, it is not thought
that this difference will not adversely influence the observations.
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3.4.1 Comparison of vCJD with Orally Acquired Experimental Scrapie.
Figure 38 (a-b) show PrP deposition in the brain of a patient diagnosed at
post-mortem with new variant CJD. Figure 39 (a-b) show PrP deposition in the
cerebellum of the brain taken from a mouse experimentally infected with scrapie by
the oral route. Examples of the typical pathology observed in the mouse brain, in
regions other than the cerebellum, for example the hippocampus and thalamus can be
seen above.
These figures clearly show the presence of large plaques in the cerebellum of
the vCJD case. These plaques are perhaps the most striking difference between the
human disease and the experimentally established murine model although the
perineuronal staining seen in the cerebellar cortex of the vCJD case is not seen in the
animal model. One other difference that can be seen in the cerebellum is the level of
staining seen in the central white matter region, the arbor vitem. In the experimental
model there is widespread, diffuse PrP deposition. This is in contrast to the vCJD
section where, relative to the rest of the cerebellum, there is very little PrP.
Furthermore what PrP is detectable in the cerebellar white matter is much more
distinct and discreet than is seen in the animal disease. In the frontal cortex there are
widespread plaques visible in the vCJD case. There is also a 'feathery' appearance to
some of the PrP deposits. This is visible at the boundary of cells and is associated
with neurones. However, the most striking feature in this section is the widespread
deposition of plaques. In the equivalent area of the brain from the experimentally
infected mouse the PrP appears to be much more diffuse and although there are some
structures which could be plaques they are in no way as widespread or intense as those
seen in the human disease. Routine H&E sections from these cases also show
considerable differences. Figures 40 and 41 show some of these differences between
vCJD and orally induced scrapie. In the molecular layer of the cerebellum, and in the
cerebellar cortex (in the case of vCJD) there are readily identifiable vacuoles. This
region is relatively spared in the animal model. The most notable feature of vCJD,
which is absent from orally induced ME7 scrapie, is the presence of 'florid' plaques.
These are deposits of amyloid surrounded by a halo of spongiform change. Figure
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Figure38a. Figure 38b.
Figure 38 a-b. Demonstrates the presence of PrP in the brain of a patient who died as a result of
nvCJD infection. Fig. 38a Shows PrP in the granular and molecular layer of the cerebellum and
illustrates the presence ofPrP in the form of plaques as well as more diffuse deposits.. Fig. 38b shows
limited deposition of PrP in the white matter of the cerebellum. X200 magnification.
Figure 39a. Figure 39b.
Figures 39a-b. Demonstrates the presence of PrP in the cerebellum of mice infected with ME7
scrapie by the oral route. Fig. 39a PrP in the granular and molecular layer of the cerebellum. Note the
absence of PrP amyloid plaques and the presence of a much more diffuse deposit than is seen in vCJD.
Fig .39b PrP present in the cerebellar white matter, this is much more involved than is the case seen in
human oral TSE infection. X200 magnification..
Figure40a. Figure 40b.
Figure 40 a-b. Illustrate some of the features seen in H&E stained sections from a patient who died as
a result of vCJD infection. Fig. 40a Shows 'florid plaques' (arrowheads) in the frontal cortex these
are a feature of vCJD not seen in any of the other human acquired TSEs. Fig. 40b shows vacuolar
degeneration of the tissue in the cerebellum around the granular and molecular layers. XI00
magnification.
Figure 41a. Figure 41b.
Figures 41 a-b. Illustrate the degree of vacuolar change in orally infected animals. Fig. 41a
vacuolation in the frontal cortex of an orally infected animal. Note the absence of any 'florid'
plaques.. Fig. 41b Vacuolation in the cerebellum. There appears to be only limited involvement.
X100 magnification.
40a shows florid plaques in the frontal cortex of a vCJD patient. In contrast the
frontal cortex of the mouse shows the presence of vacuolation but there are no
eosinophillic plaques.
3.4.2 Comparison of Iatrogenic C.JD with Intramuscularly Acquired
Experimental Disease.
Iatrogenic CJD was caused by the administration of pituitary derived growth
hormone which was inadvertently contaminated with a human TSE agent. These
hormone injections were given intramuscularly over a period of months or years with
onset of disease occurring 7-35 years later (Brown et. al., 1992).
Figure 42 demonstrates the presence of PrP in the brain of a patient who died
as a result of iatrogenic transmission of CJD. Broadly parallel sections of cerebellum
taken from a mouse that had been infected with scrapie via the biceps femoralis are
shown for comparison (Figure 43). Sections of murine brain for comparison with
human frontal cortex are presented above.
Figure 42a shows the white matter of the cerebellum of a patient who, having
received growth hormone therapy, eventually died ofCJD. Clearly there is very little
evidence of PrP deposition, especially when compared to the corresponding region of
the brain in a vCJD patient. The PrP that is present in this section appears to have
formed small aggregates which have formed a chain, possibly along the length of a
neuronal process.
When this is compared to the cerebellar white matter from a mouse infected
with scrapie by the intramuscular route, there are obvious and striking differences.
Figure 43 a demonstrates how much more significant the PrP deposition is in this
region of the murine model. In the centre of the white matter there is a widespread
diffuse covering of PrP which has the appearance of being almost laminar. There are
also some larger aggregates of protein which have the appearance of plaques. These
plaques are larger than the deposits seen in the cerebellum of the iatrogenic cases.
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In the molecular layer and cerebellar cortex of the iatrogenic case there is more
widespread, intense PrP deposition. Figure 42b illustrates clearly the borders of the
PrP deposition and the sparing of the cerebellar white matter (bottom left of the
figure). This figure also shows the presence of PrP in the cerebellar cortex. The
cortical PrP is much more diffuse than in the molecular layer. Figure 42c is a higher
magnification example of PrP in the molecular layer. Figure 43b shows a large
section of the murine cerebellum and includes regions ofwhite matter, cortex and the
molecular layer. There is a diffuse spread of PrP visible in this section. Although
there is no obvious sign of plaques there are some small discrete deposits in both the
molecular layer and in the cerebellar cortex. These do not present with the same
intensity as is seen in the human iatrogenic disease.
Figure 42d shows that the levels of PrP in the frontal cortex of an iatrogenic
CJD case are low. The PrP seen in this figure is closely associated with neuronal cell
bodies and processes By comparison there is a proportionally greater concentration
of PrP in the frontal cortex of an intramuscularly infected mouse with a more
widespread, diffuse deposition of the protein being apparent, this can be seen in the
figures in Section 3.2.2, above. However the PrP in the mouse model doesn't
demonstrate the same type of perineuronal pattern in its distribution. There are some
small plaque like aggregates present in the mouse model that are not observed in the
iatrogenic case.
Figure 42e shows the presence of vacuolar change in the frontal cortex of the
iatrogenically infected CJD case; figure 43 c shows the corresponding region in the
mouse brain. It is difficult to identify any differences in the quality and distribution of
vacuolation from these examples however, it can be seen that neither the iatrogenic
case nor the mouse model (or for that matter the mouse model of oral infection) have
any florid plaques in them. In the mouse model of intramuscular infection there are
no obvious plaques, this is also the case for this example of iatrogenic infection in the




Figures 42a-e. Illustrate the pathology seen in the brain of a patient who died as a result of iatrogenic
CJD. Fig. 42a Cerebellar white matter stained for PrP. There appears to be limited involvement.
Fig. 42b. Cerebellar cortex stained for the presence of PrP. Fig. 42c Molecular layer of cerebellum
stained for PrP. Fig. 42d PrP detected in the frontal cortex of patient with iatrogenically acquired
CJD. Fig. 42e Vacuolar change in frontal cortex of growth hormone associated iatrogenic CJD case.
Note there are no 'florid' plaques. xlOO magnification.

























Figures 43a-c. Illustrate the pathology seen in the brain of an animal that was infected with ME7
scrapie by the i.m. route. Fig. 43a Cerebellar white matter stained for PrP. There appears to be more
involvement than is seen in the human case. Fig. 43b. Large field of cerebellum including molecular
layer and cerebellar cortex labelled for PrP. Fig. 43c H & E stained section ofmurine frontal cortex
shows vacuolar degeneration. It is difficult to discern any differences in the quality and distribution of
vacuolation in i.m. infected animals and iatrogenically infected human cases. xlOO magnification.
3.4.3 Comparison of Human Sporadic CJD with Intraperitoneallv Acquired
Experimental Disease.
The aetiology of sporadic CJD is not clearly understood. Whether the disease
is purely one of host genetics or if there is an element of acquisition of an infective
agent by an unknown route is not categorically known. It is not the intention to draw
any comparisons between the pathology of sporadic CJD and intraperitoneally
established experimental infection nor is it the intention to suggest that sporadic CJD
is the result of some form of intraperitoneally acquired infection although a recent
epidemiological study has suggested that general surgery may be a risk factor for
sporadic CJD (Collins et al., 1999). The main reasons for examining the differences
in pathology between sporadic CJD and acquired scrapie is that doing so illustrates
further the differences between the types of pathology, especially PrP pathology, seen
in the human diseases at the same time as highlighting the pathological similarities
seen in the murine model where the strain of the infective agent has been controlled.
The ability to draw comparisons, especially between sporadic CJD and vCJD, is
enhanced by the fact that the PrP genotype of the patient who succumbed to sporadic
CJD is known. This patient was homozygous for methionine (M/M) at codon 129 of
the PrP gene. The same genotype has been found in all the cases of vCJD so far
identified and may be a relative risk factor for infection. Figure 44a shows PrP
deposition in the cerebellum of a sporadic CJD patient. From this figure it is evident
that the white matter of the cerebellum is almost completely spared and that there are
certainly no plaques as have been observed in the corresponding brain region in vCJD.
What little PrP there is in this section appears to be associated with cell membranes
and does not seem to involve the surrounding neuropil. This is also different to the
pattern of PrP deposition seen in the cerebellum of iatrogenic cases.
Figure 45 demonstrates the presence of PrP in the cerebellar white matter of
an i.p. infected mouse. Compared to the human diseases none of the animal models
demonstrate the same degree of sparing of the cerebellar white matter. Of the three
animal models examined the i.p. infected animals have visibly less PrP in the
cerebellum than either the i.m or the orally infected animals (which have the most).
78
However, apart from the differences in the actual amounts ofPrP detected in this
area; the pattern and morphology of the protein deposition are similar. This is unlike
the three human diseases examined. As mentioned above, in the case of sporadic CJD
the cerebellar white matter is almost completely spared. This contrasts with iatrogenic
CJD, where several small plaque-like structures are observed, and vCJD where there
is evidence of plaques as well as more diffuse PrP deposits. Some of these deposits
appear to be associated with neuronal processes giving them a 'chain-like'
appearance.
Figure 44b shows the border of the molecular layer and the cortex in the
cerebellum of a sporadic CJD case. In contrast to the cerebellar white matter these
regions are heavily affected by PrP. The cortex has a broad, diffuse covering of PrP
with some small punctate deposits. The molecular layer by contrast is affected by
larger, darkly staining, aggregates. This type of aggregate is not seen in the molecular
layer of the i.p. infected animal model to the same degree. The mouse presents with a
more uniform, diffuse pattern of protein deposition. This is the same pattern of PrP
deposition that is seen in the i.m. and orally infected animals although the intensity of
staining varies.
Figure 44c shows the deposition ofPrP in the frontal cortex of a sporadic CJD
case. The widespread diffuse deposition of PrP is in stark contrast to the pattern seen
in vCJD, where there is an incredible amount of very concentrated protein, or
iatrogenic CJD where the PrP appears in a perineuronal pattern. Vacuolation in the
cortex of the sporadic case is shown in figure 44d This is similar to the iatrogenic
case as it lacks the presence of florid plaques (found in vCJD).
This exercise has demonstrated that the differences in type and distribution of
pathology (especially PrP pathology) seen in human CJD-type diseases are not
necessarily seen in animal models of those disease.
In the animal models the distribution and type of PrP pathology seen in the
brain was broadly similar irrespective ofmethod of infection. What was different was























Figure 44c. Figure 44d.
Figures 44a-d. Illustrate the pathology observed in the CNS of a patient who died of sporadic CJD.
Fig. 44a PrP in the cerebellum of a sporadic CJD case. Note there is a total absence ofPrP amyloid
plaques and there is a general sparing of this region unlike in the case of vCJD. Fig. 44b PrP present
in the cerebellar cortex and molecular layer in a sporadic CJD case. Fig. 44c Widespread deposition
ofPrP in the frontal cortex. Fig 44d H&E stained section of frontal cortex, similar in appearance to
iatrogenic CJD but different from vCJD due to the lack of 'florid' plaques. X200 magnification.
Figure 45.
Figure 45 Illustrates the presence ofPrP in the cerebellar white matter of an i.p. infected animal.
This is in keeping with the other animal models which do not exhibit the same degree of cerebellar
white matter sparing that is generally seen in the human disease. In general there are very few
differences between the animal models at the terminal stage of infection. X200 magnification.
mice used in the study were inbred and the strain of scrapie used was kept constant
throughout. This is unlikely to be the same situation in the human cases that were
examined. This serves to illustrate that the agent strain, recipient species and other
variables are what determine pathology. Unfortunately it does not allow for the extent
of influence of each of these factors to be individually determined.
3.5 Transport of infectivitv in PrP0/Q mice.
Part of the work described in this thesis was concerned with the transport, or
lack thereof, of scrapie infectivity in the CNS of mice lacking a functional PrP gene
(prn-p). Consequently these animals are unable to produce the native PrP protein
which has been reported as being essential for propagation of disease. The details of
the experimental design are given in Chapter 2, but briefly, two groups of animals
(one group PrP-nulls the other the 129 strain wild type) were injected intraocularly
with the ME7 strain scrapie agent. At a series of time points specific regions of the
brain (regions which are known to be projections of the retina) were harvested. These
harvested tissues were used to prepare inoculum to inject into a series of C57BL,
assay mice. The C57BL mice were then maintained in the animal unit and observed
for signs of neurological disease. Animals exhibiting neurological signs were culled
and the brains taken for pathological assessment; the final diagnosis of scrapie was
confirmed solely on this assessment. The results of this experiment are given in
Tables 9 and 10.
These tables illustrate the number of animals from each group to have
succumbed to scrapie following experimental intracerebral infection with visual
system material from PrP null and PrP wild-type animals. Of special interest it should
be noted that there are three animals, in the first group ofmice (24 hours post
injection) that received tissues from PrP null animals, that succumbed to the disease.
The brains from these animals were examined histopathologically by an experienced
technician and by Dr Jan Fraser and a diagnosis of scrapie infection, with the ME7
strain of the agent, was made (Aileen Chree personal commuication). The severity
and distribution of pathology seen in these mice was however much lower than would
be expected from an end point infected mouse. This case is indicative of infection
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with a relatively low titre of the infective agent. Sections of the brains from these
animals were then immunostained for the PrP protein, the result of this was positive.
This result would appear to demonstrate that scrapie infectivity can in fact be
transported through the central nervous system of animals lacking a functional PrP
gene, although admittedly the numbers involved are very low. The incubation periods
for these three animals (2 from the optic nerve group and one from the superior
colliculus) were all around 305 days. This compares very closely with the three
positive control animals from the corresponding timepoint that developed the disease.











































































































































































































































































































































Serial kill 24 hours p.i. 41 d.p.i. 54 d.p.i. 71 d.p.i. 83 d.p.i. 117 d.p.i.
timepoint.
Tissue w.t. null w.t. null w.t. null w.t. null w.t. null w.t. null
O.N. 265 304 256 - - - 244 - 232 - 245 -
S.C. - 316 233 - - - - - 234 - 215 -
dLGN - - 244 - - - - - 254 - 241 -
Tablell: Shows the mean incubation periods of C57BL mice infected with tissues harvested from PrP-
null and PrP wild-type mice. Where no number is entered the animals were still alive at the time of
writing or they had died undetected and the brains were too autolytic for pathological determinations to
be made.
O.N. = Optic nerve, S.C. = Superior colliculus, dLGN = Dorsal lateral geniculate nucleus.
Denotes no cases of clinical/pathological disease at that timepoint.
The fact that the incubation periods in the three animals that were infected with PrP-
null derived tissue are longer than those infected with PrP-wild type tissue is to be
expected. The recent literature surrounding the role of the PrP protein in processing
and trafficking of infectivity states that animals devoid of endogenous PrP are unable
to process exogenous infectivity and cultivate the disease. This result appears to
indicate that this may not be the case and that limited transport of infectivity is
possible even although replication cannot occur. Although there is little doubt that
host-encoded PrP is important for disease development, it is reasonable to expect that
animals lacking endogenous PrP will be less efficient at processing infectivity than
their wild-type counterparts; this is suggested by the extended incubation periods in
those mice although the very small infecting dose administered in these cases is
doubtless also a factor. The amount of infectivity present in the inoculum source, the
titre, can be calculated by referring to a standard dose-response curve. The dose
response curve for C57BL mice infected intracerebrally with ME7 scrapie can be seen
in Appendix II. The infectivity titres for these cases, as determined by interpolation
with the curve are shown in Table 12. This demonstrates the very low level of









Optic Nerve 2 304
Beyond Range of
Standard Curve
Superior Colliculus 1 265* Log,0-1.3
infectious units
Table 12: Estimation of the initial infecting dose that caused disease in three C57BL mice. Tissues
harvested from the visual system of previously inoculated PrP-null mice were used as the source of the
inoculum. +Only one animal exposed to this inoculum source succumbed to disease therefore this
incubation period is an absolute value and not a mean value.
One other point of interest to arise from this work, and one that may be worth
closer examination, is the apparent 'troughing' that is seen in the recipients of PrP
wild-type (129 mouse strain) tissues between 41 days post injection and 83 days post
injection. In the case of the animals that were infected with tissues harvested from
PrP wild-type animals there were groups which demonstrate no, or very few, cases of
disease. In particular the group of animals infected with the tissues harvested from the
PrP wild-type donor animals at 54 days post injection have not produced a single case
of experimental scrapie. Furthermore in the group of animals infected with the tissues
from the 71 days post injection wild-type donors there have been only two cases of
transmission identified, both ofwhich were in recipients of the optic nerve
preparation. These two groups of animals are in contrast to those groups either side of
them where 18/23 and 18/23 animals succumbed to disease. These results will be
discussed in Chapter 4.
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Discussion and Conclusions.
4. Discussion of Results.
4.1 Objectives.
The work presented in this thesis was designed to test the hypothesis that
different routes of infection result in different patterns of development of
neuropathological lesions and hence influence the phenotype of infection. In order to
examine this hypothesis experiments were designed which had three main objectives:
(i) to map and quantify the appearance and extent of three pathological markers of
TSE infection - vacuolation , PrP accumulation and astrocytic reactivity - in mice
experimentally infected with ME7 scrapie by a variety of different routes, (ii) to
identify differences in the pathological profiles that could then be attributed solely to
the route of infection, (iii) to assess the suitability of these infections in animals for
use as models of acquisition of human spongiform encephalopathy. In concert with
this work a secondary set of experiments were undertaken, these were designed to
investigate the possibility that scrapie infectivity can be replicated and/or transported
within the CNS of animals lacking endogenous PrP protein.
In order to carry out the work as planned it was necessary to adapt and
develop protocols for the assessment of pathology; in particular the adoption of
computerised image analysis software and hardware that had not previously been
used at the Neuropathogenesis Unit.
4.2 Route of Infection Influences Pathology of Experimental Scrapie.
4.2.1 Differences in Incubation Periods.
As stated above, the main aim of the project was to test the hypothesis that
different routes of TSE infection result in different patterns of development of
neuropathological lesions and hence influence disease phenotype. It is important to
recognise that in this section efficiency is often referred to when talking about
different routes of infection. The results of the study clearly indicate that each of the
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routes examined is an efficient means of causing disease. Each of these routes
produced 100% mortality in their experimental groups, it may therefore be correct to
say that no route is more, or less, efficient than another. However for the sake of
comparison between routes of infection efficiency is used to describe not only the
ability to produce experimental disease in an animal model but also the
characteristics of the disease with respect to the mean incubation period, especially
the standard errors associated with those means, and the actual range of individual
incubation periods for a given route of infection.
As expected, the routes that were examined: intraperitoneal, intramuscular
and oral gave different incubation periods with intramuscular being the shortest
(mean incubation 238 days ± 10) and oral being the longest (307 days ± 2). The
length of the oral incubation period was not unexpected; but the apparent efficiency
(defined in this case in terms of the ability to infect a population in such a way that
the incubation period from animal to animal is very similar) of this route of infection
as indicated by the exceptionally small standard error attached to the incubation
period was somewhat surprising as the oral route of dosing has been previously
reported as being one of the least efficient at establishing infection in mice
(Kimberlin and Walker, 1988). Recent reports concerning the oral infection of
hamsters with scrapie (Diringer et. ah, 1998) suggest that repeated dosing is a more
effective method of establishing infection. While this is true of the hamster system,
the single-dose approach described in this project has resulted in a highly efficient
incidence of infection. Indeed, with the exception of the intracerebral route of
infection (mice infected by this route were used as positive controls to insure the
quality of the inoculum source) the oral route of infection has been demonstrated to
be more efficient (defined as outlined above) at causing infection than either the i.p.
or the i.m. routes although, as mentioned, oral dosing does result in a protracted
incubation period and the amount of infectivity required to establish infection is
greater. Exactly how much greater is unclear; in this study the orally infected mice
were dosed with lOOpl of inoculum as opposed to 20pl for i.e., i.p. and i.m.. This
was an arbitrarily assigned amount, which was clearly adequate and actually only
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represents the difference between a dose of 10"2 and 5x10~2 infectious units. This
small difference, equivalent to half of one log would be lost in a full titration, and is
therefore not considered a significant source of error. An experiment of this nature
would be able to identify if there is a critical dose required to establish infection and
how that dose compares to critical doses in the cases of i.m. and i.p. infections. This
would help to categorically establish the efficiency of the oral route as a means of
causing infection, certainly in a disease model and it may have ramifications for
human disease especially with regards to predicting the size of any potential vCJD
epidemic.
The extended nature of the oral incubation period is not surprising and is
certainly, at least in part, a function of the speed of infectivity transport due to the
physical distance between the mouth/digestive system and the central nervous system
and the way in which the innervation of the gut interfaces with the CNS. The high
efficiency of the oral route that has been demonstrated in this project is probably due
to the uniformity of the system. The oral route of infection can almost be considered
as a 'closed-system' where the establishment of disease is much more likely to follow
a linear series of events, such as uptake of infectivity in the lymphoid tissues
associated with the mouth such as tonsil as well as gingival tissue of the gum
(Ingrosso et. al., 1999), than is the case following i.p. infection; there is also recent
evidence that the digestive tract is involved in uptake of infectivity in the case of
experimental murine scrapie (Maignien et. al., 1999). This degree of order is
supported by the narrow range of incubation periods observed in animals infected
orally. When a source of infectivity is introduced to the main body cavity, as in i.p.
dosing, there is no way of knowing accurately how the infectivity is distributed.
Following oral dosing, the infectivity will be subject to the same uptake by the same
peripheral nerves in every case; this leads to infectivity transport to both the CNS
and to the LRS, as evidenced by the presence of detectable PrP in the spleens of
orally infected mice at the late stages of the disease. Following i.p. infection the
infectivity is likely to be taken up by a variety of routes governed by distribution of
peripheral nerves in the peritoneal space. This differential uptake of infectivity may
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be responsible for the extended incubation period range, which is reflected in the
standard error of the means.
The route taken by infectivity from the periphery to the CNS is worth closer
examination especially as the extended incubation period range seen in this study for
the animals infected by the i.p. route is much more widespread than has been seen in
comparable previous infections at the Neuropathogenesis Unit (Kimberlin and
Walker, 1988). The incubation period of the mice infected by the i.p. route in this
experiment was 251 ±9 days (based on a group of 13 observations) with an incubation
period range of 92 days. This compares with the incubation period and range from
the orally infected mice which was based on a group of 15 animals and calculated to
be 307±2 days with a range of less than 30 days. The oral route also compares
favourably to the i.m. route. The point suggested above, that the more organised
nature of oral acquisition is responsible for the narrow range of incubation periods is
supported further by the results gathered from the i.e. and i.m. infected animals. As
would be expected following direct administration of the agent to the CNS (as in the
case of i.e. infection) the incubation period range is only 14 days.
Following i.m. infection the observed incubation period range was
approximately 75 days. This is less than was observed for the i.p. infected animals
but obviously more than either the orally or i.e. infected animals. This suggests that
the degree of order governing the transport of infectivity from the biceps femoralis is
higher than in the case of i.p infection. The suggestion again is that this is due to the
limited number of nerves in the muscle that would be capable of transporting
infectivity from the periphery to the CNS. There is also a possibility that there is
some degree of blood borne transport of infectivity to the LRS perhaps prior to
invasion of the nervous system. The LRS involvement is demonstrated by the
presence of PrPsc in the spleens of i.m. infected animals. However, in order to fully
address the questions surrounding the nature of this LRS involvement, more
experimental work to investigate the events following i.m. infection would have to be
undertaken.
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The difference between the incubation period ranges of the orally infected and
the i.m. infected animals may be a function of physical distance between site of
infection and entry to CNS. One of the contributory factors may be the presence of
lymphoid tissue associated with the digestive system which may be responsible for
some processing of the infectivity. The results of this study have shown that there is
PrP in the spleen of these infected animals and that it is detectable at the late stages
of the incubation period regardless of the route of infection, this is in contrast to BSE
in cattle where although the putative route of infection is oral there is no evidence of
involvement of the LRS (Somerville et. ah, 1997). There is a replication of
infectivity phase in the course of the infection, this takes place in the spleen
(Dickinson, 1975) and probably in other lymphoid tissues (Brown et. ah, 1999).
Recent reports of PrP in the tonsil of sheep with scrapie and human variant CJD
cases, as well as in the appendix ofCJD patients support this observation. The fact
that there is almost immediate contact between lymphoid tissue and the infective
agent following oral infection, in the buccal cavity, may be in part responsible for the
efficiency of the oral route of infection. The relatively short incubation period range
of the orally infected group is suggested to be a result of (at least) two factors: (i) the
organisation of the digestive system such that the number of available relays to take
up infectivity and transport it to the CNS is relatively small and the consequent
suggestion that a given peripheral nerve will, in every case, be responsible for this
event, and (ii) the presence of lymphoid tissue in the mouth may accelerate the
processing of infectivity by supplementing the function of the spleen. The wider
incubation period range seen in i.m. cases may not reflect the same sort of differential
uptake that has been suggested for those animals infected by the i.p. route as the
inervation of the muscles in the leg is very defined. More likely is the fact that there
are fewer 'shortcuts' to lymphoid processing of the infectivity following infection at
that site and the physical distance between the biceps femoralis and the spleen or the
CNS is greater than in the case of oral infection.
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There have been studies recently concerning the pathogenesis of orally
induced scrapie in hamsters infected with the 263K strain of the agent. These studies
report that following ingestion of the agent, spread of infectivity to the brain occurs
via the vagus nerve rather than along the spinal cord (Baldauf et. ah, 1997; Beekes et.
al., 1997; Beekes et. al.,1998). This suggests an alternative or perhaps
complementary direct route by which orally acquired infectivity can access the brain.
This is an avenue that may be worthy of further study in the murine model to
determine whether or not this is simply a species (hamster) specific event. Especially
interesting would be an examination of the spinal cord pathology that was
unfortunately not possible in this study for reasons explained in Chapter 3. To assess
the pathogenesis of scrapie in mice following oral infection a number of animals
would be required as to be infected and then serially killed at intervals leading up to
the time where the first signs of pathology are evident in the brain. The spinal cord,
vagus nerve and tissues of the lymphoreticular system could then be examined for the
presence of disease specific PrP, by immunohistochemistry, and infectivity, by
bioassay. This would provide answers to the questions concerning the course of
events between ingestion of the agent and initial signs of the disease in the CNS. The
results from the work described in this thesis provide clues as to when to start
looking and what the total incubation period will be as well as details of the first
areas of the brain that are affected. This, in conjunction with the proposed
experiment should enable a map of events to be created.
4.2.2 Differences in Appearance of Pathological Markers.
As discussed above, each of the routes of infection that were examined for
this study produced disease after different lengths of incubation. It is suggested that
at least part of the reason for these differences is the way in which the infectivity is
processed and transported from the periphery to the nerves of the spinal cord and
ultimately to the brain. As a consequence of these assumed differences in routing it
is likely that there would be differences in the emergence of pathological markers (in
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this case special attention was focused on PrP and GFAP) both in terms ofwhen in
the incubation period they appear and where in the brain they are first evident.
To enable the results from the three models to be compared in a meaningful
way the incubation periods had to be converted to a percentage scale. On this scale
day zero (the day of injection/infection) was assigned to be zero percent of the
incubation time, the mean incubation period for each route of infection was assigned
as 100 percent of the incubation. It is acknowledged that as this is based on a mean,
which in all three cases have a standard error greater than zero, that the 100 percent
mark does not encompass every animal from every group. However this was
considered the most suitable way ofmaking direct comparisons between models and
the animals that exhibited incubation periods greater than the mean would not overly
influence the result as the most meaningful and significant, route-dependant,
pathological differences would be present in the early stages of the incubation.
In the case of both the i.m. and the i.p. infected mice, the first PrP was
detected at roughly the same point in the incubation period. This point was 56% of
the total incubation period for the i.p. challenged animals and 58% for the i.m.
infected group. This is considerably different from the orally challenged group where
the first detectable PrP was found relatively later at 72% of the incubation period.
Especially interesting about this observation is the fact that although each timepoint
in the experiment was based on a group of four animals in the i.p. infected group, at
this early timepoint (56% relating to 140 d.p.i) PrP could only be detected in the
brain of one animal. Furthermore at the next timepoint (166 d.p.i) none of the four
animals examined had any measurable amounts of PrP in their brains, only at
timepoints beyond this did all of the i.p. infected animals present with detectable
quantities of PrP. This compares to the i.m. group where all four of the animals
examined at the early timepoint (58% of the total incubation period, which equates to
140 d.p.i.) displayed the presence of disease-associated PrP. PrP was also detectable
in all the i.m. infected animals sacrificed at timepoints after 140 d.p.i..
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The point in the incubation period that corresponds with the upregulation of
astrocytic activity was also determined for each of the three routes of infection under
investigation. It is reasonable to expect that the similarities and differences seen
between routes of infection with respect to the deposition of PrP, (that is the relative
points in the incubation period at which they occur), would also be seen in the case
ofGFAP accumulation. This is in fact not the case. The first signs of astrocytic
hypertrophy or hyperplasia, indicated by an increase in the amount of astrocytic
reactivity as evidenced by increased amounts of GFAP, in the brains of animals
infected by the intraperitoneal route occur at the same time as the first PrP is
detected, this is at 56% of the total incubation period length. However, the first
GFAP detectable following intramuscular infection is not seen until relatively later,
at around 70% of the total incubation period for that model. This is very close to the
same relative point at which reactive astrocytes can be detected in the brains ofmice
infected orally with ME7 scrapie, the actual figure for these animals being 72% of the
total incubation period. This result appears to support the hypothesis that the route of
infection influences the progress of pathology, this may be a consequence of the
number or available relays between the peripheral nervous system in the region of
infection and the CNS. It has been shown at the Neuropathogenesis Unit that
different agent-strain/mouse-strain combinations will exhibit differences in the
sequence of appearance of pathological lesions with regards to which marker appears
earliest in the incubation period (personal communication Jan Fraser and Debbie
Brown). This is attributed to a combination of the different genetic characteristics of
the recipient mouse and differences in agent strain. However in the case of this
experiment, only a single strain of the scrapie agent was used (ME7) and all the mice
infected were genetically identical, inbred, therefore this cannot be the case in this
instance.
As well as the relative temporal differences that are observed with respect to
the appearance of PrP and GFAP in animals infected by different routes there are also
route of infection-dependant differences in the regions of the brain that are affected.
This is true of the appearance of pathology early in the incubation periods. At the
93
terminal stage of the disease it more difficult to differentiate between animals
infected by different routes on the basis of their pattern of PrP and GFAP deposition,
that is to say that there is similarly widespread gross pathology throughout the central
nervous system of animals infected by all three routes such that the best way of
differentiating between routes of infection is to consider the differences in the
severity of the pathology throughout the CNS.
In the case of the animals infected by the intraperitoneal and intramuscular
routes the earliest signs ofPrP are seen at 140 days post injection. However, the
distribution of PrP at this timepoint in these animals displays many differences.
Although there are affected areas common to both routes of infection such as the
deep mesencephalic nucleus, the red nucleus, the anterior and posterior interposed
cerebellar nuclei and the numerous nuclei of the posterior and ventral thalamic
groups there are also regions ofPrP deposition that are apparent in one model but not
in the other. For example in the intraperitoneally infected animals there is evidence
of PrP being deposited as a band in the fourth layer of the cerebral cortex. This band
runs from the forebrain to the dorsal aspect of the cerebrum and is a feature of i.p.
infection that is not seen in either i.m. or oral infection. Certainly in the case of i.m.
infected animals, although there are signs of PrP deposition in the cerebral cortex
these deposits are much more discrete and are not present throughout the length of
the cerebrum.
In cases of oral infection there is no detectable PrP in the cerebral cortex until
approximately 80% of the way through the incubation period. At this point small
deposits of PrP are detectable in the frontal area of the cerebral cortex. This PrP does
not extend dorsally through the cerebrum and is more like the deposits seen in the
i.m. infected cases than in those animals infected by the i.p. route. Other route-
dependant, early lesions have been identified in the hippocampal structure. In the
orally infected animals there is obvious PrP in the CA3 region of the hippocampus
after 221 days; this corresponds with the earliest timepoint that PrP is detectable
anywhere in the brain. Also at this timepoint PrP can be detected among other
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regions the thalamus; the venterolateral thalamic nucleus, lateral posterior nucleus
and the anterodorsal thalamic nucleus; the cerebellum, posterior interposed cerebellar
nucleus and in the pontine reticular nucleus. This represents a wide distribution of
low levels ofPrP throughout the brain at point in the incubation at which the
presence of PrP is only just becoming apparent.
Although different specific areas of the brain are affected in the i.m. and i.p.
infected mice the general observation that there is a fairly widespread distribution of
PrP is the same as in the orally infected mice. The intensity of the protein deposition
is much less than is seen at later stages of the incubation period; this is not
unexpected. The observation that the spatial development of PrP pathology, with
particular emphasis on very early pathological events, differs from group to group
depending on which route of infection has been used reinforces the suggestion that
the peripheral processing of the agent, prior to establishment in the CNS, is a factor
in determining the pattern of early pathological lesions. This is supported by the fact
that in the case of both i.m. and i.p. infections, which both have very similar
incubation periods and ultimately similar pathological profiles, there are visible
differences in the patterns of early PrP deposition which can be attributed to route of
initial infection.
These route-associated pathological differences are similarly a feature of
GFAP accumulation in the early stages of the disease. The first notable difference
occurs in those animals infected by the intramuscular route. In these animals the first
detectable signs of upregulation of astrocytic activity are seen at 166 days post
injection. This is 26 days after the first signs of detectable PrP in the same animals.
It is accepted that the 26 day interval is a function of experimental design with
regards to sampling and that it is actually the case that the first reactive astrocytes
appeared prior to 166 days post injection; somewhere between 140 and 166 days post
injection. However, this observation ofGFAP appearing after the initial
identification of disease-specific PrP is not repeated in the animals infected either
orally or by the i.p. route. In those cases GFAP was first detected at the same time as
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the first PrP. It is possible that this observed lag in GFAP hypertrophy, when
compared to the other two routes of infection, may be a response to the amount of
PrP present. If astrocytes upregulate as a response to damage in the central nervous
system and PrP either causes damage directly by some neurotoxic mechanism
(Forloni et. ah, 1993; Selvaggini et. ah, 1993) or is simply a marker of the disease
then there may be a threshold level of PrP below which astrocytes are not stimulated.
This threshold level may be below the level of sensitivity of the assay system
described in this thesis. This again could be a consequence of the peripheral
processing of the agent and the physical distance from the site of infection to the
CNS. It is conceivable that because the biceps femoralis is apparently physically
further from the CNS than either the major body cavity or the digestive system that
any infectivity introduced at this site would take longer to process. Another possible
explanation is that there may be a greater number of neuronal relays for infectivity to
negotiate whilst travelling from the i.m. site to the CNS than is the case in either of
the other routes under investigation. This question cannot be satisfactorily answered
using the data produced in this experiment and would require a more stringently
designed course ofwork to address this issue. Consequently although PrP can be
detected in both i.m. and i.p. infected animals at 140 days post injection the amount
present in the brain of i.m. infected animals may well be less than is in the brain of
their i.p. infected counterparts. If this were the case then it might not be unexpected
that the level of disease-associated PrP required to elicit an astrocytic response might
not have been reached by 140 days post injection following i.m. infection.
Suggestions for further experiments that may address this question are given below.
4.2.3 Route of Infection Influences Pathological Profile.
Disease in experimentally challenged animals has been shown to develop at
different rates depending on the route of infection. Furthermore, the pattern of
pathological changes - at least in the early stages of the incubation period - also
exhibit route-of-infection dependant differences. What has also become evident,
from the work presented in this thesis, is that the profile of terminal stage pathology
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in these experimental cases are different, even though the agent-strain/mouse-strain
combination used in this study is constant. These differences are attributed to a
combination of route of infection and incubation period. By mapping the progressive
accumulation of PrP, GFAP and vacuolation these differences have been quantified
and have allowed comparisons to be drawn between routes. The fact that the
intramuscularly infected animals had a similar incubation period to the
intraperitoneally infected mice provides a crude way of assessing the extent of
influence that the incubation period had over the eventual pathological profile.
The vacuolar profiles from all three groups are significantly different from
one and other. Of particular concern is the oral profile which displays no real
discernible pattern with respect to either linear or exponential development of
vacuolar change. Indeed the oral profile displays regions where the degree of
vacuolation detectable and measurable, within the parameters set, at relatively early
stages of the disease is very much higher than is seen at the terminal stage of the
disease the main example being at 221 d.p.i. when the degree of vacuolation
measured in the caudate and in the brainstem is much higher than is seen at the
terminal stage of the disease, 320d.p.i.. One factor that may have influenced this
result is shrinkage of the tissue as the disease develops such that lesions that may
have been identified by the computer as vacuoles (by virtue of their size and shape) at
an earlier timepoint are no longer recognised as true markers of pathology. Another
factor which may influence this result is the location of vacuoles within neurones
(Jeffrey et. al., 1992) and subsequent neuronal loss which is a feature of some scrapie
models (Jeffrey and Halliday, 1994; Fraser et. al., 1997; Chretien et. al., 1999).
Consequently loss of neurones may result in loss of vacuoles which may account for
this observation. The fact that neither the PrP or GFAP profiles exhibit the same
degree of discrepancy would appear to support this assumption, or at least suggest
that this observation does not completely represent the true course of disease
development in orally infected animals. In order to address this issue it may be
possible, with highly defined neuroanatomical regions, to compare the volume/area
of said regions at different disease timepoints and in this way determine the degree of
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tissue shrinkage. This could then be taken into account when considering the size of
a true vacuole at the later stages of the disease. This however presents other
problems being that it does not make allowances for naturally occurring biological
diversity, nor does it recognise that tissue shrinkage as a result of fixation and
processing may occur non-uniformly depending on the reagents used. One other
solution is for an experienced pathologist/pathological screener to redefine the values
that dictate to the image analysis software what is and is not a disease specific
vacuole. This detracts from the objectivity of the exercise. These suggestions also
have their own intrinsic errors and it is arguable that until better and 'smarter' image
processing software becomes available these errors will remain.
The PrP and GFAP profiles of the orally infected animals are the most
consistent and possibly the most significant results to arise from this work. The
magnitude of these profiles is far greater than their relative counterparts from the i.m.
and i.p. infected groups. In the case ofGFAP accumulation in the orally infected
animals there is an almost linear pattern to the development of astrocytic pathology.
This is especially true after the 250d.p.i. timepoint. Beyond this timepoint the traces
are virtually the same shape, the only real differences being in the height of the points
on each trace. The only real aberration to this pattern is the 250 d.p.i. trace which
shows higher than expected level ofGFAP in regions 6,8 and 9. This may be due to
sampling and animal variation. The Oral PrP trace shows a peak value in brain
region 4 of the terminal group of almost 80,000pm2 which is almost double the peak
amount seen in the same region of either of the other two groups at the same relative
time point. The shape of the PrP profiles from the orally challenged mice are broadly
similar to those seen for GFAP, which is not unexpected given the observed co-
localisation that occurs between PrP and GFAP. However, there is one region
(region3, the hippocampus) which demonstrates a much higher level ofPrP at a
preterminal timepoint that is observed at the terminal stage of the incubation period.
This can be traced back to a single animal in that preterminal sample group which
had levels of PrP far in excess of its sample partners. Indeed this particular animal
had levels of PrP that were far higher than any of the animals in the subsequent
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terminal group. This animal specific variability is an unfortunate consequence of the
small number of mice sampled at each timepoint and is indicative of a shortcoming
in the design of the study. However, the numbers of animals that can be made
available for a given experiment is strictly regulated by an ethics committee at NPU.
It is unlikely that a much larger experiment would have been approved.
As described above, the vacuolar profiles from each of the three groups under
study vary quite substantially from each other in terms of severity and distribution.
However, unlike the oral profile both the i.m. and i.p. infected mice produce
vacuolation profiles that exhibit a reasonable degree of linearity. As a general
observation there is less overlap between timepoints than has been observed in the
case of orally infected mice. Of course this is not absolute and the best case to
illustrate is in the i.m. infected group where there is consistently more vacuolation
detected throughout the brain atl89 d.p.i than there is at 221 d.p.i. and more at 221
d.p.i. than at 231 d.p.i.. This may also be a consequence of tissue shrinkage or
neuronal loss as the brain becomes more affected by the disease although the
difference between the 221 d.p.i. and 231 d.p.i groups is more likely to be a sampling
result, again a consequence of the small numbers of animals selected at each
timepoint although in this case the closeness of the timepoints may also be a factor.
The measurements ofGFAP and PrP in the i.m. infected group produce traces
that are very different from those obtained in the orally infected cases. In general the
profiles are much flatter than in the oral cases and the progression of disease much
more regular. This is suggested by the similarity in shape of the profiles for each
timepoint. One particularly interesting point concerning the i.m. results is in the
comparison between the GFAP and PrP traces. At the terminal stages the profiles for
both GFAP and PrP have similar shapes and even where the shapes are less similar
the trend is the same. However, on the whole, the GFAP results show a steady
temporal increase in the amount ofprotein present. The traces fit on top of each
other as the disease progresses towards endpoint. This is not always the case, but
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where there is a break from this pattern there is only an inversion of one timepoint
and the resulting differences do not appear to be significant.
It ought to be pointed out however that because of shortcomings in the
experimental design, in particular the small number of animals examined at each
timepoint, statistically meaningful results cannot be produced. An example of this is
in the GFAP trace where the 189 d.p.i. trace lies above the 221 d.p.i. trace throughout
much of the brain. A similar inversion is seen between 221 d.p.i. and 231 d.p.i. in
the PrP result. More striking however, in the PrP result, is the 189 d.p.i. trace. This
shows that at 189 days following infection the amount of PrP detectable in almost
every region of the brain that was examined was greater than at any other time apart
from the end stage of the disease. This is an apparently anomalous result. Scrapie
and the associated TSEs are by their nature progressive diseases. If this result is
considered solely on the information obtained from the computerised image analysis
system then the suggestion is that relatively early in the disease incubation following
i.m. infection (this is not seen in either orally or i.p. infected mice) there is a large
deposition of PrP in the brain which is subsequently cleared, or trafficked to a region
or regions of the brain out with the scope of this study, only to be redistributed back
in the same areas as it was previously detected, at the terminal stages of the
incubation period.
A different interpretation (and one which seems more plausible given the
limitations of the image analysis system that was used to produce the results) might
be that this observation is a result of protein aggregation. Consider an hypothesis
that accepts the result observed at 189 d.p.i. and the subsequent timepoints to be
genuine with regards to the area of the brain occupied by detectable PrP. The
important consideration here is that the image analysis system employed in this study
does not have the capacity to measure the actual amount of protein in the brain,
instead it measured the area that the protein of interest occupied. It is known that PrP
forms aggregates of protein, for example amyloid plaques (Bruce, 1981; Hope et. al.,
1988). One interpretation of the results might be that the PrP detected at 189 d.p.i. is
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in a non-aggregated or less-aggregated form than is present at the end-stage of the
disease. If it can be assumed that aggregation of PrP results in concentration of the
protein then it is feasible that the area occupied by a given amount of PrP would be
less if the protein was in an aggregated state. The actual amount of protein would be
identical but without a means ofmeasuring the concentration of the protein in a
section the result as obtained by the image analysis system would show an apparent
decrease in the level of PrP in the brain.
With this suggested mechanism of protein concentration the results can be
explained in terms of an early stage of PrP release into the neuropil prior to any
aggregation (Jeffrey et. ah, 1994). This would then be followed by a combined
sequence of deposition and concentration - this would explain how the level of PrP
increases to its endpoint peak - until the terminal stage of the disease. The
observations made by the image analysis system in this case would be much as has
been seen. Of course in order to test this hypothesis it would be necessary to develop
an assay capable ofmeasuring the actual amount of PrP in an aggregate. The
simplest approach would be to perform a total protein extraction from the brain and
perform a quantitative Western analysis using specific anti-PrP antibodies (ideally
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anti-PrP antibodies such as those developed by Prionics in Switzerland, Korth et.
ah, 1997) and subsequent densitometric analysis. However, as this destroys the
tissue that is under investigation it is obviously not suitable in cases where pathology
and histology are paramount considerations. Another possible method of
determining the amount of protein depends on the development of an effective tool
for measuring both area occupied by the protein and the optical density of the region
of interest. This is theoretically possible, although technically it is beyond the
capability of the system used in this study. If a system of this sort could be
developed then it would become possible to measure absolute amounts of
immunostained product, this in turn would overcome the potential problem of
comparing different types of PrP deposit that exists when they are considered only in
terms of the area that they occupy within a section or a microscope field.
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The results of this thesis with respect to orally challenged mice have been
very interesting especially in comparison to what has been reported in the literature
regarding the relative inefficiency of the system and requirement for significantly
higher infecting doses to produce disease (Kimberlin and Walker, 1988; Kimberlin,
1994). The work presented in this thesis shows that this is not in fact the case. This
is in keeping with recent reports regarding oral pathogenesis in hamsters infected
with the 263K strain of scrapie (Diringer et. al., 1997; Beekes et. al., 1998) which
report the oral route of infection as being an efficient means of establishing disease in
Syrian golden hamsters. This efficiency is increased if repeated or multiple dosing
regimes are adopted (Diringer et. al., 1998) however it is not wise to assume that the
hamster model acts in exactly the same way as the murine model described in this
thesis. The fact that 100% infection was achieved in mice following a single dose of
infectivity may simply indicate that oral dosing is perhaps more efficient in mice than
in hamsters at establishing infection. These differences in efficiency may that oral
pathogenesis is perhaps best studied in mice although the shorter incubation period
seen in the hamster/263K combination is an attractive feature for researchers in the
field.
4.3 How do the Kinetics of Infection Vary With Route?
The kinetics of experimental infection were investigated to determine what
effect any route-dependant differences in the processing of infectivity might have on
the pattern of pathology, especially the speed and rate at which pathological markers
accumulate. The results in Chapter 3 demonstrate the rate at which pathology
develops in three specific brain areas (the thalamus, the hippocampus and the frontal
cortex) following infection by each of the three routes under investigation. These
regions of the brain were chosen as they are the regions that appear to be most
involved in terms of detectable pathology (in the case of hippocampus and thalamus)
for all the routes of infection studied. The frontal cortex was chosen as it appeared to
be less involved and could be thought of as a test of the ability of the image analysis
system to detect subtle changes in the pathological status of a given region. These are
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not true kinetics as defined in terms of information regarding rate of agent
replication, but the information that they do provide can be assumed to be a parallel
of this. The most attractive feature of the information as it is presented is that it
demonstrates the development of pathology from that earliest point in the incubation
at which PrP and GFAP can be detected. In order to draw meaningful comparisons
between routes of infection it was necessary to 'normalise' the incubation period for
each model. It was decided that the simplest way to do this was to convert the
incubation period into a scale of 100 equally spaced points. In this way events
occurring at a particular point in the incubation period of an i.m. infected mouse can
be directly compared with the same relative point in an orally infected mouse. This
is not a perfect solution as the standard errors associated with the incubation periods
mean that some of the animals considered as representing 100% of the incubation
period actually succumbed to disease at some time after that point. This is
acknowledged as a source of error and represents a shortcoming in the experimental
design but as this study is especially concerned with early pathological events and
because each of the experimental groups is subject to this source of error it is
considered acceptable and not likely to significantly bias the results.
4.3.1 PrP Kinetics in Experimental Infection.
In the orally infected group ofmice the first PrP that is detectable by the
image analysis system is seen relatively later than is the case in either the i.m. or the
i.p. groups (approximately 70% of the total incubation period compared to 50% in
the i.m. cases and 56% in the i.p. cases). This could be interpreted as an indication of
the reported inefficiency of the oral route of infection (Kimberlin and Walker, 1988)
and evidence of an extended replication phase of the agent outside of the CNS.
From the time of first detection in the thalamus until the end of the incubation period
there is a rapid almost exponential increase in the amount of PrP that can be
measured. The steep gradient of this curve is indicative of a high rate of PrP
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deposition. The maximum value is reached at the very end of the incubation period.
This is not unexpected and would be an intuitive assumption given the progressive
nature of the disease. However, although the same exponential type of increase is
seen in the hippocampus and the frontal cortex, the maximum level of PrP is
achieved at a time period prior to the terminal stage of the disease. These maxima
occur in both cases at approximately 95% of the total incubation period, after which
time there is a noticeable, and especially in the case of the cortex highly substantial
diminution in the amount of PrP that can be measured. In the case of the frontal
cortex the gradient of the slope leading towards the maximum value is steeper than in
the thalamus or in the hippocampus this suggests that the rate ofPrP deposition in the
cortex of orally infected mice is greater than in the thalamus of similarly infected
animals although the amount of protein deposited there is not as great.
The apparent drop in the amount of protein in the cortex and hippocampus
prior to the terminal stage of the incubation period is a particularly puzzling feature
as it is not seen in either of the other two models under investigation nor is it seen in
the measurements ofGFAP made in parallel regions of serial sections of orally
infected mouse brain. Indeed it seems to be a feature that is particular to the orally
infected group of animals. The reasons for this are unclear but it is possible to
theorise that given the extended nature of the oral incubation period compared to the
i.m. and i.p. models that the rapid decrease is perhaps related to this longer
incubation. This theory makes no assumption about what triggers the fatal event in
scrapie infection that leads to the death of the animal. It is particularly difficult to
address that question with the information presented here: for example if death from
scrapie infection were solely the result of excessive amounts of PrP in the brain then
it may be expected, from this data, that the incubation periods of the i.m. and i.p.
infected animals (in which there was measurably less PrP at the terminal stages of the
infection than was seen in the oral cases) would be extended. This is clearly not what
has been observed in this study. It is conceivable that given the longer incubation
period which is associated with the oral infection that there is a greater degree of
processing of the disease associated PrP. PrP is known to form aggregates and the
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longer incubation period may allow the PrP to aggregate into tighter and more
defined structures, for example amyloid plaques, this is however only a theory at this
time as there is no evidence that plaque formation is a direct function of incubation
period. These would have the appearance of being darker - as the protein becomes
more concentrated - than in cases where there was a lesser degree of organisation but
it may also have the effect of reducing the total area of the brain that is occupied by
the protein whilst at the same time representing an increase in the actual amount of
PrP present. Using the image analysis system described in Chapter 2 it would be
impossible to differentiate between a protein concentration event of this type or a
genuine decrease in the amount of PrP present. However, given that scrapie is a
progressive disease and there is no evidence of any instances where the amount of
PrP in an infected animals brain has decreased, perhaps as the result of scavenging by
phagocytic cells in the CNS, prior to death this seems unlikely. What is very clear
from this study is that the maximum level of PrP, as measured by the area that the
protein occupies, in the brains of these orally infected mice is far in excess of the
levels detected in their i.m. or i.p. infected counterparts and the rate at which the
protein accumulates following its initial detection is also far greater in the orally
dosed group.
In the i.p. infected group the most heavily affected region was the thalamus.
This is also the case in the i.m. infected mice as well as in the oral group described
above. However, the maximum levels of PrP that can be detected in either the i.m. or
the i.p. group is approximately half that which is seen in the oral group (the i.p.
infected animals present with more thalamic PrP than the i.m. group, but this is still
far below the level seen following oral challenge). This is in keeping with the idea
that an extended incubation period means that there is more opportunity for greater
amounts of PrP accumulate in the brain, and that high levels of PrP alone are not
sufficient to cause death. However, neither the i.p. nor the i.m. infected mice display
the same sort of rate of accumulation. For the most part both of these groups display
a fairly steady level of PrP until very late in the incubation period. There is a notable
hump in the early part of the curves for both groups, which is not seen in the orally
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infected mice. In the i.p. group this occurs at around 75% of the way through the
incubation and in the i.m. group at around 67% of the total incubation period. This
hump is seen in all three of the brain areas examined with the exception of the
hippocampus in the i.p. infected group. This may be the result of an intermediate
stage in the processing of the PrP in the brain, as has been postulated above. If this
type of proposed packaging of the PrP protein is actually occurring then this part of
the incubation period may coincide with the key event in the formation of amyloid
plaques. This would result in a temporary reduction in the amount of diffuse non-
aggregated PrP in the brain. This level would then start to rise again as more PrPsc
was deposited in the brain. As in the case of the oral kinetics this is purely
speculation and further work, including the development of a more powerful analysis
system, capable ofmeasuring the concentration of protein contained within a given
aggregate, is required before observation can be examined more closely. Two things
are very clear from the kinetics study; first is that the amount ofPrP found in the
brain of orally infected animals is much more than is found in the brains of animals
infected by the other routes under study. This is almost certainly a function of the
extended incubation period that is seen in the case of oral infection. Second, although
the appearance of PrP in the CNS occurs later in the course of the disease, relative to
the length of the whole incubation period, of orally infected animals than in either of
the i.m. or i.p. groups, after it is detected the rate at which it accumulates is very
much higher than in the other groups.
4.3.2 GFAP Kinetics in Experimental Scrapie Infection.
As with the results of the PrP kinetics study one of the first observations that
was made regarding the deposition ofGFAP was that the levels that could be
measured in the thalamus were far higher at the end stages of oral infection than after
infection by either the i.m. or i.p. routes. This is not unexpected as there is a strong
relationship between PrP deposition and GFAP accumulation and the rate of this
GFAP accumulation appears to be similar to the rate of PrP deposition, as seen by the
almost identical gradient of the trace. However, unlike the PrP results which showed
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markedly higher levels of the protein in the orally infected animals in all three
regions studied, this is not the case for GFAP.
In the orally infected group one of the more interesting observations regards
the levels ofGFAP seen in the hippocampus compared with the frontal cortex. The
level of hippocampal GFAP is approximately double the amount that is seen in the
frontal cortex, this is an inversion ofwhat is seen with respect to the levels of PrP in
these areas. It is possible that this is due simply to the number of astrocytes that are
found in each of these respective areas but this is unclear and information regarding
the normal distribution of astrocytes in the murine CNS is not readily available.
The deposition ofGFAP in the hippocampus of orally infected mice is a
much more linear affair than is seen with the PrP accumulation. Following first
detection of reactive astrocytes, which occurs at the same time as the first PrP is seen,
there is a steady progression in the hippocampus. In the frontal cortex of the orally
infected mice the pattern of accumulation depicts a rather extended lag phase where
there is very little GFAP to be seen. This then proceeds slowly, as defined by the low-
slope of the trace, to a peak that is not only far lower than in either of the other two
regions examined in the orally infected mice but it is also much lower than is seen in
the corresponding area of the other two groups of mice, i.m. and i.p. infected. This is
unusual given that the peak amount of PrP detectable in the frontal cortex of the
orally challenged mice is many times higher (approximately five times) than the peak
amount registered in the i.m. group.
Examination of the kinetics of PrP and GFAP accumulation in each of the
three brain areas in i.m. and i.p. infected animals show that the deposition of PrP is
closely mirrored by the accumulation ofGFAP, and by inference the activation of
astrocytes. This is indicated by the similarity in shape and gradient of the PrP and
GFAP traces. It is also the case that the kinetics results from each of the three areas
in each of the i.m. and i.p. groups are very similar. This close similarity, both within
a group and between the i.m. and i.p. groups, suggests that the processing of
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infectivity and the progression of the disease in these cases are similar. The fact that
those two groups are so similar whereas the orally infected group is markedly
different - (not only from the other groups but even within it's own group, where the
GFAP and PrP traces for a given area are very different except for the thalamus),
suggest that these differences are the result of an alternate route of infection.
This suggests that infection of a given strain ofmouse with a given strain of
scrapie, via the oral route will result in an infection that develops a more severe
degree of pathology than if the infection were established by another route.
Furthermore the observed parallel between PrP and GFAP that has been seen in the
i.m. and i.p. groups is not observed. This phenomenon may not solely be a function
of route of infection but these differences coupled with the extended incubation
period (when compared to other peripheral infections) encourage questions about the
role of both PrP and GFAP in disease development and these observations again raise
questions about what the fatal event in scrapie infection actually is. If for example
death from ME7 scrapie is the result of neuronal loss brought about by a PrP
mediated acute inflammatory response (Betmouni and Perry, 1999) then it seems
intuitive that the model producing the most PrPsc would have the shortest incubation
period, or, that the model with the shortest incubation period would indicate what the
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'lethal' amount of PrP required to produce a fatal degree of neuronal loss ought to
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be. The results of this study would suggest that PrP mediated neuronal loss is not
the only factor in causing death by ME7 scrapie.
4.4 The Role of the Lvmphoreticular System in Experimental Scrapie Infection.
Replication of the scrapie agent in the tissues of the lymphoreticular system
(LRS), following extra-neural infection, is recognised as an important stage in the
development of disease prior to the observation of pathology within the CNS. This
peripheral processing occurs without obvious tissue damage to the LRS or any signs
of physiological deficit. Of particular importance in this process is the spleen
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(Eklund et. al., 1967) which constitutes the major organ of the LRS, although other
components of the LRS are involved such as the lymph nodes. In the case of human
TSE infection there is evidence for involvement of the tonsil and appendix (Hilton et.
al., 1998). There is also demonstrable involvement of the spleen following
intracerebral infection with some strains of the scrapie which appear to undergo a
replication stage in the spleen despite the fact that they have been introduced directly
to the target organ, the brain and CNS. The target cell for this replication stage is
thought to be the follicular dendritic cell, or FDC (Brown et. al., 1999; O'Rourke et.
al., 1994).
In the later stages of the studies described in this thesis it was decided to
examine the spleens of animals infected by alternate, extra-neural, routes at the late
stages of the incubation period in order to determine whether or not there was an
accumulation of disease associated PrPsc in the organ. As mentioned above the
tissues that were examined were harvested from animals in the late stages of the
disease incubation period. This unfortunately means that data concerning the early
accumulation of infectivity - as indicated by PrP accumulation- is lost. This is an
obvious shortcoming in the study. However, the decision to investigate the spleens
for markers of infection was not taken until after the early incubation period animals
had been sacrificed and examination of the lymphoreticular system was not one of
the original objectives of the study. From the tissues that were available it was
possible to show that there is detectable PrP in the spleen of animals infected orally,
i.m. or i.p. at the late stages of the disease. The PrP is restricted to the germinal
centres of the follicles, the site of residence of FDCs. This is in keeping with
previously published observations (McBride et. al., 1992).
Spleens were recovered from animals sacrificed at the three latest timepoints
in the orally infected mice. This represented a period from approximately 80% of the
total incubation until the terminal stages of the disease. PrP is detectable in the
spleen at this timepoint (80% of the total incubation) as it is in spleens of animals
sacrificed at the two subsequent time points (corresponding to 87% and 100% of the
109
incubation period respectively). However, there appears to be a decrease in the
amount of PrP that can be detected in these spleens as the end stage of the disease is
reached. In the case of the i.p. and i.m. infected animals spleens were taken from the
penultimate group of animals to be sacrificed and the terminal group. This was due
to the reduced total incubation period, compared to that of the orally infected mice.
In the spleens taken from the i.m. infected mice PrP was detectable and was localised
to the follicles as expected. However contrary to the observations made in the orally
infected mouse spleens, of an apparent decrease in PrP levels, in these animals there
appeared to be more protein in the spleens of animals sacrificed at the terminal stage
(100% of total incubation period) of the disease than at the penultimate timepoint
(89% of the total incubation period). To further confuse the issue, in the spleens
removed from the i.p. infected animals there was no apparent difference between the
amounts of PrP detected at the penultimate stage of the incubation period (91% of the
total) and the terminal stage. Given the small number of observations and the fact
that only spleens from animals at the late stages of the incubation were examined, a
further, more in-depth study is required to investigate the possibility that these results
are a function of sampling errors.
These observation demonstrate that the spleen is involved in the disease
process and remains involved up to the end of the incubation period. There is also a
suggestion that the route of infection may have an influence on the involvement of
the spleen, and by extrapolation other elements of the LRS in the processing of
scrapie infectivity as indicated by the presence of PrP. For example, in the case of the
orally infected mice where there is apparently a reduction in the amount of PrP in the
spleen as the disease reaches endpoint perhaps there is a mechanism at work to
transport the protein out of the LRS and into the CNS via the spinal nerves. This
could be part of the reason that the amount of PrP found in the brain of orally
infected animals is so much higher than in animals infected by the other routes under
study, although the extended incubation period is the most likely reason.
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These are however, subjective observations and hypotheses made on the basis
of few observations. As such there is no way to substantiate the suggestion that
route of infection influences the role of the LRS in experimental scrapie infection. In
order to decide whether or not these observations are genuine it would be necessary
to perform more experiments. Proposals for this and other further work are discussed
below.
4.5 Does the Pathology Observed in Animal TSE Models
Compare with Acquired Human Disease?
The main aim of the work described in this thesis was to test a hypothesis that
suggested that the route of infection had a significant influence on the pathological
outcome in cases of experimental scrapie. By choosing the i.p. and especially the
oral and i.m. routes of infection it was possible to examine scrapie under the guise of
an acquired TSE infection, such as has been seen in man with vCJD and iatrogenic
CJD infections.
The proximity of the Neuropathogenesis Unit, where this study was carried
out, to the National CJD Surveillance Unit in Edinburgh and the close professional
relationship that exists between both centres made it possible to examine any
similarities and differences in the pathological profiles of acquired human CJD with
an animal analogue. The basis for comparison between animal models and human
cases of acquired CJD centred on the distribution of vacuolar change and the
distribution and appearance of PrP depositions within certain brain regions.
One of the implicit drawbacks with this sort of comparative exercise is that
although there is the opportunity to study the development of pathology in the animal
models at various timepoints throughout the disease incubation, it is only possible to
examine terminally affected tissue in the human cases. On this basis the tissues
selected for comparison with the human cases were taken from the endpoint animals
infected by each of the routes under study. Immediately this poses a challenge with
respect to extracting useful information from the exercise. Although there are early
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differences in the distribution of lesions; by the time the disease reaches the terminal
stages the severity of the pathology that can be seen, in terms of vacuolation GFAP
accumulation and PrP deposition, as well as the broad regional distribution of these
markers is the same in the different animal models. The same is obviously not true
of human disease where there are obvious regional differences in the pathology that
can be seen depending on the type of infection involved (iatrogenic, vCJD or
sporadic). Indeed it is these differences in distribution along with the appearance of
other indicators (for example, 'florid plaques' in vCJD and analysis of PrP genotype)
that allow a diagnosis to be reached. It is difficult in these circumstances to draw any
conclusions regarding the influence that route of infection has in TSE infections
acquired by humans. In the animal models the observations made in this study
indicate that early pathological events are more likely to be influenced by the route of
infection than the eventual pathological profile. The animals used in this study were
all of the same inbred strain and they were all infected with the same strain of
scrapie. This is obviously not the case in human acquired disease, where not only are
the host genetics subject to variability between cases but the infecting agent cannot
be assumed to be of the same strain in each case. Proof exists that the strain of agent
responsible for vCJD in man is also the strain responsible for BSE in cattle (Bruce et.
al., 1997), this however is different from the agent responsible for infection in
iatrogenic cases or sporadic cases, although there is a possible argument that the
agent responsible for iatrogenic infection resulting from pituitary derived growth
hormone therapy may be the same as the agent responsible for sporadic CJD. Strain
typing experiments such as the one that proved that BSE in cattle and vCJD in man
were caused by the same strain of agent could be used to examine this. There is
however, no current evidence to support this assertion.
Current epidemiological evidence from Australia suggests that people who
have undergone more than three general surgical procedures double their risk of
developing sporadic CJD (Collins et. al., 1999). The likely explanation for this
increased risk is one of increased exposure with surgical exposure resulting in an
unrecognised iatrogenic infection. Reuse of surgical instruments that may not have
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been completely decontaminated following procedures, such as tonsillectomy, in
patients who may have gone on to develop CJD. It has been shown that PrP and by
association infectivity can be detected in these tissues in humans with variant CJD
(Hill et. al., 1999). Tonsils are negative for PrP both by immunohistochemistry and
Western blot in cases of sporadic CJD, this however does not discount the presence
of infectivity in other tissues and the consequent risk of carry-over infection. In
sheep (scrapie) and cattle (BSE) PrP can be detected far in advance of the onset of
any neurological symptoms (Van Keulen et. al., 1996) so it is conceivable that
residual infectivity could transmit the disease - in much the same way as
contaminated neurosurgical electrodes have been linked to transmission of the
disease. Of course transmission as a result of general surgery is likely to be far less
efficient than transmission from neurosurgery. In terms of the experimental models
described in this study sporadic CJD as a result of infection following surgery might
be an iatrogenic event that represents a route of infection similar to the i.p. infection
used in animals; unfortunately there is only very limited data on infectivity outside
the CNS in sporadic CJD.
The differences in pathology, both distribution and type, observed in the
human cases are not seen in the animal models at the terminal stages. This does not
necessarily mean that the route of infection does not influence the pathological
presentation of these diseases in humans, but, due to the number of variables that are
not controlled in human disease it is not possible to assess to what extent this route
dependant influence may extend.
It has not been possible, from this comparative study to draw any conclusions,
regarding the role that route of infection plays in the development of human CJD and
the appearance and distribution of lesions in the CNS at the terminal stages of the
disease. The fact that the terminal pathology in each of the human cases is markedly
different would suggest that the early pathological events are also different. This is
similar to what is seen in the animal models where the early pathological changes are
most likely to exhibit differences which, considering the constant agent strain/host
genetics combination, can be attributed to the route of infection. So it is possible and
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indeed likely that route of infection affects early pathology, by virtue of the way in
which the infectivity is processed in the periphery prior to invasion of the CNS. The
subsequent differences in pathology that are seen in the human disease, but which are
largely absent from the animal models must then be a function of other factors
including host genetics and agent strain. Table 13 summarises some of the
differences that are seen in the various different types of human CJD infection in
certain areas of the brain. Of particular interest are the pathological differences seen
in the sporadic cases which appear to be a function of the host genotype, in particular
at codon-129 of the PrP gene. Comparison of the methionine homozygotic, sporadic
CJD, profile with the variant CJD profile, where all cases to date share the same PrP
genotype (129MM) reveals differences in pathology that can be attributed to either
strain of agent and/or route of infection. Unfortunately neither of these factors are
known to be common to both disease subtypes. It is therefore difficult to determine
how much influence the route of infection alone exerts on the pathological
phenotype.









































Table 13: Summary of some of the key pathological differences that are seen in the various subtypes
of human CJD. Special reference to spongiform change and PrP deposition.
(Table courtesy of James W. Ironside).
In order to study the extent to which each of these individual factors
influences terminal CNS pathology it would be necessary to set up further, much
larger experiments than have been described in this thesis involving multiple strains
of inbred mice infected by multiple peripheral routes with a variety of strains of
scrapie. This was certainly not feasible within the time frame of this project.
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4.6 Can Mice Devoid of Endogenous PrP Transport Scrapie Infectivity?
It is reported in the literature that that the presence of endogenous PrP in the
central nervous system is required in order to facilitate the transport and propagation
of scrapie infectivity such that the disease can spread throughout the brain (Bueler et.
ah, 1993; Sailer et. al, 1994; Weissmann et. ah, 1994; Brandner et. ah, 1996;
Brandner et. al., 1997). The spread of the disease is explained, in the terms of the
protein-only hypothesis, as a process of sequestration and alteration of the host
encoded, endogenous, PrP into the pathogenic, disease-associated form (PrPsc). The
alteration which takes the form of a conformational change is what gives the agent its
unusual physico-chemical properties. In the case of acquired disease (such as
experimentally induced scrapie) the conformational change is driven by exogenous
'prions' which consist of the abnormal form of the protein. Once this process starts it
becomes self-catalysing such that the limiting factor is the amount of available
normal PrP. In accordance with this model mice that are devoid of endogenous PrP
are resistant to infection with the scrapie agent; however, the actual transport of
infectivity is also thought to be PrP dependant. The results gathered from this project
suggest that this is not necessarily the case.
Although the numbers involved are very small it is interesting to note that
three bioassay animals (C57BL mice) that had been injected with material from the
visual systems of PrP-null animals previously injected intraocularly with ME7
scrapie developed disease, but this was not seen in any of the recipients of PrP-null
tissue. The affected bioassay animals were injected with preparations of tissue
harvested from the PrP-null mice 24hours post intraocular injection with ME7
scrapie.
Twenty-seven (27) bioassay animals were separated into three equally sized
groups. Each of these groups was the recipient of either optic nerve, superior
colliculus or dorsal lateral geniculate nucleus homogenates which were prepared
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from a pool of six PrP-null mice sacrificed 24hours post injection. Of the nine
animals who received the optic nerve preparation, two exhibited signs of scrapie
infection and were sacrificed at 304 d.p.i. One of the animals that received the
superior colliculus preparation also developed scrapie with an incubation period of
316 days. These three animals were confirmed as having scrapie caused by the ME7
strain of the agent by experienced staff at the Neuropathogenesis Unit. None of the
animals that received the dLGN preparation developed or exhibited any sign of
disease.
The most immediate concern surrounding this result was that it could be the
consequence of contamination with extraneous, infective material not derived solely
from the PrP-null tissue donors. However, there is no readily identifiable source of
this type of contamination. The most likely source would be residual inoculum in the
globe of the eye but care was taken not to rupture the globe whilst the tissues were
harvested. Furthermore, if the inoculum pool had been contaminated in some way
then it is likely that more of the bioassay animals would go on to develop scrapie.
This is not the case.
A particularly interesting feature of this result rests in the comparison with the
control group. The control animals received similarly prepared and pooled inoculum,
but in this case the donor animals were PrP expressing 129/Ola mice. Groups of
these animals were sacrificed in parallel with the PrP-null animals. The tissues
harvested from the control group at 24 hours post infection only produced disease in
three of the bioassay mice injected with the optic nerve preparation. This may
indicate that the rate of trafficking of infectivity was actually quicker in the PrP-null
mice than in the wild-type as indicated by the transmission of disease from the
superior colliculus fraction.
This result indicates that there could be a degree of transport of infectivity in
the CNS ofPrP-null animals. The fact that the incubation periods were relatively
longer in the recipients ofPrP-null tissue coupled with the observation that only
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tissues harvested 24 hours post-injection are infective may be indicative of a diluting
effect. The discrepancy in incubation periods may be explained in terms of
infectivity titre. In the wild-type where replication of the agent is assumed, the titre
of infectivity rises and this may account for the shorter incubation period, ifwe
assume that there is no replication of infectivity in PrP-null mice. The observation
that only tissues harvested very early after initial injection with the agent are capable
of transmitting the disease indicates that the level of infectivity in these visual system
areas at the later timepoints is not as high. This could be the result of transport of a
finite amount of infectivity through the CNS, the result ofwhich is sub-infective
levels of the agent over a wider area of the visual system. It may be a worthwhile
exercise in the future to design an experiment that will enable not only regional assay
of certain CNS nuclei but also whole brain infectivity assays in PrP-null mice.
Proposals for worthwhile future work are considered at the end of this chapter.
The final feature of this result that is worth consideration concerns the pattern
of disease appearance in the control group. The results show clearly that in animals
infected with wild-type tissues harvested between 41 d.p.i. and 83 d.p.i. there is a
noticeable trough in the number of animals that develop the disease. The reason for
this is not clear, but it may represent a lag-phase in the donor animals during which
the infectivity undergoes some form of processing and is not active in promoting
disease (Kimberlin, 1979; Bruce and Dickinson, 1985). This is conjecture at this
time, and although there is always the possibility that the lack of scrapie-infections in
animals in receipt of these tissues is the result of experimental error, this seems
unlikely. However constraints of time, one of the main problems associated with
TSE research, make it impossible to repeat this experiment during the course of this
study.
What this experiment seems to show is that regardless of the PrP status of an
animal, scrapie infectivity can be transported in the CNS. The speed at which
infectivity is found in the superior colliculus of the PrP-null animals would suggest
that the transport process is active, this is in keeping with previous reports that
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infectivity travels by axonal transport (Kim et. al., 1990). Of course the result also
supports the view held in the literature that animals devoid of endogenous PrP cannot
effect the replication of the infective agent and that by association PrP is closely
associated with the agent itself.
4.7 Summary.
This thesis reports the results of a pathological investigation into the effect
that establishing scrapie infection in mice by a variety of peripheral routes, including
oral has on the pattern of pathology that subsequently develops in the CNS. The
inclusion of the oral route of infection was considered especially pertinent
considering the recent suggestion of a causal link between BSE in cattle and vCJD in
humans. A further study was conducted in parallel with this study for the purpose of
examining the possibility that mice devoid of endogenous PrP are capable of at least
transporting scrapie infectivity in the CNS. This study was conducted inoculating
PrP-null mice, and their wild-type (control) counterparts, with ME7 scrapie by the
intraocular route. By this route pathology and infectivity are targeted in a well
defined manner to the projections of the optic nerve. This facilitates the micro¬
dissection of discrete areas of the visual system and assay of these regions for the
presence of scrapie infectivity. The results suggests that infectivity can be
transported in the CNS of mice devoid of PrP although the degree of transport is
limited and does not appear to be accompanied by any replication of the agent that
would be denoted by amplification of the amount of infectivity and subsequent long
incubation (consistent with low levels of infectivity) in the affected bioassay animals.
This result contradicts the report that endogenous PrP is necessary for the
transport of scrapie infectivity in the CNS (Brandner et. al., 1997) and is the first time
that such an observation has been made. The possibility that this observation was the
result of a contamination event was fully considered. However, on review of the
experimental procedure and scrutiny of the pathology in the affected bioassay
animals, there is no reason to suspect that the result does not support the fact that
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transport of infectivity has been demonstrated in animals previously thought to be
incapable of doing so.
The investigation into the role that the route of infection plays on the
development of pathology in experimental scrapie infection constituted the major
part of the work presented in this thesis. By designing the experiment in such a way
as to restrict the experimental infection to a single strain of agent in a genetically
homogeneous population it was possible to attribute any differences in the observed
pathology to the route of infection. It is possible that the increased infecting dose
that was administered to the orally infected animals (five times the volume
administered to the i.p., i.m. and i.e. infected mice) may have had an effect on the
development of pathology that is dissociated from the influence exerted by route of
infection alone. However, considering that the oral route is thought to be up to
100,000 times less efficient at establishing infection than the i.e. route (Kimberlin
and Walker, 1988), it is unlikely that this is the case. The results of this study have
shown that the oral route of infection is actually very efficient at establishing CNS
disease in experimental mice. All of the animals infected orally succumbed to
infection in a relatively constant period of time. The incubation period observed
when infection is established by this route is longer than any of the other routes of
infection but the standard error associated with the mean incubation period for the
orally infected mice is very small. This is taken to indicate uniform and efficient
processing of infectivity in the periphery prior to invasion of the CNS. This
demonstrable efficiency of oral infection is complemented by recent studies of oral
pathogenesis in hamsters using 263K scrapie ( Diringer et. al., 1998; McBride and
Beekes, 1999) although if anything this study suggests that mice infected with ME7
are even more susceptible to disease following oral challenge. Ultimately the
pathology seen in the brains of orally challenged animals was more severe than was
seen in animals dosed by the other routes in this study. However, the actual
distribution and appearance of the pathology, in terms of the brain areas affected and
the form of the PrP protein found in those areas, was indistinguishable at the terminal
stages from the pathology seen in the brains of i.p. and i.m. infected animals. The
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increased severity of the lesions in the CNS of orally infected animals is therefore
probably due to the increased incubation period. The i.p. and i.m. infected mice had
similar incubation periods and displayed broadly similar terminal pathology both in
terms of distribution and severity. Where the results were different was in the early
stages of the disease where there were route-dependant differences in the appearance,
both spatial and temporal, of the initial pathological lesions. This suggests that the
route of infection may influence the way in which infectivity is processed in the
periphery, by directing it to certain areas of replication such as site associated
lymphoid tissues, and the route of access to the CNS, however once infection has
been established in the brain the other known governors of pathology and
pathogenesis (agent strain and host genetics) are the controlling factors.
It was intended that the establishment of a murine model of oral and
intramuscular scrapie (which may be expanded to include other experimental TSE
infections) would provide an animal model to elucidate the disease process
associated with iatrogenic CJD and new variant CJD in man. However, the marked
differences that are seen in the pathological presentation of these human diseases are
not mirrored in the animal system. This presents more questions regarding the strains
of agent involved in human disease and the role of the human PrP gene in directing
pathogenesis than it answers concerning the role of route of infection. However, it
also suggests that further studies in animals using the oral route of infection and
others may be useful in breaking down the control mechanism into its component
parts in order to assess which is the most influential. This could be done with a
combination ofwell characterised mouse strain/ scrapie strain models. Animal
models afford researchers the opportunity to examine the disease process at all times
through the incubation period, this is obviously not the case in human disease. If
there are to be any intervention type therapies for the treatment of acquired human
TSEs then it is important to know as much as possible about the disease process.
Given that oral acquisition of disease is a prime candidate in vCJD, and there is
epidemiological evidence that some sporadic CJD cases may actually be acquired (in
a manner akin to i.p. infection; Collins et. al., 1999) then studies of this type in
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animal models are potentially valuable tools to further the understanding of acquired
TSEs, both in man and in other animal species.
5. Conclusion
The experiments described in this thesis were designed to test the hypothesis
that the route of infection affects the development of pathology and thereby
thephenotype in cases of experimental murine scrapie. The results of this study
indicate that:
♦ The hypothesis is confirmed. There are measurable and identifiable differences in
the development of pathology which, due to the controlled nature of the agent/host
model, can be attributed to the route of infection.
♦ The degree of pathology observed throughout the brain following oral infection is
greater than is seen in the i.m. or i.p. infected cases. It is very likely that this is a
function of the increased incubation period seen in the orally infected animals,
such that there is simply more time for pathological lesions to develop. However,
this result raises questions regarding the critical event, or sequence of events, that
eventually leads to death.
♦ There is a close relationship between PrP deposition and GFAP accumulation in
the i.m. and i.p. infected mice that does not appear in the case of the orally
infected animals. In the i.m. and i.p. cases GFAP accumulation mirrors PrP
deposition in the thalamus, hippocampus and frontal cortex. In the orally infected
animals the PrP profile in the hippocampus and frontal cortex is very different
from the GFAP profile. The reason for this is unclear and further work may be
required to clarify the reason for this observation.
♦ The oral route of infection has been demonstrated to be an extremely efficient
method of establishing disease in the murine model examined here. This is
demonstrated by the very narrow incubation period range and the small standard
error associated with the mean incubation period. The efficiency of the oral route
of infection in mice may have implications for human disease, especially vCJD.
vCJD is acquired orally and is caused by the same agent that is responsible for
BSE in cattle. To date all reported cases of vCJD share a common prn-p
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genotype. This is analogous to the agent strain/host strain controlled murine
model that has been studied and may allow for the construction of a more accurate
model of the likely size and duration of any future vCJD epidemic.
♦ It appears from these results that the application of a semi-quantitive method of
assessing vacuolar degeneration in scrapie infected mouse brains is feasible. The
close correlation obtained between the results obtained from a computerised
image analysis system and those reported by experienced assessors of spongiform
change suggest this. Employment of such a system may allow for more
meaningful exchange of information between different laboratories and generate a
uniform standard for assessing vacuolation. However, because the automated
system is actually slower than an experienced pathologist, it will be some time
before the technology is in place to make this a widespread and feasible option.
♦ It is difficult to draw any direct comparisons between the murine models and
human diseases. Although disappointing in terms of this study it does produce
more questions and suggests that further experiments should be designed in order
to examine the influence that each component of the disease process, including
agent strain, host strain and route of infection play in the development of a
pathological phenotype.
♦ In addition to the development of CNS pathology following infection by alternate
routes, there is an indication that peripheral processing of infectivity may also be
affected by the route of infection. This is based on very few observations because
the spleens were not routinely harvested from animals at the earlier stages of their
incubation periods. Further experiments to examine more closely the involvement
of the lymphoreticular system in acquired TSE infections are required.
♦ The results of the bioassay experiment indicate that scrapie infectivity can undergo
limited transport in the CNS of animals devoid of endogenous PrP. This is, to the
best of the author's knowledge the first time that this has been demonstrated.
The results of this study have presented a number of new questions that ought
to be addressed. However, the nature of TSE infections, in particular their length,
and the number of additional animals that would be required to address these
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questions (and the associated difficulty of getting ethical approval for their use)
meant that it was not possible to investigate these questions as a part of this project.
This is unfortunate in terms of developing these questions but it is an unavoidable
feature ofworking with such time-intensive agents.
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Appendix I.
Details of pathogens excluded from spf animal facilities including NPU.
Category Excluded Organisms
1*










all diseases listed under 1 *
plus



















All common murine viruses.
Category 4* are what are generally regarded as spf.
Information for table kindly provided by Irene Mc Connell (NPU)
Appendix II.
Standard dose response curves from i.e. titration ofME7 scrapie in C57B1 mice.
Figure 46.
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Brain regions affected by PrP and GFAP following peripheral challenge with ME7
scrapie.
Oral Route of Infection
First PrP must develop between 186 and 221 days post injection; first positive immunostaining is seen in
sections from 221 days post injection.
Astrocytes would appear to be upregulating within the same time interval.
221 d.p.i.
PrP seen in Ventral Pontine reticular nucleus
Central grey matter
Central grey matter, medial




Pontine reticular nuc;eus oral
Supramamillary nucleus




Subincertal Nucleus - encircled neurons.
Anterodorsal thalamic nucleus
some early lesion in the cerebral cortex
some early lesion in CA3 of hippocampus
Ventrolateral thalamic nucleus





PrP also seen in Frontal cerebral ctx






















intermediate lateral septal nucleus
ventromedial hypothalamic nucleus
medial spetal nucleus
more evidence throughout cerebral ctx




302d.p.i. terminal Whole of hippocampus plaques limited to CA4





Throughout hippocampal structure/dentate gyrus
GFAP upregulation observed during same time interval.
221d.p.i

















Polymorph layer ofDentate gyrus V. .slight.
CA2


























Intramuscular Route of Infection
First PrP must develop between 102 and 140 days post injection; first positive immunostaining is seen in
sections from 140 days post injection.
Astrocytes would appear to be upregulating after the appearance of PrP. First signs of reactive astrocytes
seen in 166 d.p.i. Perhaps the GFAP run including tissues from 140 d.p.i. should be repeated.
140 d.p.i.
PrP seen in Medial cerebellar nucleus







Caudal Linear Nucleus Raphe
Ventral Pontine Nucleus
Interposed cerebellar nuclei (Anterior and Posterior)
Lateral hypothalamic area
Red nucleus













Hippocampus (CA3)- very early




PrP also seen in Dorsal hypothalamic nucleus
Paraventricular thalamic nucleus
Paratenial thalamic nucleus
Some small signs in olfactory system
Hippocampus CA3/CA4
More cortical PrP - still apparently within a layer.
Dorsal Lateral Geniculate Nucleus.
Ventral cochlear nucleus
189d.p.i.
PrP also seen in Widespread in cerebral cortex but still appears limited to discrete layer
Corpus callosum







Plaques in posterior thalamic nuclear group
Medial tuberal nucleus









PrP also seen in Ventromedial hypothalamic nucleus
Caudal linear nucleus raphe
septofimbrial nucleus
Detectable PrP Through the CA1 & CA2 region of hippocampus




Some PrP seen in higher layers of frontal region of Cerebral Ctx.
231 d.p.i.










Some in grey matter of cerebellum
Throughout the cortex including many plaques.
Diffuse PrP throughout hippocampus with more
discrete deposits in the CA4 region; includes plaques.
GFAP upregulation observed at the 166 days post injection.
166 d.p.i
These appear to be very early signs of astrocytic upregulation
and as such do not appear to be widespread.
Medial cerebellar nucleus
Pontine reticular nucleus
Appears to be brainstem involvement that is not
mirrored in the observed PrP deposition.
189 d.p.i








Dorsal cortex of inferior colliculus
Lateral septal nucleus
Dorsal central grey matter
Foci in many thalamic nuclei
Medioventral periolivary nucleus
Some in CA1 region of hippocampus
Subsoeruleus nucleus






Spinal trigeminal nucleus, caudal/interpolar
221d.p.i.
Extension of band in the Cerebral cortex to frontal region of brain
Septofimbrial nucleus





Extended deposition in the inferior colliculus
Sparing ofmuch of the deep mesencephalic nucleus
231 d.p.i.
Central white matter structure of cerebellum
Anterior paraventricular thalamic nucleus
subfornical organ
Dorsal medullary reticular field
Spinal trigeminal nerv
Terminal 250 d.p.i.
Astrocytosis throughout the brain.
Hippocampus is very involved.





Heavy foci in central nuclei of thalamus
Corpus callosum
Some evidence of astrocytosis in grey mattey of cerebellar lobules.
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Intraperitoneal Sequence of Events.





Dorsal Cortex, Inferior colliculus
Exterior Cortex, Inferior colliculus
Central Nucleus Inferior colliculus
Ventrolateral thalamic nucleus
Posterior thalamic nuclear group
Cuneiform nucleus
Dorsal medullary reticular field
Anterior Interposed cerebellar nucleus






Alpha parvocellular reticular nucleus
Reticular substantia nigra
Restricted layers of cerebral cortex
166 dpi.
External cuneate nucleus
Arbor vitem of the cerebellum
Very early signs of PrP in the CA4 region of the hippocampus.







Facial nerve root (facial nucleus)
Zonal layer superior colliculus
Superficial Grey layer, superior colliculus
CA3 & CA4 of hippocampus
SomeCAl involvement.
Evidence of PrP in the Caudate Putamen
Angular thalamic nucleus
antreoventral thalamic nucleus, dorsomedial
anteroventral thalamic nucleus, ventrolateral.
Reticular thalamic nucleus
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Cerebral cortex shows much more involvement.
Caudal Pontine reticular nucleus
Oral Pontine nucleus
















Lateral Posterior thalamic nuc.
Medial tuberal nuceus
Nuc horizontal limb diagonal band
Zonal layer sup col
Optic nerve layer sup col

















Central medial thalamic nucleus
parafascicular thalamic nucleus






Ventral posteromedial thalamic nucleus
Angular thalamic nucleus





bed nucleus terminalis stria
Lateroanterior hypophyseal nucleus







reuniens thalamic nucleus ( and Ventral reuniens)
parafascicular thalamic nucleus.
First appearance of GFAP is seen in the 140 dpi group.
140 dpi.
Small focal deposit in cerebral cortex
Dorsal cortex of inferior colliculus
External cortex of inferior colliculus
Central nucleus of inferior colliculus























Cortex frontal and occipital
Hippocampal fissure
Arbor vitem of cerebellum
solitary tract nucleus
Parvocellular reticular nucleus
dorsomedial spinal trigeminal nucleus
Facial nerve.
rhinal cortex near forebrain.
Oral Pontine reticular nucleus
Medial vestibular nucleus
Dorsal Paragigantocellular nucleus





























Posterior Thalamic nuclear group
bed nucleus stria terminalis lateral division
Reticular thalamic nucleus
substantia innominata
Lateral septal nucleus, intermediate
Dorsal lateral septal nucleus
Anterior paraventricular thalamic nucleus
anterior commisural nucleus
Reuniens thalamic nucleus
Intermediate grey and white matter, sup colliculus
Dorsal cortex inferior colliculus
genu corpus callosum
fornix
Lots of cortical involvement..
Anteromedial thalamic nucleus
anteroventral preoptic nucleus




















Intermediate grey and white matter of the Superior colliculus
Dorsal medullary reticular field
caudal spinal trigeminal nucleus









ventral gigantocellular reticular nucleus
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Appendix IV.
Data relating to non-disease associated tissue degradation in non-infected animals.
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All measurements of area are in (am2
Details ofmeasurements made in the brains of uninfected animals. These
measurements provided information regarding the normal state of the murine brain
against which the diseased brain could be compared.
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